



City Research Online

City St George's, University of London

Citation: Chan, F. H. F., Goh, Z. S., Zhu, X., Car, L. T., Newman, S. P., Khan, B. A. & Griva, K. (2023). Subjective cognitive complaints in end-stage renal disease: a systematic review and meta-analysis. *Health Psychology Review*, 17(4), pp. 614-640. doi: 10.1080/17437199.2022.2132980

This is the accepted version of the paper.

This version of the publication may differ from the final published version. To cite this item please consult the publisher's version.

Permanent repository link: <https://openaccess.city.ac.uk/id/eprint/29233/>

Link to published version: <https://doi.org/10.1080/17437199.2022.2132980>

Copyright and Reuse: Copyright and Moral Rights remain with the author(s) and/or copyright holders. Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge, unless otherwise indicated, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. For full details of reuse please refer to [City Research Online policy](#).

Subjective cognitive complaints in end-stage renal disease: a systematic review and meta-analysis

Frederick H. F. Chan¹, Zack Z. S. Goh¹, Xiaoli Zhu^{1,2}, Lorainne Tudor Car^{1,3}, Stanton Newman⁴, Behram A. Khan^{5,6}, Konstadina Griva^{1*}

¹ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

² Nursing Services, National Healthcare Group Polyclinics, Singapore

³ Department of Primary Care and Public Health, Imperial College London School of Public Health, London, UK

⁴ School of Health Sciences, Division of Health Services Research and Management, City University of London, London, UK

⁵ National Kidney Foundation, Singapore

⁶ Yong Loo Lin School of Medicine, National University of Singapore, Singapore

* Corresponding author: Konstadina Griva, konstadina.griva@ntu.edu.sg

Authors' Contributions: research idea and study design: FC, LTC, KG; data acquisition: FC, ZG, XZ; data analysis/interpretation: FC, KG; supervision or mentorship: LTC, KG; manuscript drafting and revision: FC, ZG, XZ, LTC, SN, BK, KG.

Funding: This work was support by the Venerable Yen Pei-National Kidney Foundation Research Fund, Singapore (NKFRC/2021/01/02).

Financial disclosure: The authors declare that they have no relevant financial interests.

Data availability statement: The authors have full control of data and agree to allow the journal to review the data if requested.

Abstract

Cognitive impairment is common in patients with end-stage renal disease (ESRD) and is associated with compromised quality of life and functional capacity, as well as worse clinical outcomes. Most previous research and reviews in this area were focused on objective cognitive impairment, whereas patients’ subjective cognitive complaints (SCCs) have been less well-understood. This systematic review aimed to provide a broad overview of what is known about SCCs in adult ESRD patients. Electronic databases were searched from inception to January 2022, which identified 221 relevant studies. SCCs appear to be highly prevalent in dialysis patients and less so in those who received kidney transplantation. A random-effects meta-analysis also shows that haemodialysis patients reported significantly more SCCs than peritoneal dialysis patients (standardised mean difference -0.20, 95% confidence interval -0.38 to -0.03). Synthesis of longitudinal studies suggests that SCCs remain stable on maintenance dialysis treatment but may reduce upon receipt of kidney transplant. Furthermore, SCCs in ESRD patients have been consistently associated with hospitalisation, depression, anxiety, fatigue, and poorer quality of life. There is limited data supporting a strong relation between objective and subjective cognition but preliminary evidence suggests that this association may be domain-specific. Methodological limitations and future research directions are discussed.

Keywords: subjective cognitive complaint; end-stage renal disease; dialysis; kidney transplantation; systematic review; meta-analysis

Introduction

Chronic kidney disease is a progressive disease defined as the presence of kidney damage or reduced kidney function for at least three months (Levey et al., 2009). It is now recognised as a global health concern, with prevalence rates rising steadily (Eckardt et al., 2013; Jha et al., 2013). According to the level of glomerular filtration rate, which is a measure of kidney function, chronic kidney disease can be classified into five stages, with stage 5 (glomerular filtration rate $< 15 \text{ mL/min/1.73 m}^2$) being the most severe stage where kidneys are no longer able to remove waste products and toxins from the body effectively (Levey & Coresh, 2012). Stage 5 chronic kidney disease is also known as end-stage renal disease (ESRD) or kidney failure. At this stage, life expectancy is drastically shortened if kidney replacement therapy is not initiated (Bello et al., 2022).

There are three main modalities of kidney replacement for ESRD patients: kidney transplantation (KTx), haemodialysis (HD), and peritoneal dialysis (PD). KTx is the preferred treatment option because it completely replaces kidney function and is associated with lower mortality risk and improved quality of life (Fleming, 2011; Sawinski & Poggio, 2021). However, due to the shortage of donor organs, dialysis remains the predominant modality globally (Himmelfarb et al., 2020). HD is an intermittent treatment that typically entails three- to four-hour-long sessions thrice-weekly in dialysis centres, during which blood is circulated and filtered through a dialyser (Fleming, 2011; Vadakedath & Kandi, 2017). In contrast, PD uses a paracorporeal method where patients' own peritoneum serves as a natural semipermeable membrane to filter blood either through three to five manual exchanges daily or overnight by a PD cyclor (Fleming, 2011; Vadakedath & Kandi, 2017). PD offers more flexibility as it can be performed at home (self-care or assisted PD) and allows for regular/daily clearance of waste products and excess fluid (Fleming, 2011; Vadakedath & Kandi, 2017). ESRD entails various treatment transitions such as initiation onto renal

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

26 replacement therapies, or switching from one modality to another with receipt of KTx or
27 return back to dialysis following acute or chronic rejection of transplant graft.

28 While medical innovation related to renal replacement therapies has transformed ESRD
29 from an acute life-limiting illness to a chronic disease, treatment and symptom burden remain
30 extremely high in ESRD and especially dialysis patients. Dialysis patients are required to
31 adhere to complex guidelines concerning their diet, fluid intake, and medication, and to
32 permanently rearrange their schedules to accommodate treatment. On average, dialysis
33 patients report 9-12 symptoms or treatment side effects (e.g., fatigue, pain, insomnia, etc.) at
34 any given time (Himmelfarb et al., 2020), contributing to impaired daily functioning, poor
35 quality of life, and psychological distress (Goh & Griva, 2018; Hedayati & Finkelstein, 2009;
36 K. Zhang et al., 2020).

37 An additional burden of ESRD is the cognitive impairments that start to manifest in
38 early renal dysfunction with progressive deterioration (Berger et al., 2016; Brodski et al.,
39 2019) and persist upon dialysis initiation or KTx (Joshee et al., 2018; San et al., 2017; Shea et
40 al., 2019; Wolfgram, 2018). ESRD patients are at significantly greater risks of cardiovascular
41 disease and related factors such as hypertension and diabetes, and cerebrovascular disease
42 such as stroke and white matter disease, which may all contribute to cognitive decline (Crowe
43 et al., 2021; Drew et al., 2019; Murray, 2008). The accumulation of uraemic toxins in ESRD
44 patients also has pathological effects on the neurological system (Crowe et al., 2021). In
45 addition, the dialysis treatment itself may further accelerate cognitive decline by inducing
46 repetitive cerebral ischemia (i.e., reduction of cerebral blood flow) during HD sessions,
47 which in the long term may result in neurological injury (Crowe et al., 2021; Cukor et al.,
48 2020; Drew et al., 2019; Murray, 2008). Cognitive impairments in ESRD patients involve
49 deficits in various domains such as attention, memory, and executive function, with severity
50 ranging from mild impairments to dementia (Berger et al., 2016; Kurella Tamura et al., 2017;

O'Lone et al., 2016; Viggiano et al., 2020). Compared to age-matched healthy controls, HD patients are more than three times more likely to have severe cognitive impairments (Murray et al., 2006). Both HD and PD patients have poorer cognitive performance than patients at earlier stages of chronic kidney disease and healthy controls (O'Lone et al., 2016; Vanderlinden et al., 2019). In contrast, KTx patients have better cognitive performance than dialysis patients and non-dialysis-dependent chronic kidney disease patients, but still perform worse than healthy controls in areas such as executive function, suggesting that KTx is also unable to fully restore cognition to a premorbid level (Joshee et al., 2018).

Cognitive impairments in ESRD patients are associated with increased hospitalisation (Murray, 2008; Murray & Knopman, 2010; Sehgal et al., 1997; Shea et al., 2019) and mortality risks (Griva et al., 2010; Kurella et al., 2006; Murray, 2008), and ultimately increased cost of care. Cognitive impairments may also interfere with patients' daily functioning, treatment adherence, self-management skills, and decision-making capacities because all these processes hinge upon patients' cognition (Iyasere et al., 2017; Murray & Knopman, 2010; Wolfgram, 2018). Given the high prevalence and potential consequences of cognitive impairments in ESRD patients, substantial research has been conducted in the past two decades, with evidence synthesised in several recent systematic reviews and meta-analyses (Ali et al., 2020; Brodski et al., 2019; Joshee et al., 2018; Shea et al., 2019; Tian et al., 2019; Vanderlinden et al., 2019). However, all these reviews were focused on objective cognitive function assessed by standardised neuropsychological tests, which albeit sensitive in detecting cognitive impairments, may provide limited understanding of patients' subjective experience with cognitive difficulties in everyday context.

The concept of subjective cognitive complaints (SCCs), or subjective cognitive decline, refers to self-reported difficulties in one or more cognitive domains (e.g., memory, attention, etc.) experienced in one's daily life or a perceived decrease in cognitive capacity in

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

76 comparison with a previously normal status (Jessen et al., 2014; Mendonça et al., 2015;
77 Molinuevo et al., 2017; Pullens et al., 2010; Van Rijsbergen et al., 2014). In 2014, a group of
78 Alzheimer’s disease researchers published a conceptual model for SCCs, which proposed that
79 SCCs occur at the preclinical stage of cognitive impairments where individuals experience
80 increasing compensatory cognitive efforts and subtle cognitive decline not yet detectable by
81 objective testing (Jessen et al., 2014). SCCs are therefore considered as an indicator of the
82 earliest symptomatic manifestation of cognitive impairments (Jessen et al., 2014) which may
83 be present as long as 15 years before the onset of objective impairments (Molinuevo et al.,
84 2017; Rabin et al., 2017). However, as individuals progress to more advanced stages of
85 cognitive impairments (i.e., dementia), SCCs may gradually level off, consistent with
86 anosognosia (i.e., lack of self-awareness about cognitive impairments) (Rabin et al., 2017).
87 This may be related to the presence of cognitive impairments interfering with an individual’s
88 ability to detect everyday cognitive task failure, to consolidate the experience of failure, and
89 to accurately estimate one’s own cognitive ability compared to previous knowledge
90 (Mazancieux et al., 2019; Morris & Mograbi, 2013).

91 Although SCCs may attenuate along the course of cognitive decline, these complaints
92 have been shown to be associated with objective markers of cognitive impairments (Farias et
93 al., 2013; Rueda et al., 2015) and are considered as a reliable predictor of future progression
94 to dementia (Farias et al., 2017; Y. C. Lee et al., 2020; Liew, 2020a, 2020b; Mendonça et al.,
95 2015; Mitchell et al., 2014; Neto & Nitrini, 2016). The importance of SCCs is also
96 exemplified by its inclusion as a core feature of mild cognitive impairment in consensus
97 reports (Winblad et al., 2004). SCCs may have potential value in identifying patients at risk
98 of cognitive impairments before these cognitive changes become more severe and irreversible
99 (Jessen et al., 2014).

SCCs are also important as they reflect individuals' accumulative everyday experience rather than cognitive performance at a single time point as assessed by objective neuropsychological tests (Rabin et al., 2017). Studies on ESRD patients have found that SCCs are indeed better predictors of real-world outcomes including functional capacity (Song et al., 2015) and decision-making (Jayanti et al., 2016) compared to objective cognition, and are consistently associated with psychological well-being and quality of life (Duarte et al., 2005; Song et al., 2018). The self-awareness of cognitive deficits may also influence judgements about behavioural efficacy, self-care ability, and independence of daily living (Crowe et al., 2021; Morris & Mograbi, 2013). Understanding SCCs may thus be essential in improving patient-centred care for ESRD-related cognitive impairments (Crowe et al., 2021).

To date, a fair amount of research has been conducted to examine SCCs in ESRD patients, but the results have not been drawn together to provide a broad overview of what is known about these complaints in the context of ESRD. As such, we conducted a systematic review and meta-analysis to synthesise existing data on SCCs in ESRD patients. Specifically, the aims of this review include: (1) to identify instruments assessing SCCs used in ESRD research; (2) to quantify the frequency and severity of SCCs as measured by these different instruments in the target population(s); (3) to compare differences (if any) in SCCs between renal replacement modalities (i.e., HD, PD, and KTx); (4) to evaluate the course of SCCs over time and across treatment transitions; and (5) to synthesise evidence on the associations of SCCs with sociodemographic profile, clinical characteristics, clinical and patient-reported outcomes (e.g., hospitalisation, quality of life, etc.), and objective cognitive function. Based on previous research on objective cognition, we hypothesised that KTx patients would have lower frequency and severity of SCCs than dialysis patients and that SCCs will improve with KTx; as evidence on cognitive impairments across dialysis modalities (HD vs. PD) is mixed no a priori hypotheses were formulated.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

The protocol was registered within the PROSPERO database (registration number: CRD42021250125). Findings were reported following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guideline (Moher et al., 2009; Page et al., 2021).

Eligibility criteria

Studies were included if they (1) involved adult patients (≥ 18 years) diagnosed with ESRD (stage 5 chronic kidney disease with glomerular filtration rate < 15 mL/min/1.73 m²) either on renal replacement therapy (any dialysis modality or kidney transplantation), conservative management (i.e., management without renal replacement therapy where the goal is to minimise symptoms and maximise the quality and length of life), or with ESRD but not yet initiated treatment, (2) used at least one measure of SCCs, and (3) reported data on frequency/severity of SCCs, differences in SCCs between treatment modalities, changes in SCCs over time, or associations of SCCs with sociodemographic and/or clinical characteristics, clinical and/or patient-reported outcomes, and/or objective cognitive function.

Studies that included only children or adolescents (under 18 years of age) or patients in stages 1-4 of chronic kidney disease were excluded. We defined SCCs as the self-reported difficulties in one or more cognitive domains or a perceived decrease in cognitive capacity in comparison with a previously normal status (Jessen et al., 2014; Mendonça et al., 2015; Molinuevo et al., 2017; Pullens et al., 2010; Van Rijsbergen et al., 2014). SCCs can be measured using self- or proxy-reported questionnaires assessing individuals' perceptions about cognitive capacity or experience of cognitive difficulties (e.g., "How much of the time in the past four weeks did you become confused?"). Self-reported measures of daily functioning (e.g., managing finances, shopping, etc.) were not considered as measures of SCCs because the capacity to carry out these activities does not solely rely on cognitive

skills. Studies using a composite measure (e.g., a measure of quality of life or depression that has a subdomain of SCCs) were included if they reported the separate SCC domain score. Studies that reported only the composite score that included the SCC domain were excluded. Unpublished studies and grey literature were excluded due to the absence of peer review. Non-English articles were excluded due to resource constraints and the research team's language skills. Only published journal articles with available English full-text were included in the final sample.

Search strategy & selection process

To identify relevant studies the following databases were searched (inception to 21 April 2021): CINAHL (EBSCOhost), Ovid – All Resources (Books@Ovid, Journals@Ovid Full Text, Your Journals@Ovid, EBM Reviews, Embase, MEDLINE), MEDLINE (PubMed), PsycINFO (EBSCOhost), and Web of Science. The search terms included exact words or synonyms of: subjective cognitive complaints, end-stage renal disease, dialysis, and kidney transplantation. We also included “kidney disease quality of life” as one of the keywords because a large number of studies in this area assessed SCCs using a subscale within this measure. Subject headings were not used because there was no subject heading in the selected databases specific to the concept of SCCs, and the use of relevant terms such as “Cognitive Dysfunction” and “Quality of Life” may decrease the specificity of the search. We performed the search in all fields including full-text because previous studies showed that full-text search is more sensitive than title/abstract search (Lin, 2009; Penning de Vries et al., 2020). An updated search was conducted to retrieve records published between the end date of the initial search and 11 January 2022. The detailed search strategy is presented in Table S1.

Titles and abstracts were scanned independently by two authors (FC & ZG) using Covidence (<https://www.covidence.org>) to exclude studies that were irrelevant. Full-texts of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

the remaining articles were then independently screened by FC and ZG to determine eligibility. Discrepancies between the two reviewers were resolved by discussion with a third reviewer (KG). The reference lists of included articles were also examined to identify additional studies.

Data extraction

Due to the large number of relevant articles included in the current review, we adopted an accelerated approach to data extraction recommended by Cochrane (Moons et al., 2021). One reviewer (FC) extracted data from all individual studies. The correctness and completeness of extracted data were then verified by two independent reviewers (ZG & XZ). Any errors detected by the two reviewers were discussed among the three reviewers and corrected if necessary.

The following data items were extracted: article citation, study location, study design, sample size, participant characteristics (i.e., gender, age, treatment modality, etc.), measure of SCCs, frequency and severity of SCCs, differences in SCCs between treatment modality groups, longitudinal change in SCCs over time, associations of SCCs with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition. If data concerning the outcomes were missing or unclear from an article, the review team contacted the corresponding authors to obtain original data or for clarification.

Quality assessment

The quality of selected studies were assessed using the quality assessment tools developed by the National Institute of Health (<https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>). This tool provides study design-specific items to assess methodological quality of observational cohort and cross-sectional studies, controlled intervention studies, and before-after (pre-post) studies with no control group (Ma et al., 2020). Reviewers could select “yes”, “no”, “not reported”, “cannot determine”, or “not applicable” in response to

each item for each individual study. Similar to data extraction, the first author (FC) rated each item for each included study, with verification performed by two other reviewers (ZG & XZ). Discrepancies in quality ratings between the reviewers were resolved by discussion and consensus.

Data synthesis

We first performed qualitative narrative synthesis of the included studies. We summarised patient responses to SCC measures that indicate different levels of frequency/severity of SCCs. For this specific aim, the mean values reported by cross-sectional studies and baseline scores in longitudinal studies were used. We also summarised the number of studies that reported significant ($p < .05$) or non-significant differences between treatment modalities (i.e., HD, PD and KTx), as well as the direction of these differences. The longitudinal course of SCCs was determined based on observational cohort studies that analysed changes in SCCs over time and intervention studies that reported changes in the control groups. Furthermore, the number of studies reporting positive, negative, or null associations of SCCs with sociodemographic, clinical and patient-reported variables, as well as objective cognitive function, were synthesised.

Meta-analyses were further conducted where data were sufficient (i.e., at least two studies using similar measurement and analysis methods). Specifically, we conducted a random-effects meta-analysis with a restricted maximum likelihood estimator to compare differences in SCCs between HD and PD patients based on the reported means, standard deviations, and sample sizes of each treatment group. Standardised mean differences and corresponding 95% confidence intervals were calculated. Meta-analyses comparing other treatment modalities (e.g., HD vs. KTx) were not performed due to the small number of studies reporting these findings. We also performed random-effects meta-analyses of correlation coefficients between SCCs and 10 patient-reported outcomes (i.e., depression,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

anxiety, overall health rating, general health perception, pain, fatigue, physical functioning, social functioning, role limitation due to physical health, and role limitation due to emotional problems). The Fisher’s *r*-to-*z* transformed correlation coefficient and corresponding 95% confidence intervals were calculated. Meta-analyses of correlation between SCCs and sociodemographic/clinical variables and objective cognition were not deemed possible due to the unavailability of original data and heterogeneity across studies in terms of the measurement and analyses methods of these variables. For all meta-analyses, heterogeneity was determined by forest plots, including summary effects along with the 95% confidence intervals and 95% prediction intervals, as well as the *Q* and *I*² statistics (IntHout et al., 2016). Small study effects were examined through Egger’s linear regression test of funnel plot asymmetry. All meta-analyses were performed using the “metafor” package (Viechtbauer, 2010) in R 4.1.2 (R Core Team, 2018).

Results

Study selection

The search flow is illustrated in Figure 1 (Page et al., 2021). The initial search (21 April 2021) retrieved 5248 records, of which 2435 were duplicates. Two reviewers (FC & ZG) independently screened titles and abstracts of the remaining 2813 articles and excluded 1543 irrelevant records. A total of 1027 full-text papers were assessed for eligibility, of which 814 were excluded due to reasons presented in Figure 1. The updated search (11 January 2022) identified eight additional relevant articles. Thus, a total of 221 studies were included.

Study characteristics

Tables S2 present characteristics and key findings of each individual study, as well as the full reference list of included studies. The 221 studies represented 105064 patients with ESRD, with the majority (*N* = 89188) receiving haemodialysis (HD), 9113 patients on peritoneal dialysis (PD) and 4449 patients who received kidney transplantation (KTx). Studies were

250 mainly conducted in the United States ($k = 33$), Brazil ($k = 29$), Japan ($k = 19$), South Korea
251 ($k = 13$), United Kingdom ($k = 11$), Canada ($k = 11$), Iran ($k = 10$), Norway ($k = 10$) and
252 mainland China ($k = 8$). Over half of the studies ($k = 134$) used an observational cross-
253 sectional design, while 49 used an observation cohort design. Moreover, there were 30
254 controlled intervention studies and eight pre-post studies with no control group.

255 **Quality assessment**

256 The quality ratings of each individual study is presented in Tables S3-S6. Quality ratings
257 were reported separately for observational cross-sectional (Table S3), observational cohort
258 (Table S4), controlled intervention (Table S5), and pre-post studies (Table S6).

259 Within the 134 cross-sectional studies, only 22.4% fulfilled at least 70% of the criteria
260 list, whereas 31.3% fulfilled less than 50% of the criteria. Some key methodological
261 shortcomings of the cross-sectional studies included insufficient description of patient
262 recruitment procedure, absence of sample size justification, and outcome assessors not
263 blinded to exposure status where possible. Methodological quality of observational cohort
264 studies appeared to be higher compared to cross-sectional studies, with 49.0% and 93.9%
265 fulfilling at least 70% and 50% of the criteria, respectively. Main methodological
266 shortcomings of observational cohort studies were similar to those identified in cross-
267 sectional studies, but include additionally the high rate of or inadequate information on loss
268 to follow-up.

269 Regarding controlled intervention studies, only 26.7% of the 30 studies met at least
270 70% of the criteria. Areas of improvement include inadequacy of randomisation, allocation
271 concealment, and blinding, as well as insufficient/unjustified sample size and absence of
272 intention-to-treat analysis. Finally, within the eight pre-post studies with no control group, the
273 majority of studies did not report response rate or provide sample size justification, and had

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

high rates of loss to follow-up. Despite these limitations, almost all included studies, regardless of the design, adopted reliable and valid outcome measures of SCCs.

Measures of SCCs

Thirteen measures of SCCs were identified and the characteristics of these measures are presented in Table 1. Of these, six questionnaires were developed specifically for SCCs, whereas the remaining were multidomain measures of quality of life or symptom checklist that included an SCC subscale/item. All measures identified in the current review were validated except for Henry et al. (2018) where four items from two validated questionnaires were selected and used as a measure of SCCs. The most commonly used measure (k = 207, 93.7%) was the Kidney Disease Quality of Life Cognitive Function subscale (KDQOL-CF), a 3-item scale that assesses patients’ experience of slow reaction, concentration difficulty, and confusion in the past four weeks (Hays et al., 1994; Kurella et al., 2004), followed by the Patient’s Assessment of Own Functioning Inventory (k = 3, 1.4%) (Chelune et al., 1986) and a single item assessing concentration difficulty from Dialysis Symptom Index (k = 2, 0.9%) (Weisbord et al., 2004). All other measures were only used once. Number of items ranged from 1 to 39 and instruments varied in cognitive domains assessed: attention/concentration (11 measures), memory (10 measures), language/comprehension (five measures), and problem-solving (four measures). Measures mainly assessed severity (seven measures) and frequency (six measures) of SCCs.

Frequency and severity of SCCs

We first synthesised data on frequency of SCCs (i.e., number of times patients experienced SCCs within a given timeframe) in ESRD patients. The KDQOL-CF data across treatment modalities (HD: k = 120, N = 37212; PD: k = 42, N = 6304; KTx: k = 17, N = 2693) were synthesised by comparing the distribution of mean scores across modalities (see Table 2). The majority of studies on HD and PD patients reported mean KDQOL-CF scores between

299 60 and 100 (HD: 103 studies, 85.8%; PD: 38 studies, 90.5%), indicating that SCCs were
300 noted from “none of the time” to “some of the time” during the past month. In contrast, the
301 majority of studies on KTx patients reported mean KDQOL-CF scores between 80 and 100
302 (11 studies, 64.7%), indicating that SCCs were reported from “none of the time” to “a little of
303 the time” during the past month. When analysing Table 2 in terms of number of patients, the
304 majority of HD (N = 28431, 76.4%) and PD (N = 4409, 69.9%) patients reported mean scores
305 lower than 80, indicating that SCCs were experienced sometimes or more often. In contrast,
306 the majority of KTx patients (N = 1922, 71.4%) reported mean scores higher than 80,
307 indicating SCCs no more than “a little of the time”.

308 Considering other measures assessing frequency of SCCs, three studies found that
309 SCCs in HD patients were experienced from “rarely” to “sometimes” on average (Brickman
310 et al., 1996; Fan et al., 2020; Jassal et al., 2006), which were similar to findings from
311 KDQOL-CF. Additionally, using the concentration difficulty item in the Dialysis Symptom
312 Index (yes/no), 30.2% to 32.3% of HD patients in Columbia reported the presence of
313 concentration difficulties during a one-year course (Alarcon et al., 2021), whereas 57.8% of
314 HD patients in Korea reported presence of these difficulties (Cho et al., 2018).

315 There is a paucity of research on severity of SCCs in ESRD (i.e., level of difficulty in
316 performing cognitive tasks or degree of seriousness). Five studies were identified and these
317 had used different indices assessing different cognitive domains. One study used the
318 cognition subscale of the WHO Disability Assessment Schedule and noted that HD patients
319 reported “no difficulty” to “mild difficulty” in daily cognitive tasks (i.e., concentration,
320 memory, problem-solving, learning, comprehension, conversation) (Castro et al., 2018).
321 Another study used a single item in Dialysis Symptom Index and HD patients reported that
322 their concentration difficulties were “somewhat bothersome” to “quite bothersome” (Cho et
323 al., 2018). A further study used the cognition subscale of Health Utilities Index Mark 3,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

where HD patients reported on average that they were “somewhat forgetful, but able to think clearly and solve everyday problems” (Gorodetskaya et al., 2005). When using the British Columbia Cognitive Complaints Inventory which assesses SCC severity in six domains (i.e., memory, concentration, thought expression, word finding, thinking, problem-solving) and classifies patients into four levels of severity (0-4: normal; 5-9: mild; 10-14: moderate; 15-18: severe), one study reported that 86.9% of HD patients had mild to severe SCCs (Zubair & Butt, 2017). No study assessed severity of SCCs in PD patients. The only study to assess SCC severity in KTx used the cognition subscale of ESRD Symptom Checklist and concluded that SCCs in concentration and memory were only very mild in the first year following KTx (M = 13.0-14.3 on a scale of 0 = not at all - 100 = extreme) (Ortega et al., 2007).

Differences in SCCs between treatment modalities

Of the 23 studies which compared frequency of SCCs between HD and PD patients, 17 reported no difference (Chen et al., 2021; Czyżewski et al., 2014; Frimat et al., 2006; Fructuoso et al., 2011; Gonçalves et al., 2015; Kang et al., 2017; Kostro et al., 2016; Kutner, Zhang, Barnhart, et al., 2005; Malekmakan et al., 2016; Manavalan et al., 2017; Molsted et al., 2007; Neumann et al., 2018; Okpechi et al., 2013; Rebollo Rubio et al., 2017; Song et al., 2015; Tannor et al., 2017; Wright & Wilson, 2015), whereas six reported more frequent SCCs in HD compared to PD patients (Carmichael et al., 2000; Chrifi Alaoui et al., 2022; Kutner, Zhang, & Brogan, 2005; A. J. Lee et al., 2005; Tanaka et al., 2020; Türk et al., 2020).

Of these 23 studies, 20 provided data necessary for a random-effects meta-analysis (see Figure 2). All 20 studies used the KDQOL-CF as the measure of SCCs. There was a small but significant difference between the HD and PD groups (standardised mean difference - 0.20, 95% confidence interval -0.38 to -0.03), with HD patients reporting more frequent SCCs than PD patients. The prediction interval for this comparison was large and included

zero (95% prediction interval -0.92 to 0.51). There was high heterogeneity across studies ($Q = 90.81$, $df = 19$, $p < .001$; $I^2 = 89.5\%$). Egger's test did not detect funnel plot asymmetry ($z = -0.52$, $p = .600$). It is of note however that this significant difference may be mainly driven by one study with a particularly large sample size (total $N = 3302$) that almost equals the total sample sizes of the rest of the studies (Kutner, Zhang, & Brogan, 2005).

Four studies using the KDQOL-CF compared frequency of SCCs between HD and KTx patients, with three reporting no difference (Barotfi et al., 2006; Czyżewski et al., 2014; Painter et al., 2012) and one reporting more frequent SCCs in HD patients (A. J. Lee et al., 2005). Two studies compared KDQOL-CF scores between PD and KTx patients and both reported no difference (Czyżewski et al., 2014; A. J. Lee et al., 2005). No study compared severity of SCCs among HD, PD and KTx patients.

Course of SCCs

A subset of included studies ($k = 46$) reported on changes in SCCs over time in ESRD patients. These include observational cohort studies ($k = 26$), pre-post studies ($k = 1$), and intervention studies that reported changes in the control groups ($k = 19$).

Twenty studies assessed SCCs at multiple time points in patients on HD, with 19 reporting no change over time (Alarcon et al., 2021; Boudville et al., 2009; Duarte et al., 2009; Frimat et al., 2006; Hayashi et al., 2017; Korevaar et al., 2002; L. C. C. Lopes et al., 2019; Maynard et al., 2019; Mazairac et al., 2013; Neumann et al., 2018; Painter et al., 2012; Poulsen et al., 2017; Scott et al., 2009; Shahnavazi et al., 2018; Simic-Ogrizovic et al., 2009; Soares et al., 2017; Unruh et al., 2004; Wu et al., 2014; Zheng et al., 2019). The follow-up periods of these studies ranged from six weeks to six years. Similarly, 11 out of 12 studies on PD patients with follow-up periods ranging from one month to three years also reported no change in SCCs over time (Chow & Wong, 2010; Frimat et al., 2006; Jiao et al., 2017; Jung et al., 2016; Korevaar et al., 2002; Li et al., 2014; Lo et al., 1998; Michels et al., 2011;

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Neumann et al., 2018; Uchiyama et al., 2019; Wong et al., 2010). Of note, all these studies reporting no change in SCCs in dialysis patients adopted the KDQOL-CF which only contains three items. When using a more comprehensive measure (i.e., Patient’s Assessment of Own Functioning Inventory), Song et al. (2018) found a significant reduction in SCCs over a one-year course in both HD and PD patients.

Regarding the effect of KTx, there is evidence of a significant reduction in SCCs among HD, PD, or pre-emptive patients from pre- to post-KTx (Kostro et al., 2016; McAdams-DeMarco et al., 2018; Ortega et al., 2007; Peipert et al., 2020; Rajkumar et al., 2019; Tsarpali et al., 2021). Following KTx, SCCs appear to be stable over time and may be maintained for up to six years post-KTx (Costa-Requena et al., 2017; Czyżewski et al., 2014; Hernández Sánchez et al., 2021; Lønning et al., 2018; Ortega et al., 2007; Peipert et al., 2020; Ryu et al., 2021; Tsarpali et al., 2021).

The effect of transplant graft rejection and return to dialysis and the effect of dialysis initiation on SCCs could not be synthesised since there is a paucity of research comparing SCCs across these treatment transitions (i.e., KTx to dialysis and pre- to post-initiation of dialysis).

Associations with sociodemographic, clinical, and patient-reported variables

Evidence concerning associations of SCCs with sociodemographic, clinical, and patient-reported variables were synthesised by the number and percentage of studies that reported a positive, negative, or null association with each variable (see Table 3). There was high heterogeneity in terms of the quantification of these variables. Study authors were contacted for data on correlations or between-group comparisons but the response rate was very low. Associations with sociodemographic and clinical variables were therefore not meta-analysed due to the lack of data.

398 Among sociodemographic variables, the majority of studies found no association
399 between SCCs and age, gender, marital status, household income, and smoking status.
400 Regarding education level, seven studies reported that lower education was associated with
401 higher SCCs (Brickman et al., 1996; Duarte et al., 2005; Kontodimopoulos & Niakas, 2005;
402 Kutner et al., 2007; A. A. Lopes et al., 2007; Ortega et al., 2007; Song et al., 2015) whereas
403 seven others found no association (Anees et al., 2018; Boudida et al., 2014; Fan et al., 2020;
404 Ho et al., 2013; Neumann et al., 2018; Sorensen et al., 2012; Zubair & Butt, 2017). It
405 appeared that the seven studies reporting a significant association with education had
406 generally larger sample sizes, and adopted more lengthy and comprehensive measures of
407 SCCs, compared to studies reporting null associations. In terms of employment status, four
408 studies found a significant association between SCCs and unemployment (de Oliveira et al.,
409 2012; A. A. Lopes et al., 2007; Ortega et al., 2007; Vázquez et al., 2005) and these studies
410 had generally larger sample sizes compared to the two that reported no association (Anees et
411 al., 2018; Neumann et al., 2018).

412 Clinical parameters were largely unrelated to SCCs as shown in Table 3, where null
413 associations were reported in at least 70% of the studies for most variables. However,
414 hospitalisation was consistently associated with SCCs in all six studies assessing this
415 outcome. Specifically, four cross-sectional studies reported that patients with more frequent
416 and/or longer hospitalisation events in the preceding 12 months reported higher frequency of
417 ensuing SCCs (Hays et al., 1994; Kontodimopoulos & Niakas, 2005; Poulsen et al., 2017;
418 Türk et al., 2020). Two other prospective cohort studies with very large sample sizes (N =
419 6151 and 10030 respectively) reported that higher SCCs at baseline were associated with
420 significantly greater risk of future hospitalisation (A. A. Lopes et al., 2003; Mapes et al.,
421 2003).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

In terms of patient-reported outcomes (see Table 3), SCCs have been consistently associated higher depressive symptoms (18 studies, 85.7%), higher anxious symptoms (9 studies, 90.0%), higher bodily pain (6 studies, 85.7%), higher fatigue symptoms (6 studies, 100.0%), worse physical functioning (5 studies, 83.3%), more overall physical symptoms (5 studies, 100.0%), poorer sleep quality (3 studies 75.0%), and lower functional capacity (3 studies 75.0%). Results regarding some other quality-of-life domains (i.e., overall health rating, social functioning, general health perception, role limitation due to physical health or emotional problems, and physical inactivity) were less consistently reported but still showed an overall association between higher SCCs and worse quality of life.

For 10 of these patient-reported outcomes (i.e., depression, anxiety, overall health rating, general health perception, bodily pain, fatigue, physical functioning, social functioning, role limitation due to physical health, and role limitation due to emotional problems) where data were sufficient, random-effects meta-analyses of correlation coefficients were further conducted to determine the strength of associations. Results and forest plots of these meta-analyses are presented in Figures S1-S10. The pooled effects showed significant correlations between SCCs and all 10 patient-reported outcomes (95% confidence interval not including zero). The strength of these associations ranged from small (0.22) to moderate (0.49), with depressive symptoms (correlation coefficient 0.46, 95% confidence interval 0.39 to 0.53), anxious symptoms (correlation coefficient 0.40, 95% confidence interval 0.33 to 0.47), fatigue symptoms (correlation coefficient 0.49, 95% confidence interval 0.45 to 0.54), and role limitation due to emotional problems (correlation coefficient 0.43, 95% confidence interval 0.37 to 0.48) showing the strongest correlations with SCCs. Details with regards to the prediction interval, heterogeneity, and funnel plot asymmetry, are presented in Figures S1-S10.

Association with objective cognitive function

Only five studies evaluated association between SCCs and objective cognitive function in ESRD patients (Brickman et al., 1996; Henry et al., 2018; Jayanti et al., 2016; Song et al., 2015; Sorensen et al., 2012). Some studies assessed objective cognition using global screening tests that provides a total sum score across cognitive domains such as the Mini-Mental State Examination (Henry et al., 2018; Sorensen et al., 2012) and the Modified Mini-Mental State test (Jayanti et al., 2016), while others used individual neuropsychological tests assessing specific domains, such as the Trail-Making Test and the Digit Span Task (Brickman et al., 1996; Henry et al., 2018; Jayanti et al., 2016; Sorensen et al., 2012).

When operationalising objective cognition and/or SCCs as a single construct (i.e., calculating only the total score of global cognitive tests or sum score of SCC measures), studies generally found no association between objective and subjective cognition (Brickman et al., 1996; Henry et al., 2018; Jayanti et al., 2016; Song et al., 2015; Sorensen et al., 2012). However, there is preliminary evidence suggesting that this association may be domain-specific. In particular, although Henry et al. (2018) found no association between overall SCCs and global cognitive test scores, complaints about slow reaction in this study was associated with poorer performance on Digit Span Task (short-term verbal memory) and Trail-Making Test (attention/concentration and executive function), and self-reported confusion was also associated with poorer performance on Digit Span Task, Visual Retention Test (visual memory), and Trail-Making Test. Similarly, Jayanti et al. (2016) found that self-reported concentration difficulties (but not memory complaints) were associated with poorer performance in the Trail-Making Test (but not performance on global cognitive test).

All five studies assessing the association between objective tests and subjective complaints adopted a cross-sectional design (Brickman et al., 1996; Henry et al., 2018; Jayanti et al., 2016; Song et al., 2015; Sorensen et al., 2012). Therefore, it was not possible to determine whether SCCs in ESRD patients may predict future risks of progression to mild

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

cognitive impairments or dementia. We were also unable to determine the relationship between objective and subjective cognition over time and how they may interact with one another along the course of kidney disease, renal replacement therapies, and/or treatment transitions.

Discussion

To the best of our knowledge, this is the first systematic review and meta-analysis on SCCs in patients with ESRD. By including 221 relevant articles, we provided a comprehensive overview of this commonly experienced but poorly understood problem. We synthesised evidence of the frequency, severity, and course of SCCs in ESRD patients, differences between treatment modalities, associations of SCCs with sociodemographic, clinical, and patient-reported variables, and relationship between subjective and objective cognition. Although there is substantial heterogeneity across studies in terms of the study design, sample characteristics, and measures used to assess SCCs, some preliminary conclusions can be drawn. First, SCCs are highly prevalent in dialysis patients, with over two thirds of HD (76.4%) and PD (69.9%) patients reporting SCCs sometimes or more often. Within dialysis patients, those who are on HD experience significantly more frequent SCCs compared to those on PD, with a small effect size. In contrast, SCCs are much less prevalent in KTx patients with over two thirds (71.4%) reporting these complaints only a little of time or never. When analysing the longitudinal course, SCCs appear relatively stable over time on HD and PD treatments but may reduce significantly upon receipt of KTx. In addition, there is either no or mixed evidence on associations between SCCs and most sociodemographic/clinical variables, except for hospitalisation which has been consistently associated with higher SCCs. Patient-reported outcomes including depression, anxiety, fatigue, and quality of life in various domains appear to be more consistently associated with SCCs, with small to medium magnitude. Finally, the association between subjective and objective cognition in ESRD

497 patients could not be established due to the lack of data but there is preliminary evidence
498 suggesting domain-specificity of this association.

499 Our findings regarding the prevalence of SCCs and differences between treatment
500 modalities are generally in line with the objective cognition literature. Two recent meta-
501 analyses have confirmed that PD patients have better performance on objective cognitive
502 tests and lower risk of cognitive impairments compared to HD patients (Ali et al., 2020; Tian
503 et al., 2019). Our meta-analysis extends these findings to subjective reports. PD, by being a
504 daily treatment, offers a more gentle and continuous clearance of toxins and waste products,
505 without the more acute and variable haemodynamic changes and fluid shifts reported in HD
506 (Viggiano et al., 2020). As such, PD is expected to provoke fewer and less severe instances of
507 brain injury, hence better preserving cognitive function (Drew et al., 2019; Murray, 2008;
508 Tian et al., 2019). However, caution is needed when interpreting this meta-analysis since the
509 prediction interval was very wide and contained zero, suggesting that the comparison in
510 future similar studies can fluctuate across a wide range of effects (IntHout et al., 2016). It is
511 also important to note that according to our quality assessment, the outcome assessors in
512 studies comparing HD and PD groups were often not blinded to patients' exposure status,
513 which may introduce experimenter bias where the assessors expect HD patients to have more
514 SCCs than PD patients. Furthermore, it is possible that this observed difference is a mere
515 reflection of pre-existing differences between those who opt for HD versus PD (Crowe et al.,
516 2021). One included study found that more severe SCCs in pre-dialysis patients were
517 associated with a higher likelihood of choosing fully-assisted (i.e., HD) over self-care dialysis
518 (i.e., PD) (Jayanti et al., 2016). These confounding factors are important to address in future
519 studies as they may undermine interpretation of the true effect of dialysis modality on
520 cognition. To date, transplantation remains the optimal treatment for restoring cognition in
521 ESRD patients as it completely replaces the kidneys and has been associated with cerebral

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

benefits and improvements in objective cognitive performance (Crowe et al., 2021; Joshee et al., 2018). Our review further supported the advantages of KTx by showing a lower prevalence rate of SCCs in KTx than in dialysis patients, and a reduction in SCCs from pre- to -post-KTx.

Regarding the longitudinal course, SCCs appear relatively stable in patients receiving HD or PD treatments. This conclusion was inconsistent with the objective cognition literature where several longitudinal studies showed a significant decline in executive function over the course of HD/PD (Drew et al., 2017; Iyasere et al., 2017; Kurella Tamura et al., 2017). The majority of studies assessing change in SCCs in our review used the KDQOL-CF measure which does not assess executive function and thus may have missed the opportunity to observe changes in complaints about this important domain. Indeed, one study used a more comprehensive questionnaire that includes memory, language, sensory-perceptual, and executive function domains and found a significant reduction in overall SCCs over a one year course in both HD and PD patients (Song et al., 2018). This again seems to contradict the studies using objective tests in the direction of change. However, according to the conceptual model of SCCs mentioned earlier, SCCs may be the most evident during preclinical cognitive impairments when objective performance is still within normal limits (Jessen et al., 2014). As cognitive impairments become more severe, SCCs may recede due to diminished accuracy in estimating own cognitive abilities (Mazancieux et al., 2019; Morris & Mograbi, 2013; Rabin et al., 2017). In the context of ESRD, the decline in executive function over the dialysis treatment course may interfere with patients' ability to monitor everyday task performance and detect failure/lapses which are essential for updating self-perception of cognitive ability (Morris & Mograbi, 2013), thus contributing to decreasing SCCs. Besides the course of SCCs on dialysis, future longitudinal investigations are also needed to determine the effect of dialysis initiation on SCCs, as well as change in SCCs shifting across treatment modalities

(e.g., shifting from HD to PD) since SCCs may become particularly frequent/severe during these transition periods due to the associated symptoms, side effects, complications, and changes to treatment and self-care requirements (Broers et al., 2015).

The analyses of associations between SCCs and sociodemographic/clinical variables revealed mainly no or mixed evidence. Hospitalisation was the only variable shown to be consistently associated with higher SCCs across six studies (Hays et al., 1994; Kontodimopoulos & Niakas, 2005; A. A. Lopes et al., 2003; Mapes et al., 2003; Poulsen et al., 2017; Türk et al., 2020), in line with previous research which showed significantly greater hospitalisation risks in dialysis patients with objective cognitive impairments compared to those without (Murray, 2008; Sehgal et al., 1997; Shea et al., 2019; Y. Zhang et al., 2018). It is noteworthy that this relation may be bi-directional. On one hand, hospitalisation entails potential surgical procedures, associated need for anaesthesia, heightened risks for infection and other adverse events, medication exposure, and depression and sleep difficulty that may all contribute to cognitive impairments (Mathews et al., 2014). On the other hand, SCCs reflect everyday cognitive difficulties that may interfere with patients' independence in daily functioning, medication taking, diet and fluid control, and other self-care activities and may therefore result in poor disease management which may increase hospitalisation risk (Murray & Knopman, 2010). Future studies that include serial assessments and long-term follow-ups are needed to confirm the nature and direction of this relation.

Similarly, the observed associations of SCCs with patient-reported outcomes are likely to be bi-directional. The strongest and most consistent associations were found between SCCs and depression, anxiety, and fatigue, consistent with previous research in other patient populations, including cancer, stroke, and Alzheimer's (O'Farrell et al., 2017; Pullens et al., 2010; Rabin et al., 2017; Van Rijsbergen et al., 2014). SCCs often overlap with psychological distress and fatigue and are considered as symptoms of these problems. For example, the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Chalder Fatigue Scale includes items assessing concentration difficulties, memory, and word finding (Cella & Chalder, 2010). The experience of cognitive difficulties or failure in daily living may also increase individuals’ distress and worry about these problems. In addition, individuals with depression and anxiety exhibit attentional biases toward negative information and therefore may be hypersensitive to cognitive failure, resulting in an overreporting of SCCs (Rabin et al., 2017). Future longitudinal studies are required to disentangle whether these mood and fatigue symptoms are the precursors, consequences, or concurrent factors of SCCs.

There is very limited data concerning the relation between objective and subjective cognition in ESRD patients. Overall studies indicated no or weak association between these two assessment methods, yet we found some preliminary evidence that the relationship between SCCs and objective cognition may be domain-specific. For example, one study suggests that SCCs specific to concentration ability (e.g., “I am good at concentrating when reading”) were associated with poorer performance in part B of the Trail-Making Test, which is a measure of attention/concentration and executive function (Jayanti et al., 2016). Studies in the Alzheimer’s disease literature have also found support for the domain-specificity hypothesis of the objective-subjective cognition relation (Farias et al., 2008, 2013) and therefore may be worth replicating in the context of ERSD. Future studies should adopt multi-domain measures of objective and subjective cognition and should align the specific SCC items/domains with the corresponding objective cognitive domain tests (e.g., association between memory complaints and delayed recall task performance).

Nevertheless, there are several reasons why SCCs may not be consistently associated with objective cognition. First, SCCs are reported based on accumulative everyday experience whereas objective tests may only reflect performance in a controlled environment at a single time point (Molinuevo et al., 2017; Rabin et al., 2015, 2017). Second, theories

1
2
3 597 suggest that SCCs may recede as objective cognitive impairments progress due to
4
5 598 anosognosia (Jessen et al., 2014; Morris & Mograbi, 2013; Rabin et al., 2017). The
6
7 599 relationship between subjective and objective cognition may therefore be expected to be
8
9 600 modest and may vary along the course of cognitive decline and renal replacement therapies.
10
11 601 SCCs have been proposed as a more accurate and meaningful measure at preclinical and early
12
13 602 stages of cognitive impairments, whereas objective tests become increasingly sensitive at
14
15 603 advanced stages (Jessen et al., 2014). Relatedly, informant-reports of SCCs may be a useful
16
17 604 alternative to self-reports at stages of established cognitive impairments. In the current
18
19 605 review, we did not identify any study using an informant measure of SCCs, but research has
20
21 606 shown that informant-reports are more closely linked to objective test scores and markers
22
23 607 such as brain atrophy compared to self-reports (Rueda et al., 2015), and may also predict
24
25 608 future progression (Farias et al., 2017). Longitudinal studies assessing objective performance
26
27 609 and self- and informant-reported SCCs at multiple time points are needed to understand the
28
29 610 temporal dynamic relations among various cognitive assessment tools in ESRD patients.
30
31
32

33
34
35 611 It is important to note that the disconnect between subjective ratings and objective
36
37 612 assessments has been shown not just in terms of cognition, but also other symptoms and
38
39 613 functioning outcomes. For example, subjective (e.g., questionnaires) and objective measures
40
41 614 of sleep quality (e.g., polysomnography) are typically weakly associated, yet subjective sleep
42
43 615 complaint remains an essential component of insomnia diagnosis (Savard & Ganz, 2016).
44
45 616 Research has also shown that the intensity of physical symptoms is not always associated
46
47 617 with the meaning that individuals attribute to the symptoms (Petersen et al., 2011) and that
48
49 618 clinical markers of disease severity are not always correlated with individuals' perceptions of
50
51 619 severity (Haverstock & Feldman, 2006). According to Leventhal's Common-Sense Model,
52
53 620 individuals construct meanings or mental representations for their illness or symptoms
54
55 621 (Hagger & Orbell, 2003; Leventhal et al., 1984, 2016). These representations include
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

622 individuals' interpretations and beliefs about illness/symptom identity (i.e.,
623 frequency/severity), as well as perceived causes, anticipated timeline, consequences, and
624 controllability of these illness/symptoms (Leventhal et al., 2016). These representations can
625 appear inconsistent with medical models or clinical indicators, but may determine how
626 patients respond to or cope with the illness/symptoms (Donovan et al., 2008; Hagger &
627 Orbell, 2003; Leventhal et al., 2016). The lack of association between subjective and
628 objective cognition therefore does not necessarily imply that SCCs are inaccurate because
629 SCCs can also be viewed as patients' representations of cognitive failure/lapses which
630 influence their coping or compensatory responses.

631 A key limitation of studies included in this review is the overreliance on the KDQOL-
632 CF measure. The KDQOL-CF contains three items assessing the frequency of slow reaction,
633 concentration difficulties, and confusion in the past four weeks (Kurella et al., 2004). Despite
634 its ease of administration and potential value in clinical settings, KDQOL-CF is limited in its
635 content as it fails to cover domains such as memory and executive function shown to be most
636 impaired in ESRD patients (Joshee et al., 2018; O'Lone et al., 2016). Therefore, the reported
637 prevalence of SCCs are most likely underestimated and the comparison between treatment
638 modalities may fail to capture differences in certain important domains. Additional
639 limitations of the KDQOL-CF include the use of double-barrelled items (e.g., did you have
640 difficulty concentrating or thinking) which may undermine accuracy of responses, and the
641 use of generic/broad wording (e.g., did you become confused) rather than specific items (e.g.,
642 do you have difficulty recalling conversations a few days later) (Rabin et al., 2015). There is
643 hence a need to refine existing or develop new SCC measures specifically for ESRD that
644 capture multiple cognitive domains (in particular memory and executive function) and
645 include specific items that are simple and easy to understand (Rabin et al., 2015).

646 It should be acknowledged that non-English articles and grey literature were excluded
647 from the current review and therefore some relevant papers may have been missed. Also,
648 within the included studies, there was limited information on the severity of SCCs, effect of
649 treatment transitions (i.e., dialysis initiation or return to dialysis after KTx rejection) on
650 SCCs, and associations of SCCs with key outcomes such as treatment adherence, self-care
651 capacity, dementia risk, and mortality. In addition, we were not able to perform meta-
652 analyses for all research questions because data were not always reported in the included
653 studies and there was high heterogeneity in terms of how SCCs and other factors were
654 operationalised. Although study authors were contacted for original data or additional
655 analyses, the response rate was very low.

656 Despite the limitations, we believe that this paper provides a comprehensive overview
657 of current evidence regarding the extent and course of SCCs, as well as factors associated
658 with these complaints in patients living with ESRD. This field of research remains in its
659 infancy since the majority of studies only considered SCCs as a secondary outcome that
660 reflects a subdomain of quality of life or overall symptoms. We call for further research on
661 SCCs in ESRD patients that are well-grounded in relevant theories, utilise longitudinal
662 designs, adopt valid and reliable measures of multiple cognitive domains and symptom
663 representation dimensions, and include both patients and informants. Improving our
664 understanding of SCCs in ESRD patients have important clinical implications because
665 subjective reports may improve the clinical meaningfulness of objective tests and may allow
666 early detection and early intervention for patients with higher risk of progression to objective
667 cognitive impairments.

668

References

Alarcon, J. C., Bunch, A., Ardila, F., Zuñiga, E., Vesga, J. I., Rivera, A., Sánchez, R., & Sanabria, R. M. (2021). Impact of Medium Cut-Off Dialyzers on Patient-Reported Outcomes: COREXH Registry. *Blood Purification*, 50, 110–118. <https://doi.org/10.1159/000508803>

Ali, H., Soliman, K., Mohamed, M. M., Daoud, A., Shafiq, T., Fülöp, T., & Baharani, J. (2020). The effects of dialysis modality choice on cognitive functions in patients with end-stage renal failure: a systematic review and meta-analysis. *International Urology and Nephrology*. <https://doi.org/10.1007/s11255-020-02603-x>

Anees, M., Batool, S., Imtiaz, M., & Ibrahim, M. (2018). Socio-economic factors affecting quality of life of hemodialysis patients and its effects on mortality. *Pakistan Journal of Medical Sciences*, 34(4), 811–816. <https://doi.org/10.12669/pjms.344.15284>

Barotfi, S., Molnar, M. Z., Almasi, C., Kovacs, A. Z., Remport, A., Szeifert, L., Szentkiralyi, A., Vamos, E., Zoller, R., Eremenco, S., Novak, M., & Mucsi, I. (2006). Validation of the Kidney Disease Quality of Life-Short Form questionnaire in kidney transplant patients. *Journal of Psychosomatic Research*, 60, 495–504. <https://doi.org/10.1016/j.jpsychores.2005.09.009>

Bello, A. K., Okpechi, I. G., Osman, M. A., Cho, Y., Htay, H., Jha, V., Wainstein, M., & Johnson, D. W. (2022). Epidemiology of haemodialysis outcomes. *Nature Reviews Nephrology*. <https://doi.org/10.1038/s41581-022-00542-7>

Berger, I., Wu, S., Masson, P., Kelly, P. J., Duthie, F. A., Whiteley, W., Parker, D., Gillespie, D., & Webster, A. C. (2016). Cognition in chronic kidney disease: A systematic review and meta-analysis. *BMC Medicine*, 14, 206. <https://doi.org/10.1186/s12916-016-0745-9>

Boudville, N., Horner, M., McEwan, E., Lim, W. H., Mudge, D. W., & Markus, H. E. (2009). Effect of FX dialysers on systemic inflammation and quality of life in chronic

- haemodialysis patients. *Blood Purification*, 27, 187–193.
<https://doi.org/10.1159/000190786>
- Boudida, B., Rhou, H., Ezaitouni, F., Ouzeddoun, N., Bayahia, R., Elhajji, K., Roudiès, R., Sekkat, F. Z., Razine, R., Abouqal, R., Alghadi, A., Azennoud, A., & Benamar, L. (2014). Translation, cultural adaptation and validation of the kidney disease quality of life-short form 1.3 in an African country. *Transplantation Proceedings*, 46, 1295–1301.
<https://doi.org/10.1016/j.transproceed.2014.02.011>
- Brickman, A. L., Yount, S. E., Blaney, N. T., Rothberg, S., & De-Nour, A. K. (1996). Pathogenesis of cognitive complaints in patients on hemodialysis. *General Hospital Psychiatry*, 18, 36–43. [https://doi.org/10.1016/0163-8343\(95\)00093-3](https://doi.org/10.1016/0163-8343(95)00093-3)
- Brodski, J., Rossell, S. L., Castle, D. J., & Tan, E. J. (2019). A systematic review of cognitive impairments associated with kidney failure in adults before natural age-related changes. *Journal of the International Neuropsychological Society*, 25, 101–114.
<https://doi.org/10.1017/S1355617718000917>
- Broers, N. J. H., Cuijpers, A. C. M., Van Der Sande, F. M., Leunissen, K. M. L., & Kooman, J. P. (2015). The first year on haemodialysis: A critical transition. *Clinical Kidney Journal*, 8, 271–277. <https://doi.org/10.1093/ckj/sfv021>
- Carmichael, P., Popoola, J., John, I., Stevens, P. E., & Carmichael, A. R. (2000). Assessment of quality of life in a single centre dialysis population using the KDQOL-SF(Tm) questionnaire. *Quality of Life Research*, 9, 195–205.
<https://doi.org/10.1023/A:1008933621829>
- Castro, S. S., Leite, C. F., Baldin, J. E., & Accioly, M. F. (2018). Validation of the Brazilian version of WHODAS 2.0 in patients on hemodialysis therapy. *Fisioterapia Em Movimento*, 31, e003130. <https://doi.org/10.1590/1980-5918.031.ao30>
- Cella, M., & Chalder, T. (2010). Measuring fatigue in clinical and community settings.

- Journal of Psychosomatic Research*, 69, 17–22.
<https://doi.org/10.1016/j.jpsychores.2009.10.007>
- Chelune, G. J., Heaton, R. K., & Lehman, R. A. W. (1986). Neuropsychological and Personality Correlates of Patients' Complaints of Disability. In G. Goldstein & R. E. Tarter (Eds.), *Advances in Clinical Neuropsychology* (Vol. 3, pp. 95–126). Springer.
https://doi.org/10.1007/978-1-4613-2211-5_4
- Chen, L., Chen, G., & Kong, X. (2021). Serum level of high mobility group box protein-1 and prognosis of patients with end-stage renal disease on hemodialysis and peritoneal dialysis. *Medicine*, 100(5), e24275. <https://doi.org/10.1097/MD.00000000000024275>
- Cho, M. K., Kim, S. Y., & Shim, H. Y. (2018). Validity and Reliability of the Korean Version of the Dialysis Symptom Index for Hemodialysis Patients. *Journal of Nursing Research*, 26(6), 399–410. <https://doi.org/10.1097/jnr.0000000000000267>
- Chow, S. K. Y., & Wong, F. K. Y. (2010). Health-related quality of life in patients undergoing peritoneal dialysis: Effects of a nurse-led case management programme. *Journal of Advanced Nursing*, 66(8), 1780–1792. <https://doi.org/10.1111/j.1365-2648.2010.05324.x>
- Chrifi Alaoui, A., Touti, W., Al Borgi, Y., Sqalli Houssaini, T., & El Rhazi, K. (2022). Comparison of quality of life in end-stage renal disease patients undergoing hemodialysis and peritoneal dialysis in a Moroccan city. *Seminars in Dialysis*.
<https://doi.org/10.1111/sdi.13034>
- Costa-Requena, G., Cantarell, M. C., Moreso, F., Parramon, G., & Seron, D. (2017). Health related quality of life in renal transplantation: 2 years of longitudinal follow-up. *Medicina Clínica*, 149(3), 114–118. <https://doi.org/10.1016/j.medcle.2017.06.028>
- Crowe, K., Quinn, T. J., Mark, P. B., & Findlay, M. D. (2021). “Is It Removed During Dialysis?”—Cognitive Dysfunction in Advanced Kidney Failure—A Review Article.

- Frontiers in Neurology*, 12, 787370. <https://doi.org/10.3389/fneur.2021.787370>
- Cukor, D., Cohen, S. D., & Kimmel, P. L. (Eds.). (2020). *Psychosocial Aspects of Chronic Kidney Disease: Exploring the Impact of CKD, Dialysis, and Transplantation on Patients* (1st ed.). Academic Press.
- Czyżewski, Ł., Sańko-Resmer, J., Wyzgał, J., & Kurowski, A. (2014). Assessment of health-related quality of life of patients after kidney transplantation in comparison with hemodialysis and peritoneal dialysis. *Annals of Transplantation*, 19, 576–585. <https://doi.org/10.12659/AOT.891265>
- de Oliveira, M. P., Kusumota, L., Marques, S., Ribeiro, R. de C. H. M., Rodrigues, R. A. P., & Haas, V. J. (2012). Work and Health-Related Quality of Life of patients on peritoneal dialysis. *ACTA Paulista de Enfermagem*, 25(3), 352–357. <https://doi.org/10.1590/s0103-21002012000300006>
- Donovan, H. S., Ward, S., Sherwood, P., & Serlin, R. C. (2008). Evaluation of the Symptom Representation Questionnaire (SRQ) for Assessing Cancer-Related Symptoms. *Journal of Pain and Symptom Management*, 35(3), 242–257. <https://doi.org/10.1016/j.jpainsymman.2007.04.017>
- Drew, D. A., Weiner, D. E., & Sarnak, M. J. (2019). Cognitive Impairment in CKD: Pathophysiology, Management, and Prevention. *American Journal of Kidney Diseases*, 74(6), 782–790. <https://doi.org/10.1053/j.ajkd.2019.05.017>
- Drew, D. A., Weiner, D. E., Tighiouart, H., Duncan, S., Gupta, A., Scott, T., & Sarnak, M. J. (2017). Cognitive Decline and Its Risk Factors in Prevalent Hemodialysis Patients. *American Journal of Kidney Diseases*, 69(6), 780–787. <https://doi.org/10.1053/j.ajkd.2016.11.015>
- Duarte, P. S., Ciconelli, R. M., & Sesso, R. (2005). Cultural adaptation and validation of the “Kidney Disease and Quality of Life - Short Form (KDQOL-SF™ 1.3)” in Brazil.

Brazilian Journal of Medical and Biological Research, 38, 261–270.

<https://doi.org/10.1590/S0100-879X2005000200015>

- Duarte, P. S., Miyazaki, M. C., Blay, S. L., & Sesso, R. (2009). Cognitive-behavioral group therapy is an effective treatment for major depression in hemodialysis patients. *Kidney International*, 76, 414–421. <https://doi.org/10.1038/ki.2009.156>
- Eckardt, K.-U., Coresh, J., Devuyst, O., Johnson, R. J., Köttgen, A., Levey, A. S., & Levin, A. (2013). Evolving importance of kidney disease: From subspecialty to global health burden. *The Lancet*, 382, 158–169. [https://doi.org/10.1016/S0140-6736\(13\)60439-0](https://doi.org/10.1016/S0140-6736(13)60439-0)
- Fan, S. S., Lin, L. F., Chen, V. C. H., Hsieh, C. W., Hsiao, H. P., McIntyre, R. S., Iacobucci, M., Coles, A. S., Tsai, D. J., Weng, J. C., & Chen, Y. L. (2020). Effects of Lower Past-Year Serum Sodium and Hyponatremia on Depression Symptoms and Cognitive Impairments in Patients With Hemodialysis. *Therapeutic Apheresis and Dialysis*, 24(2), 169–177. <https://doi.org/10.1111/1744-9987.13395>
- Farias, S. T., Lau, K., Harvey, D., Denny, K. G., Barba, C., & Mefford, A. N. (2017). Early Functional Limitations in Cognitively Normal Older Adults Predict Diagnostic Conversion to Mild Cognitive Impairment. *Journal of the American Geriatrics Society*, 65(6), 1152–1158. <https://doi.org/10.1111/jgs.14835>
- Farias, S. T., Mungas, D., Reed, B. R., Cahn-Weiner, D., Jagust, W., Baynes, K., & DeCarli, C. (2008). The Measurement of Everyday Cognition (ECog): Scale Development and Psychometric Properties. *Neuropsychology*, 22(4), 531–544. <https://doi.org/10.1037/0894-4105.22.4.531>
- Farias, S. T., Park, L. Q., Harvey, D. J., Simon, C., Reed, B. R., Carmichael, O., & Mungas, D. (2013). Everyday Cognition in Older Adults: Associations with Neuropsychological Performance and Structural Brain Imaging. *Journal of the International Neuropsychological Society*, 19(4), 430–441.

<https://doi.org/10.1017/S1355617712001609>

Fleming, G. M. (2011). Renal replacement therapy review: Past, present and future.

Organogenesis, 7(1), 2–12. <https://doi.org/10.4161/org.7.1.13997>

Frimat, L., Durand, P. Y., Loos-Ayav, C., Villar, E., Panescu, V., Briançon, S., & Kessler, M.

(2006). Impact of first dialysis modality on outcome of patients contraindicated for kidney transplant. *Peritoneal Dialysis International*, 26, 231–239.

<https://doi.org/10.1177/089686080602600220>

Fructuoso, M. R., Castro, R., Oliveira, I., Prata, C., & Morgado, T. (2011). Quality of life in chronic kidney disease. *Nefrologia*, 31(1), 91–96.

<https://doi.org/10.3265/Nefrologia.pre2010.Jul.10483>

Goh, Z. S., & Griva, K. (2018). Anxiety and depression in patients with end-stage renal

disease: impact and management challenges – a narrative review. *International Journal of Nephrology and Renovascular Disease*, 11, 93–102.

<https://doi.org/10.2147/IJNRD.S126615>

Gonçalves, F. A., Dalosso, I. F., Borba, J. M. C., Bucaneve, J., Valerio, N. M. P., Okamoto,

C. T., & Bucharles, S. G. E. (2015). Quality of life in chronic renal patients on

hemodialysis or peritoneal dialysis: a comparative study in a referral service of Curitiba

- PR. *Jornal Brasileiro de Nefrologia : 'orgao Oficial de Sociedades Brasileira e*

Latino-Americana de Nefrologia, 37(4), 467–474. <https://doi.org/10.5935/0101->

2800.20150074

Gorodetskaya, I., Zenios, S., McCulloch, C. E., Bostrom, A., Hsu, C. Y., Bindman, A. B.,

Go, A. S., & Chertow, G. M. (2005). Health-related quality of life and estimates of utility in chronic kidney disease. *Kidney International*, 68, 2801–2808.

<https://doi.org/10.1111/j.1523-1755.2005.00752.x>

Griva, K., Stygall, J., Hankins, M., Davenport, A., Harrison, M., & Newman, S. P. (2010).

- Cognitive Impairment and 7-Year Mortality in Dialysis Patients. *American Journal of Kidney Diseases*, 56(4), 693–703. <https://doi.org/10.1053/j.ajkd.2010.07.003>
- Hagger, M. S., & Orbell, S. (2003). A meta-analytic review of the common-sense model of illness representations. *Psychology and Health*, 18(2), 141–184. <https://doi.org/10.1080/088704403100081321>
- Haverstock, C. L., & Feldman, S. R. (2006). Prescribing on the basis of subjective disease severity. *Journal of Dermatological Treatment*, 17, 261.
- Hayashi, A., Yamaguchi, S., Waki, K., Fujiu, K., Hanafusa, N., Nishi, T., Tomita, H., Kobayashi, H., Fujita, H., Kadowaki, T., Nangaku, M., & Ohe, K. (2017). Testing the feasibility and usability of a novel smartphone-based self-management support system for dialysis patients: A pilot study. *JMIR Research Protocols*, 6(4), e63. <https://doi.org/10.2196/resprot.7105>
- Hays, R. D., Kallich, J. D., Mapes, D. L., Coons, S. J., & Carter, W. B. (1994). Development of the Kidney Disease Quality of Life (KDQOL) Instrument. *Quality of Life Research*, 3, 329–338. <https://doi.org/10.1007/BF00451725>
- Hedayati, S. S., & Finkelstein, F. O. (2009). Epidemiology, Diagnosis, and Management of Depression in Patients With CKD. *American Journal of Kidney Diseases*, 54(4), 741–752. <https://doi.org/10.1053/j.ajkd.2009.05.003>
- Henry, S. L., Jamner, L. D., Choi, S. E., & Pahl, M. V. (2018). The effect of the interdialytic interval on cognitive function in patients on haemodialysis. *Journal of Renal Care*, 44(1), 44–51. <https://doi.org/10.1111/jorc.12231>
- Hernández Sánchez, S., Carrero, J. J., Morales, J. S., & Ruiz, J. R. (2021). Effects of a resistance training program in kidney transplant recipients: A randomized controlled trial. *Scandinavian Journal of Medicine and Science in Sports*, 31, 473–479. <https://doi.org/10.1111/sms.13853>

- Himmelfarb, J., Vanholder, R., Mehrotra, R., & Tonelli, M. (2020). The current and future landscape of dialysis. *Nature Reviews Nephrology*, 16, 573–585.
<https://doi.org/10.1038/s41581-020-0315-4>
- Ho, S. E., Ho, C. C. K., Norshazwani, N., Teoh, K. H., Ismail, M. S., Jaafar, M. Z., & Das, S. (2013). Perception of quality of life amongst end stage renal failure patients undergoing haemodialysis. *Clinica Terapeutica*, 164(6), 391–397.
<https://doi.org/10.7417/CT.2013.1627>
- IntHout, J., Ioannidis, J. P. A., Rovers, M. M., & Goeman, J. J. (2016). Plea for routinely presenting prediction intervals in meta-analysis. *BMJ Open*, 6, e010247.
<https://doi.org/10.1136/bmjopen-2015-010247>
- Iyasere, O., Okai, D., & Brown, E. (2017). Cognitive function and advanced kidney disease: longitudinal trends and impact on decision-making. *Clinical Kidney Journal*, 10(1), 89–94. <https://doi.org/10.1093/ckj/sfw128>
- Jassal, S. V., Devins, G. M., Chan, C. T., Bozanovic, R., & Rourke, S. (2006). Improvements in cognition in patients converting from thrice weekly hemodialysis to nocturnal hemodialysis: A longitudinal pilot study. *Kidney International*, 70, 956–962.
<https://doi.org/10.1038/sj.ki.5001691>
- Jayanti, A., Foden, P., Brenchley, P., Wearden, A., & Mitra, S. (2016). The Burden of Cognitive Impairment in Patients With End-Stage Renal Disease and Impact on Dialysis Modality Choice. *Kidney International Reports*, 1, 240–249.
<https://doi.org/10.1016/j.ekir.2016.07.010>
- Jessen, F., Amariglio, R. E., Van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., Van Der Flier, W. M., Glodzik, L., Van Harten, A. C., De Leon, M. J., McHugh, P., Mielke, M. M., Molinuevo, J. L., Mosconi, L., Osorio, R. S., Perrotin, A., ... Wagner, M. (2014). A conceptual framework for research on

- subjective cognitive decline in preclinical Alzheimer's disease. *Alzheimer's and Dementia*, 10(6), 844–852. <https://doi.org/10.1016/j.jalz.2014.01.001>
- Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. Y.-M., & Yang, C.-W. (2013). Chronic kidney disease: Global dimension and perspectives. *The Lancet*, 382, 260–272. [https://doi.org/10.1016/S0140-6736\(13\)60687-X](https://doi.org/10.1016/S0140-6736(13)60687-X)
- Jiao, Y., Gao, S., Wu, L., & Song, A. (2017). Continuity of care for quality of life and clinical outcomes in patients with peritoneal dialysis. *International Journal of Clinical and Experimental Medicine*, 10(12), 16586–16594.
- Joshee, P., Wood, A. G., Wood, E. R., & Grunfeld, E. A. (2018). Meta-analysis of cognitive functioning in patients following kidney transplantation. *Nephrology Dialysis Transplantation*, 33, 1268–1277. <https://doi.org/10.1093/ndt/gfx240>
- Jung, H. Y., Jang, H. M., Kim, Y. W., Cho, S., Kim, H. Y., Kim, S. H., Bang, K., Kim, H. W., Lee, S. Y., Jo, S. K., Lee, J., Choi, J. Y., Cho, J. H., Park, S. H., Kim, C. D., & Kim, Y. L. (2016). Depressive symptoms, patient satisfaction, and quality of life over time in automated and continuous ambulatory peritoneal dialysis patients: a prospective multicenter propensity-matched study. *Medicine*, 95(21), 1–10. <https://doi.org/10.1097/MD.00000000000003795>
- Kang, S. H., Do, J. Y., Lee, S. Y., & Kim, J. C. (2017). Effect of dialysis modality on frailty phenotype, disability, and health-related quality of life in maintenance dialysis patients. *PLoS ONE*, 12(5), e0176814. <https://doi.org/10.1371/journal.pone.0176814>
- Kontodimopoulos, N., & Niakas, D. (2005). Determining the basic psychometric properties of the Greek KDQOL-SF™. *Quality of Life Research*, 14, 1967–1975. <https://doi.org/10.1007/s11136-005-3868-6>
- Korevaar, J. C., Merkus, M. P., Jansen, M. A. M., Dekker, F. W., Boeschoten, E. W., & Krediet, R. T. (2002). Validation of the KDQOL-SF™: A dialysis-targeted health

measure. *Quality of Life Research*, 11, 437–447.

<https://doi.org/10.1023/A:1015631411960>

Kostro, J. Z., Hellmann, A., Kobiela, J., Skóra, I., Lichodziejewska-Niemierko, M., Dębska-Slizień, A., & Sledzinski, Z. (2016). Quality of life after kidney transplantation: A prospective study. *Transplantation Proceedings*, 48, 50–54.

<https://doi.org/10.1016/j.transproceed.2015.10.058>

Kurella, M., Luan, J., Yaffe, K., & Chertow, G. M. (2004). Validation of the Kidney Disease Quality of Life (KDQOL) Cognitive Function subscale. *Kidney International*, 66, 2361–2367. <https://doi.org/10.1111/j.1523-1755.2004.66024.x>

Kurella, M., Mapes, D. L., Port, F. K., & Chertow, G. M. (2006). Correlates and outcomes of dementia among dialysis patients: The dialysis outcomes and practice patterns study. *Nephrology Dialysis Transplantation*, 21, 2543–2548. <https://doi.org/10.1093/ndt/gfl275>

Kurella Tamura, M., Vittinghoff, E., Hsu, C., Tam, K., Seliger, S. L., Sozio, S., Fischer, M., Chen, J., Lustigova, E., Strauss, L., Deo, R., Go, A. S., & Yaffe, K. (2017). Loss of executive function after dialysis initiation in adults with chronic kidney disease. *Kidney International*, 91, 948–953. <https://doi.org/10.1016/j.kint.2016.11.015>

Kutner, N. G., Zhang, R., Barnhart, H., & Collins, A. J. (2005). Health status and quality of life reported by incident patients after 1 year on haemodialysis or peritoneal dialysis. *Nephrology Dialysis Transplantation*, 20, 2159–2167.

<https://doi.org/10.1093/ndt/gfh973>

Kutner, N. G., Zhang, R., & Brogan, D. (2005). Race, gender, and incident dialysis patients' reported health status and quality of life. *Journal of the American Society of Nephrology*, 16, 1440–1448. <https://doi.org/10.1681/ASN.2004080639>

Kutner, N. G., Zhang, R., Huang, Y., & Bliwise, D. L. (2007). Association of sleep difficulty with kidney disease quality of life cognitive function score reported by patients who

- recently started dialysis. *Clinical Journal of the American Society of Nephrology*, 2, 284–289. <https://doi.org/10.2215/CJN.03000906>
- Lee, A. J., Morgan, C. L., Conway, P., & Currie, C. J. (2005). Characterisation and comparison of health-related quality of life for patients with renal failure. *Current Medical Research and Opinion*, 21(11), 1777–1783. <https://doi.org/10.1185/030079905X65277>
- Lee, Y. C., Kang, J. M., Lee, H., Kim, K., Kim, S., Yu, T. Y., Lee, E. M., Kim, C. T., Kim, D. K., Lewis, M., Won, H. H., Jessen, F., & Myung, W. (2020). Subjective cognitive decline and subsequent dementia: a nationwide cohort study of 579,710 people aged 66 years in South Korea. *Alzheimer's Research and Therapy*, 12, 52. <https://doi.org/10.1186/s13195-020-00618-1>
- Leventhal, H., Nerenz, D. R., & Steele, D. J. (1984). Illness Representations and Coping with Health Threats. In A. Baum, S. E. Taylor, & J. E. Singer (Eds.), *Handbook of Psychology and Health, Volume IV: Social Psychological Aspects of Health* (pp. 219–252). Erlbaum.
- Leventhal, H., Phillips, L. A., & Burns, E. (2016). The Common-Sense Model of Self-Regulation (CSM): a dynamic framework for understanding illness self-management. *Journal of Behavioral Medicine*, 39, 935–946. <https://doi.org/10.1007/s10865-016-9782-2>
- Levey, A. S., & Coresh, J. (2012). Chronic kidney disease. *The Lancet*, 379, 165–180. [https://doi.org/10.1016/S0140-6736\(11\)60178-5](https://doi.org/10.1016/S0140-6736(11)60178-5)
- Levey, A. S., Stevens, L. A., & Coresh, J. (2009). Conceptual Model of CKD: Applications and Implications. *American Journal of Kidney Diseases*, 53(3 SUPPL. 3), S4–S16. <https://doi.org/10.1053/j.ajkd.2008.07.048>
- Li, J., Wang, H., Xie, H., Mei, G., Cai, W., Ye, J., Zhang, J., Ye, G., & Zhai, H. (2014).

- Effects of post-discharge nurse-led telephone supportive care for patients with chronic kidney disease undergoing peritoneal dialysis in China: A randomized controlled trial. *Peritoneal Dialysis International*, 34, 278–288. <https://doi.org/10.3747/pdi.2012.00268>
- Liew, T. M. (2020a). Subjective cognitive decline, anxiety symptoms, and the risk of mild cognitive impairment and dementia. *Alzheimer's Research and Therapy*, 12, 107. <https://doi.org/10.1186/s13195-020-00699-y>
- Liew, T. M. (2020b). Trajectories of subjective cognitive decline, and the risk of mild cognitive impairment and dementia. *Alzheimer's Research and Therapy*, 12, 135. <https://doi.org/10.1186/s13195-020-00699-y>
- Lin, J. (2009). Is searching full text more effective than searching abstracts? *BMC Bioinformatics*, 10, 46. <https://doi.org/10.1186/1471-2105-10-46>
- Lo, C., Li, L., Lo, W., Chan, M., So, E., Tang, S., Yuen, M., Cheng, I. K. P., & Chan, T. (1998). Benefits of exercise training in patients on continuous ambulatory peritoneal dialysis. *American Journal of Kidney Diseases*, 32(6), 1011–1018. [https://doi.org/10.1016/S0272-6386\(98\)70076-9](https://doi.org/10.1016/S0272-6386(98)70076-9)
- Lønning, K., Heldal, K., Bernklev, T., Brunborg, C., Andersen, M. H., Von Der Lippe, N., Reisæter, A. V., Line, P. D., Hartmann, A., & Midtvedt, K. (2018). Improved health-related quality of life in older kidney recipients 1 year after transplantation. *Transplantation Direct*, 4(4), e351. <https://doi.org/10.1097/TXD.0000000000000770>
- Lopes, A. A., Bragg-Gresham, J. L., Goodkin, D. A., Fukuhara, S., Mapes, D. L., Young, E. W., Gillespie, B. W., Akizawa, T., Greenwood, R. N., Andreucci, V. E., Akiba, T., Held, P. J., & Port, F. K. (2007). Factors associated with health-related quality of life among hemodialysis patients in the DOPPS. *Quality of Life Research*, 16, 545–557. <https://doi.org/10.1007/s11136-006-9143-7>
- Lopes, A. A., Bragg-Gresham, J. L., Satayathum, S., McCullough, K., Pifer, T., Goodkin, D.

- A., Mapes, D. L., Young, E. W., Wolfe, R. A., Held, P. J., & Port, F. K. (2003). Health-related quality of life and associated outcomes among hemodialysis patients of different ethnicities in the United States: The dialysis outcomes and practice patterns study (DOPPS). *American Journal of Kidney Diseases*, 41(3), 605–615.
<https://doi.org/10.1053/ajkd.2003.50122>
- Lopes, L. C. C., Mota, J. F., Prestes, J., Schincaglia, R. M., Silva, D. M., Queiroz, N. P., Freitas, A. T. V. de S., Lira, F. S., & Peixoto, M. do R. G. (2019). Intradialytic Resistance Training Improves Functional Capacity and Lean Mass Gain in Individuals on Hemodialysis: A Randomized Pilot Trial. *Archives of Physical Medicine and Rehabilitation*, 100(11), 2151–2158. <https://doi.org/10.1016/j.apmr.2019.06.006>
- Ma, L. L., Wang, Y. Y., Yang, Z. H., Huang, D., Weng, H., & Zeng, X. T. (2020). Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: What are they and which is better? *Military Medical Research*, 7, 7.
<https://doi.org/10.1186/s40779-020-00238-8>
- Malekmakan, L., Roozbeh, J., Zonnoor, S. L., Azadian, F., Sayadi, M., & Tadayoni, A. (2016). The Comparison of Quality of Life among Peritoneal and Hemodialysis Patients. *International Journal of Medical Research & Health Science*, 5(4), 127–132.
- Manavalan, M., Majumdar, A., Harichandra Kumar, K. T., & Priyamvada, P. S. (2017). Assessment of health-related quality of life and its determinants in patients with chronic kidney disease. *Indian Journal of Nephrology*, 27, 37–43. <https://doi.org/10.4103/0971-4065.179205>
- Mapes, D. L., Lopes, A. A., Satayathum, S., McCullough, K. P., Goodkin, D. A., Locatelli, F., Fukuhara, S., Young, E. W., Kurokawa, K., Saito, A., Bommer, J., Wolfe, R. A., Held, P. J., & Port, F. K. (2003). Health-related quality of life as a predictor of mortality and hospitalization: The dialysis outcomes and practice patterns study (DOPPS). *Kidney*

- International*, 64, 339–349. <https://doi.org/10.1046/j.1523-1755.2003.00072.x>
- Mathews, S. B., Arnold, S. E., & Epperson, C. N. (2014). Hospitalization and cognitive decline: Can the nature of the relationship be deciphered? *American Journal of Geriatric Psychiatry*, 22(5), 465–480. <https://doi.org/10.1016/j.jagp.2012.08.012>
- Maynard, L. G., De Menezes, D. L., Lião, N. S., De Jesus, E. M., Andrade, N. L. S., Santos, J. C. D., Da Silva Júnior, W. M., Bastos, K. D. A., & Barreto Filho, J. A. S. (2019). Effects of Exercise Training Combined with Virtual Reality in Functionality and Health-Related Quality of Life of Patients on Hemodialysis. *Games for Health Journal*, 8(5), 339–348. <https://doi.org/10.1089/g4h.2018.0066>
- Mazairac, A. H. A., de Wit, G. A., Grooteman, M. P. C., Penne, E. L., van der Weerd, N. C., den Hoedt, C. H., Lévesque, R., van den Dorpel, M. A., Nubé, M. J., ter Wee, P. M., Bots, M. L., & Blankestijn, P. J. (2013). Effect of hemodiafiltration on quality of life over time. *Clinical Journal of the American Society of Nephrology*, 8, 82–89. <https://doi.org/10.2215/CJN.00010112>
- Mazancieux, A., Souchay, C., Casez, O., & Moulin, C. J. A. (2019). Metacognition and self-awareness in Multiple Sclerosis. *Cortex*, 111, 238–255. <https://doi.org/10.1016/j.cortex.2018.11.012>
- McAdams-DeMarco, M. A., Olorundare, I. O., Ying, H., Warsame, F., Haugen, C. E., Hall, R., Garonzik-Wang, J. M., Desai, N. M., Walston, J. D., Norman, S. P., & Segev, D. L. (2018). Frailty and Postkidney Transplant Health-Related Quality of Life. *Transplantation*, 102(2), 291–299. <https://doi.org/10.1097/TP.0000000000001943>
- Mendonça, M. D., Alves, L., & Bugalho, P. (2015). From Subjective Cognitive Complaints to Dementia: Who Is at Risk?: A Systematic Review. *American Journal of Alzheimer's Disease and Other Dementias*, 31(2), 105–114. <https://doi.org/10.1177/1533317515592331>

- 1
2
3 Michels, W. M., van Dijk, S., Verduijn, M., le Cessie, S., Boeschoten, E. W., Dekker, F. W.,
4
5 & Krediet, R. T. (2011). Quality of life in automated and continuous ambulatory
6
7 peritoneal dialysis. *Peritoneal Dialysis International*, 31(2), 138–147.
8
9 <https://doi.org/10.3747/PDI.2010.00063>
10
11
12 Mitchell, A. J., Beaumont, H., Ferguson, D., Yadegarfar, M., & Stubbs, B. (2014). Risk of
13
14 dementia and mild cognitive impairment in older people with subjective memory
15
16 complaints: meta-analysis. *Acta Psychiatrica Scandinavica*, 130(6), 439–451.
17
18 <https://doi.org/10.1111/acps.12336>
19
20
21 Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group. (2009). Preferred
22
23 reporting items for systematic reviews and meta-analyses: The PRISMA statement.
24
25 *Journal of Clinical Epidemiology*, 62, 1006–1012.
26
27 <https://doi.org/10.3736/jcim20090918>
28
29
30 Molinuevo, J. L., Rabin, L. A., Amariglio, R., Buckley, R., Dubois, B., Ellis, K. A., Ewers,
31
32 M., Hampel, H., Klöppel, S., Rami, L., Reisberg, B., Saykin, A. J., Sikkes, S., Smart, C.
33
34 M., Snitz, B. E., Sperling, R., van der Flier, W. M., Wagner, M., & Jessen, F. (2017).
35
36 Implementation of subjective cognitive decline criteria in research studies. *Alzheimer's*
37
38 *and Dementia*, 13(3), 296–311. <https://doi.org/10.1016/j.jalz.2016.09.012>
39
40
41
42 Molsted, S., Prescott, L., Heaf, J., & Eidemak, I. (2007). Assessment and clinical aspects of
43
44 health-related quality of life in dialysis patients and patients with chronic kidney disease.
45
46 *Nephron - Clinical Practice*, 106, c24–c33. <https://doi.org/10.1159/000101481>
47
48
49 Moons, P., Goossens, E., & Thompson, D. R. (2021). Rapid reviews: the pros and cons of an
50
51 accelerated review process. *European Journal of Cardiovascular Nursing*, 20, 515–519.
52
53 <https://doi.org/10.1093/eurjcn/zvab041>
54
55
56 Morris, R. G., & Mograbi, D. C. (2013). Anosognosia, autobiographical memory and self
57
58 knowledge in Alzheimer's disease. *Cortex*, 49, 1553–1565.
59
60

<https://doi.org/10.1016/j.cortex.2012.09.006>

Murray, A. M. (2008). Cognitive Impairment in the Aging Dialysis and Chronic Kidney Disease Populations: an Occult Burden. *Advances in Chronic Kidney Disease*, 15(2), 123–132.

Murray, A. M., & Knopman, D. S. (2010). Cognitive impairment in CKD: No longer an occult burden. *American Journal of Kidney Diseases*, 56(4), 615–618.

<https://doi.org/10.1053/j.ajkd.2010.08.003>

Murray, A. M., Tupper, D. E., Knopman, D. S., Gilbertson, D. T., Pederson, S. L., Li, S., Smith, G. E., Hochhalter, A. K., Collins, A. J., & Kane, R. L. (2006). Cognitive impairment in hemodialysis patients is common. *Neurology*, 67, 216–223.

Neto, A. S., & Nitrini, R. (2016). Subjective cognitive decline: The first clinical manifestation of Alzheimer's disease? *Dementia and Neuropsychologia*, 10(3), 170–177. <https://doi.org/10.1590/s1980-5764-2016dn1003002>

Neumann, D., Mau, W., Wienke, A., & Girndt, M. (2018). Peritoneal dialysis is associated with better cognitive function than hemodialysis over a one-year course. *Kidney International*, 93, 430–438. <https://doi.org/10.1016/j.kint.2017.07.022>

O'Farrell, E., Smith, A., & Collins, B. (2017). Objective–subjective disparity in cancer-related cognitive impairment: does the use of change measures help reconcile the difference? *Psycho-Oncology*, 26, 1667–1674.

O'Lone, E., Connors, M., Masson, P., Wu, S., Kelly, P. J., Gillespie, D., Parker, D., Whiteley, W., Strippoli, G. F. M., Palmer, S. C., Craig, J. C., & Webster, A. C. (2016). Cognition in people with end-stage kidney disease treated with hemodialysis: A systematic review and meta-analysis. *American Journal of Kidney Diseases*, 67(6), 925–935. <https://doi.org/10.1053/j.ajkd.2015.12.028>

Okpechi, I. G., Nthite, T., & Swanepoel, C. R. (2013). Health-related quality of life in

- patients on hemodialysis and peritoneal dialysis. *Saudi Journal of Kidney Diseases and Transplantation*, 24(3), 519–526. <https://doi.org/10.4103/1319-2442.111036>
- Ortega, T., Valdés, C., Rebollo, P., & Ortega, F. (2007). Evaluation of reliability and validity of Spanish version of the end-stage renal disease symptom checklist-transplantation module. *Transplantation*, 84(11), 1428–1435. <https://doi.org/10.1097/01.tp.0000290231.39240.df>
- Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., ... Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*, 372, n71. <https://doi.org/10.1136/bmj.n71>
- Painter, P., Krasnoff, J. B., Kuskowski, M., Frassetto, L., & Johansen, K. (2012). Effects of modality change on health-related quality of life. *Hemodialysis International*, 16(3), 377–386. <https://doi.org/10.1111/j.1542-4758.2012.00676.x>
- Peipert, J. D., Caicedo, J. C., Friedewald, J. J., Abecassis, M. M. I., Cella, D., Ladner, D. P., & Butt, Z. (2020). Trends and predictors of multidimensional health-related quality of life after living donor kidney transplantation. *Quality of Life Research*, 29(9), 2355–2374. <https://doi.org/10.1007/s11136-020-02498-2>
- Penning de Vries, B. B. L., van Smeden, M., Rosendaal, F. R., & Groenwold, R. H. H. (2020). Title, abstract, and keyword searching resulted in poor recovery of articles in systematic reviews of epidemiologic practice. *Journal of Clinical Epidemiology*, 121, 55–61. <https://doi.org/10.1016/j.jclinepi.2020.01.009>
- Petersen, S., van den Berg, R. A., Janssens, T., & Van den Bergh, O. (2011). Illness and symptom perception: A theoretical approach towards an integrative measurement model. *Clinical Psychology Review*, 31, 428–439. <https://doi.org/10.1016/j.cpr.2010.11.002>

- Poulsen, C. G., Kjaergaard, K. D., Peters, C. D., Jespersen, B., & Jensen, J. D. (2017). Quality of life development during initial hemodialysis therapy and association with loss of residual renal function. *Hemodialysis International*, 21, 409–421. <https://doi.org/10.1111/hdi.12505>
- Pullens, M. J. J., De Vries, J., & Roukema, J. A. (2010). Subjective cognitive dysfunction in breast cancer patients: A systematic review. *Psycho-Oncology*, 19, 1127–1138. <https://doi.org/10.1002/pon.1673>
- R Core Team. (2018). *R: A language and environment for statistical computing*. R Foundation for Statistical Computing. <https://www.r-project.org/>
- Rabin, L. A., Smart, C. M., & Amariglio, R. E. (2017). Subjective Cognitive Decline in Preclinical Alzheimer's Disease. *Annual Review of Clinical Psychology*, 13, 369–396. <https://doi.org/10.1146/annurev-clinpsy-032816-045136>
- Rabin, L. A., Smart, C. M., Crane, P. K., Amariglio, R. E., Berman, L. M., Boada, M., Buckley, R. F., Chételat, G., Dubois, B., Ellis, K. A., Gifford, K. A., Jefferson, A. L., Jessen, F., Katz, M. J., Lipton, R. B., Luck, T., Maruff, P., Mielke, M. M., Molinuevo, J. L., ... Sikkes, S. A. M. (2015). Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. *Journal of Alzheimer's Disease*, 48, S63–S86. <https://doi.org/10.3233/JAD-150154>
- Rajkumar, T., Mazid, S., Vucak-Dzumhur, M., Sykes, T. M., & Elder, G. J. (2019). Health-related quality of life following kidney and simultaneous pancreas kidney transplantation. *Nephrology*, 24, 975–982. <https://doi.org/10.1111/nep.13523>
- Rebollo Rubio, A., Morales Asencio, J. M., & Eugenia Pons Raventos, M. (2017). Depression, anxiety and health-related quality of life amongst patients who are starting dialysis treatment. *Journal of Renal Care*, 43(2), 73–82. <https://doi.org/10.1111/jorc.12195>

- Rueda, A. D., Lau, K. M., Saito, N., Harvey, D., Risacher, S. L., Aisen, P. S., Petersen, R. C., Saykin, A. J., & Farias, S. T. (2015). Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease. *Alzheimer's and Dementia*, 11(9), 1080–1089. <https://doi.org/10.1016/j.jalz.2014.09.002>
- Ryu, J. H., Koo, T. Y., Ro, H., Cho, J. H., Kim, M. G., Huh, K. H., Park, J. B., Lee, S., Han, S., Kim, J., Oh, K. H., & Yang, J. (2021). Better health-related quality of life in kidney transplant patients compared to chronic kidney disease patients with similar renal function. *PLoS ONE*, 16(10), e0257981. <https://doi.org/10.1371/journal.pone.0257981>
- San, A., Hiremagalur, B., Muircroft, W., & Grealish, L. (2017). Screening of Cognitive Impairment in the Dialysis Population: A Scoping Review. *Dementia and Geriatric Cognitive Disorders*, 44, 182–195. <https://doi.org/10.1159/000479679>
- Savard, J., & Ganz, P. A. (2016). Subjective or Objective Measures of Cognitive Functioning-What's More Important? *JAMA Oncology*, 2(10), 1263–1264. <https://doi.org/10.1001/jamaoncol.2016.2047>
- Sawinski, D., & Poggio, E. D. (2021). Introduction to kidney transplantation: Long-term management challenges. *Clinical Journal of the American Society of Nephrology*, 16, 1262–1263. <https://doi.org/10.2215/CJN.13440820>
- Scott, M. K., Shah, N. A., Vilay, A. M., Thomas, J., Kraus, M. A., & Mueller, B. A. (2009). Effects of Peridialytic Oral Supplements on Nutritional Status and Quality of Life in Chronic Hemodialysis Patients. *Journal of Renal Nutrition*, 19(2), 145–152. <https://doi.org/10.1053/j.jrn.2008.08.004>
- Sehgal, A. R., Grey, S. F., DeOreo, P. B., & Whitehouse, P. J. (1997). Prevalence, recognition, and implications of mental impairment among hemodialysis patients. *American Journal of Kidney Diseases*, 30(1), 41–49. [https://doi.org/10.1016/S0272-6386\(97\)90563-1](https://doi.org/10.1016/S0272-6386(97)90563-1)

- Shahnavazi, M., Parsa-Yekta, Z., Yekaninejad, M. S., Amaniyan, S., Griffiths, P., & Vaismoradi, M. (2018). The effect of the emotional intelligence education programme on quality of life in haemodialysis patients. *Applied Nursing Research*, 39, 18–25. <https://doi.org/10.1016/j.apnr.2017.10.017>
- Shea, Y. fung, Lee, M. suen C., Mok, M. yee M., Chan, F. H. wai, & Chan, T. M. (2019). Prevalence of cognitive impairment among peritoneal dialysis patients: a systematic review and meta-analysis. *Clinical and Experimental Nephrology*, 23, 1221–1234. <https://doi.org/10.1007/s10157-019-01762-1>
- Simic-Ogrizovic, S., Jemcov, T., Pejanovic, S., Stosovic, M., Radovic, M., & Djukanovic, L. (2009). Health-related quality of life, treatment efficacy, and hemodialysis patient outcome. *Renal Failure*, 31, 201–206. <https://doi.org/10.1080/08860220802669842>
- Soares, V., Oliveira-Silva, I., Silva, M. S., Venâncio, P. E. M., Oliveira, L. V. F., Lima, W. A., Júnior, J. T., Tolentino, G. P., & Bizinotto, T. (2017). Inspiratory muscle training improves strength and health-related quality of life in hemodialysis patients. *Manual Therapy, Posturology & Rehabilitation Journal*, 15, 506. <https://doi.org/10.17784/mtprehabjournal.2017.15.506>
- Song, M.-K., Paul, S., Ward, S. E., Gilet, C. A., & Hladik, G. A. (2018). One-Year Linear Trajectories of Symptoms, Physical Functioning, Cognitive Functioning, Emotional Well-being, and Spiritual Well-being Among Patients Receiving Dialysis. *American Journal of Kidney Diseases*, 72(2), 198–204. <https://doi.org/10.1053/j.ajkd.2017.11.016>
- Song, M.-K., Ward, S. E., Bair, E., Weiner, L. J., Bridgman, J. C., Hladik, G. A., & Gilet, C. A. (2015). Patient-reported cognitive functioning and daily functioning in chronic dialysis patients. *Hemodialysis International*, 19, 90–99. <https://doi.org/10.1111/hdi.12202>
- Sorensen, E. P., Sarnak, M. J., Tighiouart, H., Scott, T., Giang, L. M., Kirkpatrick, B., Lou,

- K., & Weiner, D. E. (2012). The Kidney Disease Quality of Life Cognitive Function subscale and cognitive performance in maintenance hemodialysis patients. *American Journal of Kidney Diseases*, 60(3), 417–426. <https://doi.org/10.1053/j.ajkd.2011.12.029>
- Tanaka, M., Ishibashi, Y., Hamasaki, Y., Kamijo, Y., Idei, M., Kawahara, T., Nishi, T., Takeda, M., Nonaka, H., Nangaku, M., & Mise, N. (2020). Health-related quality of life on combination therapy with peritoneal dialysis and hemodialysis in comparison with hemodialysis and peritoneal dialysis: A cross-sectional study. *Peritoneal Dialysis International*, 40(5), 462–469. <https://doi.org/10.1177/0896860819894066>
- Tannor, E. K., Archer, E., Kapembwa, K., Van Schalkwyk, S. C., & Davids, M. R. (2017). Quality of life in patients on chronic dialysis in South Africa: A comparative mixed methods study. *BMC Nephrology*, 18, 4. <https://doi.org/10.1186/s12882-016-0425-1>
- Tian, X., Guo, X., Xia, X., Yu, H., Li, X., & Jiang, A. (2019). The comparison of cognitive function and risk of dementia in CKD patients under peritoneal dialysis and hemodialysis: A PRISMA-compliant systematic review and meta-analysis. *Medicine*, 98(6), e14390. <https://doi.org/10.1097/md.00000000000014390>
- Tsarpali, V., Midtvedt, K., Lønning, K., Bernklev, T., Lippe, N. von der, Reisæter, A. V., Brunborg, C., & Heldal, K. (2021). Health-Related Quality of Life in Older Kidney Transplant Recipients: A National Cohort Study of Short- and Longer-Term Outcomes. *Kidney Medicine*, 3(6), 974–983. <https://doi.org/10.1016/j.xkme.2021.05.007>
- Türk, İ., Ateş, K., & Bıyıklı, Z. (2020). Quality of life and associated factors in hemodialysis and peritoneal dialysis patients. *Cukurova Medical Journal*, 45(1), 79–88. <https://doi.org/10.17826/cumj.628274>
- Uchiyama, K., Washida, N., Morimoto, K., Muraoka, K., Kasai, T., Yamaki, K., Miyashita, K., Wakino, S., & Itoh, H. (2019). Home-based Aerobic Exercise and Resistance Training in Peritoneal Dialysis Patients: A Randomized Controlled Trial. *Scientific*

- Reports*, 9, 2632. <https://doi.org/10.1038/s41598-019-39074-9>
- Unruh, M. L., Benz, R., Greene, T., Yan, G., Beddhu, S., DeVita, M., Dwyer, J. T., Kimmel, P. L., Kusek, J. W., Martin, A., Rehm-McGillicuddy, J., Teehan, B. P., & Meyer, K. B. (2004). Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. *Kidney International*, 66, 355–366.
- Vadakedath, S., & Kandi, V. (2017). Dialysis: A Review of the Mechanisms Underlying Complications in the Management of Chronic Renal Failure. *Cureus*, 9(8), e1603. <https://doi.org/10.7759/cureus.1603>
- Van Rijnsbergen, M. W. A., Mark, R. E., De Kort, P. L. M., & Sitskoorn, M. M. (2014). Subjective cognitive complaints after stroke: A systematic review. *Journal of Stroke and Cerebrovascular Diseases*, 23(3), 408–420. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.05.003>
- Vanderlinden, J. A., Ross-White, A., Holden, R., Shamseddin, M. K., Day, A., & Boyd, J. G. (2019). Quantifying cognitive dysfunction across the spectrum of end-stage kidney disease: A systematic review and meta-analysis. *Nephrology*, 24, 5–16. <https://doi.org/10.1111/nep.13448>
- Vázquez, I., Valderrábano, F., Fort, J., Jofré, R., López-Gómez, J. M., Moreno, F., & Sanz-Guajardo, D. (2005). Psychosocial factors and health-related quality of life in hemodialysis patients. *Quality of Life Research*, 14, 179–190. <https://doi.org/10.1007/s11136-004-3919-4>
- Viechtbauer, W. (2010). Conducting meta-analyses in R with the metafor. *Journal of Statistical Software*, 36(3), 1–48. <https://doi.org/10.18637/jss.v036.i03>
- Viggiano, D., Wagner, C. A., Martino, G., Nedergaard, M., Zoccali, C., Unwin, R., & Capasso, G. (2020). Mechanisms of cognitive dysfunction in CKD. *Nature Reviews Nephrology*, 16, 452–469. <https://doi.org/10.1038/s41581-020-0266-9>

- Weisbord, S. D., Fried, L. F., Arnold, R. M., Rotondi, A. J., Fine, M. J., Levenson, D. J., & Switzer, G. E. (2004). Development of a symptom assessment instrument for chronic hemodialysis patients: The dialysis symptom index. *Journal of Pain and Symptom Management*, 27(3), 226–240. <https://doi.org/10.1016/j.jpainsymman.2003.07.004>
- Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. O., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., Arai, H., Basun, H., Blennow, K., De Leon, M., Decarli, C., Erkinjuntti, T., Giacobini, E., Graff, C., Hardy, J., ... Petersen, R. C. (2004). Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. *Journal of Internal Medicine*, 256, 240–246. <https://doi.org/10.1111/j.1365-2796.2004.01380.x>
- Wolfgram, D. F. (2018). Filtering the Evidence: Is There a Cognitive Cost of Hemodialysis? *Journal of the American Society of Nephrology*, 29, 1087–1089. <https://doi.org/10.1681/ASN.2018010077>
- Wong, F. K. Y., Chow, S. K. Y., & Chan, T. M. F. (2010). Evaluation of a nurse-led disease management programme for chronic kidney disease: A randomized controlled trial. *International Journal of Nursing Studies*, 47, 268–278. <https://doi.org/10.1016/j.ijnurstu.2009.07.001>
- Wright, L. S., & Wilson, L. (2015). Quality of Life and Self-Efficacy in Three Dialysis Modalities: Incenter Hemodialysis, Home Hemodialysis, and Home Peritoneal Dialysis. *Nephrology Nursing Journal : Journal of the American Nephrology Nurses' Association*, 42(5), 463–477.
- Wu, Y., He, Q., Yin, X., He, Q., Cao, S., & Ying, G. (2014). Effect of individualized exercise during maintenance haemodialysis on exercise capacity and health-related quality of life in patients with uraemia. *Journal of International Medical Research*, 42(3), 718–727. <https://doi.org/10.1177/0300060513509037>

- Zhang, K., Hannan, E., Scholes-Robertson, N., Baumgart, A., Guha, C., Kerklaan, J.,
Hanson, C. S., Craig, J. C., Davison, S. N., Hecking, M., & Tong, A. (2020). Patients'
perspectives of pain in dialysis: systematic review and thematic synthesis of qualitative
studies. *Pain*, 161(9), 1983–1994. <https://doi.org/10.1097/j.pain.0000000000001931>
- Zhang, Y., Yang, Z., Wang, J., Xiong, Z., Liao, J., Hao, L., Liu, G., Ren, Y., Wang, Q.,
Duan, L., Zheng, Z., & Dong, J. (2018). Cognitive Changes in Peritoneal Dialysis
Patients: A Multicenter Prospective Cohort Study. *American Journal of Kidney
Diseases*, 72(5), 691–700. <https://doi.org/10.1053/j.ajkd.2018.04.020>
- Zheng, Z., Chen, J., He, D., Xu, Y., Chen, L., & Zhang, T. (2019). The effects of megestrol
acetate on nutrition, inflammation and quality of life in elderly haemodialysis patients.
International Urology and Nephrology, 51(9), 1631–1638.
<https://doi.org/10.1007/s11255-019-02245-8>
- Zubair, U. Bin, & Butt, B. (2017). Association Of Quality Of Sleep With Cognitive Decline
Among The Patients Of Chronic Kidney Disease Undergoing Haemodialysis. *Journal of
Ayub Medical College, Abbottabad : JAMC*, 29(4), 619–622.

Table 1. *Measures used to assess SCCs in ESRD patients.*

Measures	No. of Items	Recall Period	Response Format	Measurement Dimensions	Content Dimensions	Frequency of Use
<i>SCC-specific measures</i>						
Brief Metacognition Questionnaire	9	N/A	5-point Likert - Strongly disagree - Disagree - Neither agree nor disagree - Agree - Strongly agree	Severity of SCCs	1. Memory 2. Concentration	1
British Columbia Cognitive Complaints Inventory (BC-CCI)	6	Past 7 days	4-point Likert - Not at all - Some - Quite a bit - Very much	Severity of SCCs	1. Memory 2. Concentration 3. Thought Expression 4. Word Finding 5. Thinking Speed 6. Problem Solving	1
Cognitive Difficulties Scale (CDS)	39	Past month	5-point Likert - Not at all - Rarely - Sometimes - Often - Very often	Frequency of SCCs	1. Attention & Concentration 2. Praxis 3. Prospective Memory 4. Speech 5. People's Names 6. Temporal Orientation	1

Measures	No. of Items	Recall Period	Response Format	Measurement Dimensions	Content Dimensions	Frequency of Use
Henry et al., 2017	4	Current	Smartphone-based electronic diary reports (6 times/day for a week) with 6-point Likert - None of the time - A little of the time - Some of the time - A good bit of the time - Most of the time - All of the time	Frequency of SCCs	1. Reaction time 2. Concentration & Thinking 3. Confusion 4. Decision Making	1
Patient's Assessment of Own Functioning Inventory (PAOFI)	33	Recent	6-point Likert - Almost always - Very often - Fairly often - Once in a while - Very infrequently - Almost never	Frequency of SCCs Change in SCCs	1. Memory 2. Language & Communication 3. Use of Hands 4. Sensory-Perceptual 5. Higher Level Cognitive & Intellectual Functions	3
Perceived Deficits Questionnaire 5-item version (PDQ-5)	5	Past 7 days	5-point Likert - Never - Rarely - Sometimes - Often - Almost always	Frequency of SCCs	1. Attention 2. Retrospective memory 3. Prospective memory 4. Planning & Organization	1

1						
2						
3						
4	Measures	No. of	Recall Period	Response Format	Measurement	Frequency of
5		Items			Dimensions	Use
6	Composite measures with SCC subscale					
7						
8				Yes/No;		
9				5-point Likert		
10				- Not at all bothersome	Presence of	
11	Dialysis Symptom	1	Past 7 days	- A little bothersome	SCCs	2
12	Index (DSI)			- Somewhat bothersome	Severity of	
13				- Quite bothersome	SCCs	
14				- Very bothersome		
15						
16						
17	End-Stage Renal			5-point Likert		
18	Disease Symptom	5	N/A	- 0 = Not at all	Severity of	1
19	Checklist (ESRD-			- 4 = Extremely	SCCs	
20	SCL)					
21						
22						
23				6 levels ranging from "Able to		
24	Health Utilities			remember most things, think clearly		
25	Index Mark 3	1	N/A	and solve day to day problems." to	Severity of	1
26	(HUI3)			"Unable to remember anything at all,	SCCs	
27				and unable to think or solve day to		
28				day problems."		
29						
30						
31				6-point Likert		
32				- None of the time		
33				- A little of the time		
34	Kidney Disease			- Some of the time	Frequency of	
35	Quality of Life	3	Past 4 weeks	- A good bit of the time	SCCs	207
36	(KDQOL)			- Most of the time		
37				- All of the time		
38						
39						
40						
41						
42						
43						
44						
45						
46						

Measures	No. of Items	Recall Period	Response Format	Measurement Dimensions	Content Dimensions	Frequency of Use
Patient-Reported Outcomes Measurement Information System (PROMIS)	4 to 12	Past 7 days	5-point Likert - Never - Rarely (Once) - Sometimes (Two or three times) - Often (About once a day) - Very often (Several times a day)	Frequency of SCCs	1. Mental Acuity 2. Concentration 3. Verbal and Nonverbal Memory 4. Verbal Fluency 5. Interference with Daily Functioning 6. Other People's Observation 7. Impact on Quality of Life	1
Visual Analogue Scale (10 items of quality of life)	1	Current	Visual Analogue Scale (0-100)	Severity of SCCs	1. Memory	1
WHO Disability Assessment Schedule (WHODAS 2.0)	6	Past 30 days	5-point Likert - No difficulty - Mild difficulty - Moderate difficulty - Severe difficulty - Extreme difficulty or inability to do	Severity of SCCs	1. Concentration 2. Memory 3. Problem Solving 4. Learning 5. Communication	1

Notes. SCCs = Subjective cognitive complaints; ESRD = End-stage renal disease.

Table 2. *Distribution of mean KDQOL-CF scores within different ranges across treatment modalities.*

Score Range	In-centre Haemodialysis		Peritoneal Dialysis		Kidney Transplantation	
	k (%)	N (%)	k (%)	N (%)	k (%)	N (%)
0-19	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (11.8%)	119 (4.4%)
20-39	7 (5.8%)	796 (2.1%)	2 (4.8%)	955 (15.1%)	0 (0.0%)	0 (0.0%)
40-59	10 (8.3%)	1058 (2.8%)	2 (4.8%)	97 (1.5%)	0 (0.0%)	0 (0.0%)
60-79	52 (43.3%)	26577 (71.4%)	19 (45.2%)	3357 (53.3%)	4 (23.5%)	652 (24.2%)
80-100	51 (42.5%)	8781 (23.6%)	19 (45.2%)	1895 (30.1%)	11 (64.7%)	1922 (71.4%)
Overall	120 (100.0%)	37212 (100.0%)	42 (100.0%)	6304 (100.0%)	17 (100.0%)	2693 (100.0%)

Notes. Studies that reported medians were not included in this table; For longitudinal studies that reported mean KDQOL-CF scores at multiple time points, only the baseline data were included; A score of 0, 20, 40, 60, 80, and 100 on the KDQOL-CF indicates that cognitive difficulties are experienced all of the time, most of the time, a good bit of the time, some of the time, a little of the time, and none of the time, respectively; KDQOL-CF = Cognitive Function subscale of the Kidney Disease Quality of Life questionnaire; k = Number of studies that reported means within each range; N = Total sample size of studies that reported means within each range.

Table 3. *Associations of subjective cognitive complaints with sociodemographic, clinical, and patient-reported variables reported by at least two studies.*

Variables	Total	Higher SCCs	Lower SCCs	No Association
Number of studies (percentage)				
Sociodemographic				
Older age	29	2 (6.9%)	2 (6.9%)	25 (86.2%)
Female gender	17	2 (11.8%)	-	15 (88.2%)
Lower education level	14	7 (50.0%)	-	7 (50.0%)
Unemployment	6	4 (66.7%)	-	2 (33.3%)
Marital status	4	-	-	4 (100.0%)
Lower household income	3	1 (33.3%)	-	2 (66.7%)
Smoking	3	-	-	3 (100.0%)
Clinical				
Longer dialysis vintage	15	1 (6.7%)	2 (13.3%)	12 (80.0%)
Comorbidity	13	4 (30.8%)	-	9 (69.2%)
Higher albumin	13	2 (15.4%)	3 (23.1%)	8 (61.5%)
Higher dialysis adequacy	11	1 (9.1%)	1 (9.1%)	9 (81.8%)
Higher haemoglobin	8	1 (12.5%)	1 (12.5%)	6 (75%)
Diabetes	8	-	1 (12.5%)	7 (87.5%)
BMI	8	-	-	8 (100.0%)
Hospitalisation	6	6 (100.0%)	-	-
Mortality	6	2 (33.3%)	-	4 (66.7%)
Higher GFR	5	1 (20.0%)	-	4 (80.0%)
Higher creatinine	3	2 (66.7%)	-	1 (33.3%)
Higher phosphorus	3	1 (33.3%)	-	2 (66.7%)
Hematocrit	3	-	-	3 (100.0%)
nPNA	3	-	-	3 (100.0%)
Lower SGA score	3	1 (33.3%)	-	2 (66.7%)
Lower systolic blood pressure	3	1 (33.3%)	-	2 (66.7%)
Time after KTx	2	-	-	2 (100.0%)
Cancer	2	-	-	2 (100.0%)
Sarcopenia	2	-	-	2 (100.0%)
Sodium	2	-	-	2 (100.0%)
Calcium	2	-	-	2 (100.0%)
Cholesterol	2	-	-	2 (100.0%)
cPENS	2	-	-	2 (100.0%)
Higher TNF- α	2	1 (50.0%)	-	1 (50.0%)
Higher IL-6	2	1 (50.0%)	-	1 (50.0%)
Higher Ferritin	2	1 (50.0%)	-	1 (50.0%)
Patient-reported				
Higher depressive symptoms	21	18 (85.7%)	1 (4.8%)	2 (9.5%)
Higher anxious symptoms	10	9 (90.0%)	1 (10.0%)	-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Total	Higher SCCs	Lower SCCs	No Association
Variables	Number of studies (percentage)			
Lower overall health rating	9	6 (66.7%)	-	3 (33.3%)
Higher level of pain	7	6 (85.7%)	-	1 (14.3%)
Higher fatigue symptoms	6	6 (100.0%)	-	-
Worse physical functioning	6	5 (83.3%)	-	1 (16.7%)
Worse social functioning	6	4 (66.7%)	-	2 (33.3%)
Worse perceived general health	5	3 (60.0%)	-	2 (40.0%)
Role limitation due to physical health	5	3 (60.0%)	-	2 (40.0%)
Role limitation due to emotional problems	5	3 (60.0%)	-	2 (40.0%)
More overall symptoms	5	5 (100.0%)	-	-
Poorer sleep quality	4	3 (75.0%)	-	1 (25.0%)
Lower functional capacity	4	3 (75.0%)	-	1 (25.0%)
Physical inactivity	3	2 (66.7%)	-	1 (33.3%)
Medication adherence	2	-	-	2 (100.0%)

Notes. SCCs = Subjective cognitive complaints; BMI = Body mass index; GFR = Glomerular filtration rate; nPNA = Normalised protein nitrogen appearance; SGA = Subjective global assessment; KTx = Kidney transplantation; cPENS = Composite score on protein-energy nutritional status; TNF- α = Tumour Necrosis Factor alpha; IL-6 = Interleukin 6.




Figure 1. PRISMA flow diagram




Figure 2. Forest plot showing the results of 20 studies examining difference in subjective cognitive complaints between haemodialysis and peritoneal dialysis patients. SD = Standard deviation; SMD = Standardised mean difference; CI = Confidence interval.

Table S1. *Search strategy*

Database	S#	Search Terms
CINAHL (EBSCOhost)	1	TX ("subjective cogniti*" OR "self-reported cogniti*" OR "patient-reported cogniti*" OR "self-perceived cogniti*" OR "patient-perceived cogniti*" OR "cognitive complaint*" OR "cognitive concern*" OR "cognitive failure*" OR "cognitive difficult*" OR "everyday cogniti*" OR metacogniti* OR "kidney disease quality of life" OR KDQOL OR "patient's assessment of own functioning" OR PAOF*)
	2	TX ("chronic kidney disease*" OR "end-stage kidney disease*" OR "end-stage renal disease*" OR "renal insufficien*" OR "kidney failure" OR dialy* OR hemodia* OR haemodia* OR "renal transplant*" OR "kidney transplant*" OR "renal replacement" OR "kidney replacement" OR "artificial kidney")
	3	#1 AND #2
Ovid – All Resources (Books@Ovid, Journals@Ovid Full Text, Your Journals@Ovid, EBM Reviews, Embase, MEDLINE)	1	("subjective cogniti*" or "self-reported cogniti*" or "patients-reported cogniti*" or "self-perceived cogniti*" or "patient-perceived cogniti*" or "cognitive complaint*" or "cognitive concern*" or "cognitive failure*" or "cognitive difficult*" or "everyday cogniti*" or "metacogniti*" or "kidney disease quality of life" or KDQOL or "patient's assessment of own functioning" or PAOF*).mp. [mp=tx, bt, ti, ot, ab, ct, sh, kw, fx, hw, tn, dm, mf, dv, kf, dq, nm, ox, px, rx, an, ui, ds, on, sy]
	2	("chronic kidney disease*" or "end-stage kidney disease" or "end-stage renal disease" or "renal insufficien*" or "kidney failure" or dialy* or hemodia* or haemodia* or "renal transplant*" or "kidney transplant*" or "renal replacement" or "kidney replacement" or "artificial kidney").mp. [mp=tx, bt, ti, ot, ab, ct, sh, kw, fx, hw, tn, dm, mf, dv, kf, dq, nm, ox, px, rx, an, ui, ds, on, sy]
	3	#1 AND #2
MEDLINE (PubMed)	1	"subjective cogniti*"[All Fields] OR "self reported cogniti*"[All Fields] OR "patient reported cogniti*"[All Fields] OR "self perceived cogniti*"[All Fields] OR "patient perceived cogniti*"[All Fields] OR "cognitive complaint*"[All Fields] OR "cognitive concern*"[All Fields] OR "cognitive failure*"[All Fields] OR "cognitive difficult*"[All Fields] OR "everyday cogniti*"[All Fields] OR "metacogniti*"[All Fields] OR "kidney disease quality of life"[All Fields] OR "KDQOL"[All Fields] OR "patient's assessment of own functioning"[All Fields] OR "PAOF*"[All Fields]
	2	"chronic kidney disease*"[All Fields] OR "end stage kidney disease*"[All Fields] OR "end stage renal disease*"[All Fields] OR "renal insufficien*"[All Fields] OR "kidney failure"[All Fields] OR "dialy*"[All Fields] OR "hemodia*"[All Fields]

		OR “haemodia*”[All Fields] OR “renal transplant*”[All Fields] OR “kidney transplant*”[All Fields] OR “renal replacement”[All Fields] OR “kidney replacement”[All Fields] OR “artificial kidney”[All Fields]
	3	#1 AND #2
PsycINFO (EBSCOhost)	1	TX (“subjective cogniti*” OR “self-reported cogniti*” OR “patient-reported cogniti*” OR “self-perceived cogniti*” OR “patient-perceived cogniti*” OR “cognitive complaint*” OR “cognitive concern*” OR “cognitive failure*” OR “cognitive difficult*” OR “everyday cogniti*” OR metacogniti* OR “kidney disease quality of life” OR KDQOL OR “patient’s assessment of own functioning” OR PAOF*)
	2	TX (“chronic kidney disease*” OR “end-stage kidney disease*” OR “end-stage renal disease*” OR “renal insufficien*” OR “kidney failure” OR dialy* OR hemodia* OR haemodia* OR “renal transplant*” OR “kidney transplant*” OR “renal replacement” OR “kidney replacement” OR “artificial kidney”)
	3	#1 AND #2
Web of Science	1	(ALL=(“subjective cogniti*” OR “self-reported cogniti*” OR “patient-reported cogniti*” OR “self-perceived cogniti*” OR “patient-perceived cogniti*” OR “cognitive complaint*” OR “cognitive concern*” OR “cognitive failure*” OR “cognitive difficult*” OR “everyday cogniti*” OR metacogniti* OR “kidney disease quality of life” OR karol OR “patient’s assessment of own functioning” OR PAOF*)) AND ALL=(“chronic kidney disease*” OR “end-stage kidney disease*” OR “end-stage renal disease*” OR “renal insufficien*” OR “kidney failure” OR dialy* OR hemodia* OR haemodia* OR “renal transplant*” OR “kidney transplant*” OR “renal replacement” OR “kidney replacement” OR “artificial kidney”)

Notes. Kidney Disease Quality of Life (KDQOL) was included in the keywords because it contains a cognitive function subscale and has been frequently used in patients with end-stage renal disease. Patient’s Assessment of Own Functioning (PAOF) is a comprehensive questionnaire of subjective cognitive complaints that has been used in several key studies relevant to this review.

Table S2. *Characteristics and key findings of included studies.*

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Abbasi Abianeh et al., 2020, Iran (1)	Pre-post study with no control group	HD: 45, 58.5 (10.0), 46.7%	KDQOL-CF	HD: M = 58.56	N/A	N/A	N/A
Ahmadzadeh et al., 2017, Iran (2)	Pre-post study with no control group	HD: 53, 54.0 (N/A), 41.5%	KDQOL-CF	HD: M = 62.66	N/A	N/A	N/A
Al-Jumaih et al., 2011, Saudi Arabia (3)	Observational cross-sectional study	HD: 100, 53.4 (10.3), 31.3%	KDQOL-CF	HD: M = 25.60	N/A	N/A	N/A
Alarcon et al., 2021, Colombia (4)	Observational cohort study	HD: 992, 60.5 (15.1), 37.6%	DSI-Difficulty Concentrating	HD: prevalence = 30.23%	N/A	No change in SCCs from baseline (high-flux) to 6 and 12 months (medium cut-off) in HD patients	No difference in SCCs between high-flux and medium cut-off HD
Amro et al., 2014, Norway (5)	Observational cross-sectional study	HD & PD: 243 (HD), 58 (PD), 59.8 (16.2), 33.9%	KDQOL-CF		N/A	N/A	SCCs positively associated with three symptom clusters: uraemic (nausea, lack of appetite, dizziness/faintness, feeling squeezed out, shortness of breath, chest pain), neuromuscular (numbness in extremities, sore muscles, cramps) and skin (itching, dry skin)
Anees et al., 2016, Pakistan (6)	Observational cross-sectional study	HD: 130, 43.1 (13.5), 35.9%	KDQOL-CF	HD: Median = 33.33	N/A	N/A	N/A
Anees et al., 2018, Pakistan (7)	Observational cohort study	HD: 135, N/A (N/A), N/A	KDQOL-CF	HD: M = 31.78	N/A	N/A	SCCs not associated with education level, employment status, household income, funding for dialysis, or mortality at 2 years
Aoun et al., 2020, Lebanon (8)	Observational cohort study	HD: 71, 68.4 (13.1), 36.6%	KDQOL-CF	HD: M = 83.00	N/A	N/A	SCCs not associated with mortality at 1 year or at 2 years; SCCs not associated with Duchenne smile
Aramwit et al., 2012, Thailand (9)	Pre-post study with no control group	HD: 47, 49.6 (11.2), 63.8%	KDQOL-CF	HD: M = 65.53	N/A	N/A	N/A

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Bacci et al., 2018, Brazil (10)	Observational cross-sectional study	HD: 30, 41.0 (N/A), 55.0%	KDQOL-CF	HD: Median = 5.00	N/A	N/A	SCCs not associated with inflammatory markers (TNF-alpha, IL-6, CRP, Hcy, Ferritin) or anthropometric parameters (abdominal circumference, BMI, triceps skinfold, arm circumference)
Bagasha et al., 2021, Uganda (11)	Observational cross-sectional study	HD: 124, N/A (N/A), 34.2%; Conservative management: 240, N/A (N/A), 42.6%	KDQOL-CF	HD: M = 63.66; Conservative management: M = 67.39	No difference in SCCs between HD and conservative management patients	N/A	N/A
Bakewell et al., 2001, UK (12)	Observational cross-sectional study	HD: 40, 52.5 (14.8), 35.0%; PD: 40, 49.0 (14.4), 30.0% KTx: 40, 46.0 (10.4), 30.0%	KDQOL-CF	N/A	N/A	N/A	Asian patients reported more SCCs than white patients
Barbosa et al., 2017, Brazil (13)	Observational cross-sectional study	HD: 47, 50.9 (13.3), 44.7%	KDQOL-CF	HD: M = 80.14	N/A	N/A	No difference in SCCs between patients on HD < 3 years and patients on HD > 3 years
Barotfi et al., 2006, Hungary (14)	Observational cross-sectional study	HD: 418, 53.0 (14.0), 44.0%; KTx: 418, 49.0 (12.0), 41.0%	KDQOL-CF	HD: M = 78.00; KTx: M = 79.00	No difference in SCCs between HD and KTx patients	N/A	SCCs associated with lower overall health rating and higher depressive symptoms; SCCs not associated with age or GFR
Barzegar et al., 2017, Iran (15)	Observational cross-sectional study	HD: 246, 56.5 (12.8), 41.5%	KDQOL-CF	HD: M = 54.30	N/A	N/A	No difference in SCCs between patients on HD < 3 years and patients on HD > 3 years
Bataclan et al., 2009, Philippines (16)	Observational cross-sectional study	HD: 80, 53.0 (2.0), 56.0%	KDQOL-CF	HD: M = 89.11	N/A	N/A	SCCs not associated with overall health rating
Bawazier et al., 2018, Indonesia (17)	Observational cohort study	HD: 39, N/A (N/A), 53.8%	KDQOL-CF	HD: M = 82.05	N/A	N/A	Patients reported more SCCs with reusable dialyser than with single-use dialyser
Bele et al., 2012, India (18)	Observational cross-sectional study	HD: 54, 42.1 (13.5), 27.8%	KDQOL-CF	HD: M = 71.85	N/A	N/A	SCCs associated with greater concerns about death, hopelessness, meaninglessness, and futility

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Bedtoni et al., 2017, Brazil (19)	Observational cross-sectional study	HD: 100, 53.3 (14.7), 34.0%	KDQOL-CF	N/A	N/A	N/A	SCCs associated with lower perceived self-care capacity
Boudville et al., 2009, Australia (20)	Controlled intervention study	HD: 33, 59.1 (19.4), 39.0%	KDQOL-CF	N/A	N/A	No change in SCCs switching between dialysers in HD patients	No difference in SCCs between FX and HF80 dialysers
Boudida et al., 2014, Morocco (21)	Observational cross-sectional study	HD & PD: 62 (HD), 18 (PD), 43.9 (14.2), N/A	KDQOL-CF	N/A	N/A	N/A	Females reported more SCCs than males; SCCs associated with lower overall health rating; SCCs not associated with age, education level, or dialysis vintage
Praga et al., 2011, Brazil (22)	Observational cross-sectional study	HD: 223, 69.5 (7.1), 43.5%	KDQOL-CF	HD: M = 84.78	N/A	N/A	N/A
Brickman et al., 1996, US (23)	Observational cross-sectional study	HD: 426, 42.9 (12.7), 59.0%	CDS	HD: M = 33.80	N/A	N/A	SCCs associated with lower education level, higher haemoglobin, higher depressive symptoms, higher state anxiety, and neuroticism; SCCs negatively associated with extraversion; SCCs not associated with age, sex, race, first language, marital status, HD vintage, albumin, diabetes, glucose, sodium, or creatinine; SCCs not associated with performance on WAIS-R Vocabulary Scale, Trail Making Test Part B, Stroop Color-Word Interference Test, Continuous Performance Test, WAIS-R Digit Symbol, WAIS-R Digit Span, Enhanced Cued Recall, or Wechsler Memory Test-Revised
Carmichael et al., 2000, UK (24)	Observational cross-sectional study	HD: 49, 57.8 (13.0), 34.7%; PD: 97, 57.0 (15.0), 40.2%	KDQOL-CF	HD: M = 40.6; PD: M = 81.0	HD patients reported more SCCs than PD patients	N/A	SCCs not associated with age or haemoglobin

4Author & Year & 5Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
6Castro et al., 2018, 7Brazil (25)	Observational cross- sectional study	HD: 51, 54.6 (15.8), 39.2%	KDQOL-CF; WHODAS 2.0-Cognition	HD (KDQOL-CF): M = 93.72; HD (WHODAS 2.0- Cognition): M = 11.17	N/A	N/A	SCCs (KDQOL-CF) associated with poorer quality of life in getting alone, life activities, and participation domains of WHODAS 2.0; SCCs (KDQOL-CF) not associated with mobility or self-care domains of WHODAS 2.0; SCCs (WHODAS 2.0-Cognition) associated with poorer quality of life in physical, psychological, social, and environmental domains of WHOQOL-BREF; SCCs (WHODAS 2.0-Cognition) associated with poorer quality of life in symptom/problem list, burden of kidney disease, physical functioning, pain, emotional well-being, and energy/fatigue domains of KDQOL; SCCs (WHODAS 2.0-Cognition) not associated with effects of kidney disease, work status, quality of social interaction, sexual function, sleep, social support, dialysis staff encouragement, overall health rating, patient satisfaction, role physical, general health perceptions, role emotional, and social function domains of KDQOL
28Avalcante et al., 292013, Brazil (26)	Observational cross- sectional study	HD: 291, N/A (N/A), 44.7%	KDQOL-CF	HD: Median = 93.30	N/A	N/A	N/A
30Cepeda Marte et al., 312019, Dominican 32Republic (27)	Observational cross- sectional study	HD: 21, N/A (N/A), 19.0%	KDQOL-CF	HD: M = 26.35	N/A	N/A	N/A
34Chan et al., 2010, 35Hong Kong (28)	Observational cross- sectional study	PD: 153, 60.0 (14.0), 45.8%	KDQOL-CF	PD: M = 72.11	N/A	N/A	N/A
36Zhen et al., 2021, 37Mainland China (29)	Observational cohort study	HD: 151, 56.5 (17.0), 46.4%; PD: 102, 59.7 (17.3), 51.0%	KDQOL-CF	HD: M = 66.75; PD: M = 69.64	No difference in SCCs between HD and PD patients	N/A	N/A

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Cheung et al., 2012, Singapore (30)	Observational cohort study	Conservative management: 78, N/A (N/A), 44.9%	KDQOL-CF	Conservative management: M = 92.10	N/A	N/A	SCCs not associated with GFR; SCCs associated with functional disability assessed by Karnofsky Performance Status, self-rated change of general health compared to one year ago, and poorer quality of life in the physical functioning, role physical, emotion well-being, role emotional, and energy/fatigue domains of RAND 36; SCCs not associated with quality of life in the pain, general health, and social function domains of RAND 36
Cho et al., 2018, Korea (31)	Observational cross-sectional study	HD: 230, 60.5 (14.0), 47.4%	DSI-Difficulty Concentrating	HD: M = 2.08; prevalence = 57.8%	N/A	N/A	N/A
Chow et al., 2010, Hong Kong (32)	Controlled intervention study	PD: 85, 56.9 (13.5), 38.8%	KDQOL-CF	PD: M = 66.18	N/A	No change in SCCs from baseline to 6 and 12 weeks in PD patients (control group)	N/A
Chrif Alaoui et al., 2022, Morocco (33)	Observational cross-sectional study	HD: 71, N/A (N/A), 52.1%; PD: 20, N/A (N/A), 40.0%	KDQOL-CF	HD: Median = 53.30; PD: Median = 60.00	HD patients reported more SCCs than PD patients	N/A	N/A
Costa-Requena et al., 2017, Spain (34)	Observational cohort study	KTx: 124, 53.2 (14.2), 32.3%	KDQOL-CF	N/A	N/A	SCCs reduced from 1 to 6 months post-KTx; no change in SCCs from 6 to 24 months post-KTx	N/A
Czyżewski et al., 2014, Poland (35)	Observational cohort study	HD: 40, N/A (N/A), 42.5%; PD: 30, N/A (N/A), 50.0%; KTx: 47, N/A (N/A), 44.7%	KDQOL-CF	HD: M = 78.00; PD: M = 76.41; KTx: M = 68.89	No difference in SCCs between HD, PD, and KTx patients	No change in SCCs from 3 to 12 months post-KTx	N/A
Czyżewski et al., 2018, Poland (36)	Observational cross-sectional study	KTx: 118, 45.0 (N/A), 53.4%	KDQOL-CF	KTx: M = 68.50	N/A	N/A	No difference in SCCs between patients who received KTx < 1 year, patients who received KTx between 1 and 10 years, and patients who received KTx > 10 years

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
D'Onofrio et al., 2017, Italy (37)	Observational cross-sectional study	HD: 103, 66.2 (N/A), 37.9%	KDQOL-CF	HD: M = 70.00	N/A	N/A	N/A
Dai et al., 2020, Mainland China (38)	Controlled intervention study	HD (thrice-weekly): 70, 50.6 (4.9), 40.0%; HD (twice-weekly): 70, 50.9 (4.3), 44.3%	KDQOL-CF	HD: M = 73.10	N/A	N/A	Thrice-weekly HD associated with more SCCs than twice-weekly HD
de Oliveira Cordeiro et al., 2020, Brazil (39)	Observational cross-sectional study	KTx: 222, 45.8 (12.8), 39.6%	KDQOL-CF	KTx: M = 82.80	N/A	N/A	N/A
de Oliveira et al., 2012, Brazil (40)	Observational cross-sectional study	PD: 82, 61.0 (N/A), 61.0%	KDQOL-CF	PD: M = 83.23	N/A	N/A	Patients who do not work reported more SCCs than patients who work
de Roij van Zuijdewijn et al., 2016, Netherlands, Norway, and Canada (41)	Observational cross-sectional study	HD: 489, 63.3 (13.8), 39.5%	KDQOL-CF	HD: M = 77.00	N/A	N/A	SCCs associated with higher Malnutrition Inflammation Score, lower Subjective Global Assessment score, and higher creatinine; SCCs not associated with Geriatric Nutritional Risk Index, Composite Score on Protein-Energy Nutritional Status, albumin, BMI, or Normalized Protein Nitrogen Appearance
Debnath et al., 2018, US (42)	Observational cross-sectional study	HD: 40, N/A (N/A), 65.0%	KDQOL-CF	N/A	N/A	N/A	SCCs associated with higher depressive symptoms
Dehesa-Lopez et al., 2016, Mexico (43)	Observational cross-sectional study	HD: 194, 54.0 (16.0), 45.4%	KDQOL-CF	HD: M = 21.80	N/A	N/A	SCCs associated with higher serum phosphorus and serum albumin; SCCs not associated with age, HD vintage, haemoglobin, serum calcium, or dialysis adequacy (Kt/V)
Dehghan et al., 2020, Iran (44)	Observational cross-sectional study	HD: 113, 58.1 (13.6), 40.7%	KDQOL-CF	HD: M = 68.35	N/A	N/A	SCCs not associated with use of relaxation methods
Diamant et al., 2011, Canada (45)	Observational cross-sectional study	HD: 277, 65.9 (14.8), 41.8%	KDQOL-CF	HD: M = 79.28	N/A	N/A	No difference in SCCs between patients receiving HD in satellite units and in-center units

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Duarte et al., 2005, Brazil (46)	Observational cross-sectional study	HD & PD: 53 (HD), 41 (PD), 49.0 (13.0), 45.0%	KDQOL-CF	N/A	N/A	N/A	SCCs associated lower education level; SCCs not associated with age, HD vintage, number of comorbidities, or hematocrit; SCCs associated with poorer quality of life in the level of energy, pain, emotional reaction, sleep, social isolation, and physical capacity domains of the Nottingham Health Profile; SCCs associated with poorer quality of life in the physical symptom, fatigue, depression, relationship with others, and frustration domains of the Kidney Disease Questionnaire; SCCs not associated with functional disability assessed by Karnofsky Performance Status
Duarte et al., 2009, Brazil (47)	Controlled intervention study	HD: 85, 53.2 (14.3), 58.8%	KDQOL-CF	HD: M = 66.83	N/A	No change in SCCs from baseline to 3 and 9 months in HD patients (control group)	N/A
Fan et al., 2020, Taiwan (48)	Observational cross-sectional study	HD: 200, 62.0 (11.4), 49.5%	PDQ-5	HD: M = 1.80	N/A	N/A	SCCs associated with older age, lower serum albumin, and higher depressive symptoms; SCCs not associated with sex, education level, marital status, family history of mental disorders, BMI, HD vintage, dialysis adequacy (urea reduction ratio), smoking, alcohol use, diabetes, cardiovascular disease, hypertension, cancer, serum sodium, haemoglobin, cholesterol, triglycerides, or uric acid
Fiderkiewicz et al., 2011, Poland (49)	Observational cross-sectional study	HD: 196, 63.9 (13.2), 39.8%	KDQOL-CF	N/A	N/A	N/A	SCCs associated with irritable bowel syndrome symptoms
Foley et al., 2009, Canada (50)	Controlled intervention study	HD: 596, 50.8 (N/A), 39.6%	KDQOL-CF	HD: M = 66.62	N/A	N/A	N/A

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Fong et al., 2007, Canada (51)	Observational cross-sectional study	PD: 57, 61.0 (13.0), 45.0%; NHD: 36, 49.0 (12.0), 33.0%	KDQOL-CF	PD: M = 81.40; NHD: M = 75.60	No difference in SCCs between PD and NHD patients	N/A	N/A
Primat et al., 2006, France (52)	Observational cohort study	HD: 284, 67.6 (11.3), 40.1%; PD: 103, 70.8 (11.4), 43.7%	KDQOL-CF	HD: M = 63.50; PD: M = 63.40	No difference in SCCs between HD and PD patients at any time point	No change in SCCs from predialysis to 6 or 12 months post-initiation of HD/PD	N/A
Fructuoso et al., 2011, Portugal (53)	Observational cross-sectional study	HD: 37, 67.3 (14.9), 43.2%; PD: 14, 38.9 (13.3), 42.9%	KDQOL-CF	HD: M = 68.83; PD: M = 82.56	No difference in SCCs between HD and PD patients	N/A	N/A
Fukuhara et al., 2003, US, France, Germany, Italy, Spain, UK, and Japan (54)	Observational cross-sectional study	HD: 7378, 59.4 (N/A), 42.7%	KDQOL-CF	HD: M = 77.30	N/A	N/A	European patients reported more SCCs than Japanese and US patients
G. B. Lopes et al., 2014, Brazil (55)	Observational cross-sectional study	HD: 800, 49.0 (13.9), 39.6%	KDQOL-CF	HD: Median = 86.70	N/A	N/A	Patients who reported needing some time to recover after HD sessions had more SCCs than patients who felt well immediately after the end of HD sessions
Garcia et al., 2010, Brazil (56)	Observational cross-sectional study	HD: 47, 39.4 (8.9), 0.0%	KDQOL-CF	HD: Median = 93.30	N/A	N/A	SCCs not associated with depressive symptoms
Giglio et al., 2018, Brazil (57)	Observational cross-sectional study	HD: 170, 70.6 (7.2), 34.7%	KDQOL-CF	HD: Median = 86.70, 87.00, 80.00, 93.30, 80.00, 93.00 in patients with low and appropriate muscle mass, low and appropriate muscle strength, and with and without sarcopenia, respectively	N/A	N/A	SCCs associated lower muscle strength; SCCs not associated with muscle mass or sarcopenia status

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Goldfarb-Rumyantzev et al., 2006, US (58)	Pre-post study with no control group	HD (week 1-4) switching to DHD (week 5-12) and then to HD (week 13-16): 12, 52.0 (18.0), 50.0%	KDQOL-CF	HD: M = 74.50; DHD: M = 84.80	No difference in SCCs between HD (week 1-4 & 13-16) and DHD (week 5-12)	No change in SCCs switching from HD (weeks 1-4) to DHD (weeks 5-12) and back to HD (weeks 13-16)	N/A
Gonçalves et al., 2015, Brazil (59)	Observational cross-sectional study	HD: 222, 54.4 (15.2), N/A; PD: 116, 58.0 (13.9), N/A	KDQOL-CF	HD: M = 79.64; PD: M = 81.09	No difference in SCCs between HD and PD patients	N/A	N/A
Gorodetskaya et al., 2005, US (60)	Observational cohort study	HD: 38, 57.3 (16.5), 34.0%	HUI3-Cognition	HD: M = 0.93	N/A	N/A	N/A
Green et al., 2001, Japan (61)	Observational cross-sectional study	HD & PD: 690 (HD), 103 (PD), 55.0 (N/A), 45.9%	KDQOL-CF	N/A	N/A	N/A	Patients who received assistance in filling out the survey had more SCCs than those who filled out the survey themselves
Giriva et al., 2012, UK (62)	Observational cross-sectional study	KTx: 218, 49.7 (12.3), 40.4%	KDQOL-CF	N/A	N/A	N/A	SCCs not associated with medication adherence
Gumprecht et al., 2010, Poland (63)	Observational cross-sectional study	HD: 114, 55.7 (15.1), 47.4%	KDQOL-CF	HD: M = 75.89	N/A	N/A	SCCs not associated with diabetes
Hasan et al., 2021, Egypt (64)	Observational cohort study	HD: 100, 48.8 (5.9), 49.0%	KDQOL-CF	HD: M = 84.27	N/A	N/A	SCCs associated with lower dialysis adequacy (Kt/V); improvement of Kt/V associated with reduction of SCCs over 3 months
Hayashi et al., 2017, Japan (65)	Controlled intervention study	HD: 18, 54.7 (13.6), 35.0%	KDQOL-CF	HD: M = 86.54	N/A	No change in SCCs from baseline to 16 weeks in HD patients (control group)	N/A

4Author & Year & 5Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
6Hays et al., 1994, US 7(66)	Observational cross- sectional study	HD: 165, 53.0 (N/A), 52.0%	KDQOL-CF	HD: M = 78.51	N/A	N/A	SCCs associated with number of hospital days in the past 6 months; SCCs associated with number of good days in the last seven days, number of bad days in the last seven days, rating of one's life compared with people without kidney disease, extent to which the individual is able to do everything they want to do, days health caused one to stay in bed for one-half day or longer during the last 30 days, and overall health rating
16Henry et al., 2018, US 17(67)	Observational cross- sectional study	HD: 26, 42.7 (15.8), 57.7%	Four items from KDQOL-CF and BDI	HD: M = 0.27 for reaction time, M = 0.36 for concentration and thinking, M = 0.12 for confusion, and M = 0.12 for decision-making	N/A	N/A	Patients reported more SCCs of confusion on dialysis days than non-dialysis days; patients reported more SCCs of reaction time on short interdialytic interval than on day 2 of the long interdialytic interval; SCCs of reaction time associated with poorer performance in Digit Span Task and Trail Making Test B; SCCs of confusion associated with poorer performance in Digit Span Task, Visual Retention Test, and Trail-Making Test B; SCCs not associated with MMSE scores
27Hernández Sánchez et 28al., 2021, Spain (68)	Controlled intervention study	KTx: 16, 49.2 (9.8), 43.8%	KDQOL-CF	KTx: M = 12.00	N/A	No change in SCCs from baseline to 10 weeks in KTx patients (control group)	
30Ho et al., 2013, 31Malaysia (69)	Observational cross- sectional study	HD: 72, N/A (N/A), 58.3%	KDQOL-CF	HD: M = 83.70	N/A	N/A	Non-Malays reported more SCCs than Malays; SCCs not associated with age, sex, education level, or presence of comorbidities
34Hornik et al., 2019, 35Poland (70)	Observational cross- sectional study	HD: 72, 57.8 (16.0), 50.0%	KDQOL-CF	HD: M = 71.30	N/A	N/A	SCCs not associated with adherence to recommended physical activity
37Hyodo et al., 2004, 38Japan (71)	Observational cross- sectional study	HD: 21, 55.9 (11.3), 0.0%	KDQOL-CF	HD: M = 89.27	N/A	N/A	No difference in SCCs between patients who desired Slidenafil and patients who did not

1
2
3

4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
	J. M. Lopes et al., 2014, Brazil (72)	Observational cross-sectional study	HD: 101, 56.4 (14.4), 32.0%	KDQOL-CF	HD: M = 89.31	N/A	N/A	N/A
	Jansz et al., 2018, Netherlands (73)	Observational cross-sectional study	NHD: 31, 53.9 (12.5), 38.0%; KTx: 41, 54.0 (13.8), 25.0%	KDQOL-CF	NHD: M = 78.00 KTx: M = 81.00	No difference in SCCs between NHD and KTx patients	N/A	N/A
	Zassal et al., 2006, Canada (74)	Observational cohort study	HD (baseline) switching to NHD (6 month): 12, 39.6 (3.3), 50.0%	PAOFI	HD (baseline): M = 36.90; NHD (6 months): M = 26.70	Patients reported more SCCs on HD (baseline) than on NHD (6 months)	SCCs reduced after switching from HD (baseline) to NHD (6 months)	N/A
	Jayanti et al., 2016, UK (75)	Observational cross-sectional study	Predialysis: 204, 59.4 (13.0), 38.7%	Brief Metacognition Questionnaire	Predialysis: M = 17.84 for metamemory; M = 14.48 for metaconcentration	N/A	N/A	SCCs of concentration (not memory) associated with lower odds of choosing self-care dialysis (PD/HHD) over a fully assisted dialysis modality (HD); SCCs of concentration (not memory) associated with poorer performance in the Trail Making Test part B (not part A or 3MS)
	Jiao et al., 2017, Mainland China (76)	Controlled intervention study	PD: 118, 58.0 (7.0), 44.1%	KDQOL-CF	PD: M = 67.32	N/A	No change in SCCs from baseline to 6 and 12 weeks in PD patients (control group)	N/A
	Joshi et al., 2010, Singapore (77)	Observational cross-sectional study	HD: 980, 56.0 (21.0), 43.9%	KDQOL-CF	N/A	N/A	N/A	SCCs associated with lower overall health rating
	Jung et al., 2016, Korea (78)	Observational cohort study	APD: 80, 50.9 (11.2), 33.7%; CAPD: 80, 51.4 (11.8), 35.0%	KDQOL-CF	APD: M = 83.42; CAPD: M = 79.08; PD (combining two groups): M = 81.25	No difference in SCCs between APD and CAPD at either time point	No change in SCCs from 1 to 12 months post-initiation of PD	N/A
	Kanamori et al., 2012, Japan (79)	Observational cohort study	HD: 211, 59.0 (12.3), 37.4%	Visual Analogue Scale of Memory (0-100)	HD: Median = 45 and 51 in elderly and non-elderly patients	N/A	N/A	SCCs of memory not associated with age or mortality at 3 years

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Kang et al., 2017, Korea (80)	Observational cohort study	HD: 1250, 56.4 (13.2), 43.4%; PD: 366, 54.1 (11.9), 46.7%	KDQOL-CF	HD: M = 86.20; PD: M = 85.40	No difference in SCCs between HD and PD patients	N/A	N/A
Kim et al., 2011, Korea (81)	Pre-post study with no control group	HD: 24, 51.9 (7.2), 41.7%	KDQOL-CF	HD: M = 81.94	N/A	N/A	N/A
Kim et al., 2020, Korea (82)	Observational cohort study	HD: 1461, 58.3 (14.2), 38.3%	KDQOL-CF	HD: M = 82.79	N/A	N/A	CVC associated with more SCCs than AVF at 3 months post-initiation of HD; No difference in SCCs between AVF and AVG, or between AVG and CVC at 3 months; No difference in SCCs between the three access types at 12 months
Kim et al., 2021, Korea (83)	Observational cross-sectional study	HD: 1247, 56.4 (13.2), 43.5%; PD: 364, 54.1 (11.9), 46.4%	KDQOL-CF	HD: Median = 93.00 and 95.00 in patients with non-high and high physical activity; PD: Median = 93.00	N/A	N/A	HD patients with low physical activity reported more SCCs than HD patients with high physical activity; SCCs not associated with physical activity in PD patients
Knudsen et al., 2016, Denmark (84)	Observational cross-sectional study	HD: 81, 66.0 (13.0), 32.1%	KDQOL-CF	HD: M = 85.00	N/A	N/A	N/A
Ko et al., 2007, US (85)	Observational cross-sectional study	HD: 112, 55.5 (16.9), 58.0%	KDQOL-CF	HD: M = 78.70	N/A	N/A	N/A
Kontodimopoulos et al., 2005, Greece (86)	Observational cross-sectional study	HD: 483, 59.9 (14.6), 38.8%	KDQOL-CF	HD: M = 74.49	N/A	N/A	SCCs associated with female gender, older age, lower education level, presence of comorbidities, and more times of hospitalisations in the past year; SCCs associated with poorer quality of life in the physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health domains of SF-36

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Korevaar et al., 2002, Netherlands (87)	Observational cohort study	HD & PD: 234 (HD), 141 (PD), 60.0 (16.0), 39.0%	KDQOL-CF	N/A	N/A	No change in SCCs from 3 to 12 months post-initiation of HD/PD	SCCs associated with number of comorbidities; SCCs associated with higher dialysis adequacy (Kt/V) in HD but not PD patients; SCCs not associated with GFR; increase in SCCs from 3 to 12 months post-initiation of dialysis associated with reduction in serum albumin; SCCs associated with lower overall health rating
Kostro et al., 2016, Poland (88)	Observational cohort study	HD switching to KTx: 44, 49.0 (N/A), 31.8%; PD switching to KTx: 25, 42.0 (N/A), 44.0%	KDQOL-CF	HD (before KTx): M = 67.00; PD (before KTx): M = 59.00; KTx (combining two groups): M = 75.91	No difference in SCCs between HD and PD patients	SCCs reduced from pre-KTx (HD/PD) to 12 months post-KTx	N/A
Krishnasamy et al., 2019, Australia (89)	Observational cross-sectional study	HD: 32, 71.4 (10.6), 37.5%	KDQOL-CF	HD: M = 83.15	N/A	N/A	Isolation due to multidrug-resistant organisms not associated with SCCs
Kurella et al., 2004, US (90)	Observational cross-sectional study	HD: 79, 61.2 (14.4), 41.0%	KDQOL-CF	HD: Median = 73.00	N/A	N/A	SCCs positively associated with benzodiazepine use and stroke; SCCs negatively associated with beta-blocker use; SCCs associated with higher depressive symptoms
Kusumoto et al., 2008, Brazil (91)	Observational cross-sectional study	HD: 194, N/A (N/A), 36.6%	KDQOL-CF	HD: M = 80.83	N/A	N/A	No difference in SCCs between adults (< 60 years) and elderly (> 60 years)
Kutner et al., 2005a, US (92)	Observational cohort study	HD: 455, 61.2 (15.6), 43.3%; PD: 413, 56.1 (14.7), 47.2%	KDQOL-CF	HD: M = 75.84; PD: M = 79.72	No difference in SCCs between HD and PD patients at any time point	N/A	
Kutner et al., 2005b, US (93)	Observational cross-sectional study	HD: 1679, 61.6 (15.4), 46.9%; PD: 1623, 56.4 (15.3), 47.0%	KDQOL-CF	HD: M = 74.89; PD: M = 78.60	HD patients reported more SCCs than PD patients	N/A	SCCs not associated with sex or race
Kutner et al., 2007, US (94)	Observational cross-sectional study	HD & PD: 1170 (HD), 1116 (PD), 60.0 (16.0), 39.0%	KDQOL-CF	N/A	N/A	N/A	SCCs associated with lower education level, sleep medication prescription, self-reported sleep difficulty, higher depressive symptoms, and more bodily pain

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Lai et al., 2018, Italy (95)	Observational cohort study	PD: 51, 63.1 (14.6), 45.1%	KDQOL-CF	PD: M = 88.60	N/A	N/A	SCCs not associated with age
Lazarus, 2019, Oman (96)	Controlled intervention study	HD: 150, 48.8 (10.3), 44.7%	KDQOL-CF	HD: M = 61.50	N/A	N/A	N/A
Lee et al., 2005, UK (97)	Observational cross-sectional study	HD: 99, 63.0 (14.2), 39.4%; PD: 74 58.7 (15.3), 48.6%; KTx: 209, 52.8 (13.9), 40.2%	KDQOL-CF	HD: M = 72.60; PD: M = 79.60; KTx: M = 80.90	HD patients reported more SCCs than PD and KTx patients; No difference in SCCs between PD and KTx patients	N/A	N/A
Lee et al., 2020, Korea (98)	Observational cohort study	HD: 568, 60.8 (13.5), 38.4%	KDQOL-CF	N/A	N/A	N/A	SCCs not associated with mortality at 5 years
Leone et al., 2021, Brazil (99)	Observational cross-sectional study	HD: 162, N/A (N/A), 37.1%	KDQOL-CF	HD: M = 81.28	N/A	N/A	SCCs not associated with patient activation
Li et al., 2014, Mainland China (100)	Controlled intervention study	PD: 135, 56.3 (12.4), 41.5%	KDQOL-CF	PD: M = 73.09	N/A	No change in SCCs from baseline to 6 and 12 weeks in PD patients (control group)	N/A
Li et al., 2016, US (101)	Observational cross-sectional study	HD: 72, 52.0 (13.0), 32.0%	KDQOL-CF	HD: M = 82.20	N/A	N/A	SCCs associated with depressive and anxious symptoms (BAI, BDI, HADS); SCCs associated self-reported physical inactivity, but not associated with physical inactivity measured by a physical activity monitor; SCCs not associated with physical performance assessed by 6-minute walk test, sit-to-stand test, and stair climbing test
Lim et al., 2020, Korea (102)	Controlled intervention study	HD: 49, 63.0 (14.4), 32.7%	KDQOL-CF	HD: M = 83.11	N/A	N/A	No difference in SCCs between medium cut-off and high-flux dialysers

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Lo et al., 1998, Hong Kong (103)	Controlled intervention study	PD: 20, 45.7 (11.1), 50.0%	KDQOL-CF	PD: M = 63.18	N/A	No change in SCCs from baseline to 12 weeks in PD patients (control group)	N/A
Lønning et al., 2018a, Norway (104)	Observational cohort study	KTx: 120, 71.6 (4.3), 29.0%	KDQOL-CF	N/A	N/A	No change in SCCs from pre-KTx (HD/PD/preemptive) to 2, 6, and 12 months post-KTx	Longer waiting time for KTx associated with increase in SCCs; Change in SCCs not associated with age, sex, comorbidity, pre-KTx dialysis vintage, GFR, donor age, or HLA-DR
Lønning et al., 2018b, Norway (105)	Observational cohort study	KTx waiting list: 261, 71.2 (4.1), 33.0%	KDQOL-CF	N/A	N/A	No change in SCCs between baseline (KTx acceptance) to 6 and 12 months on KTx waiting list	N/A
Loos-Ayav et al., 2008, France (106)	Observational cohort study	HD & PD: 161 (HD), 34 (PD), 54.6 (12.8), 39.0%	KDQOL-CF	N/A	N/A	N/A	Non-autonomous patients reported more SCCs than autonomous (independent, self-care) patients at 12 months post-initiation of HD/PD
Lopes et al., 2003, US (107)	Observational cohort study	HD: 6151, 60.1 (15.5), 46.8%	KDQOL-CF	HD: M = 77.29	N/A	N/A	Hispanic patients had more SCCs than white patients: SCCs associated with hospitalisation and mortality only in white patients
Lopes et al., 2007, US, France, Germany, Italy, Spain, UK, and Japan (108)	Observational cross-sectional study	HD: 9526, 59.5 (14.8), 41.5%	KDQOL-CF	N/A	N/A	N/A	SCCs associated with lower household income, lower education level, unemployment, cerebrovascular or neurological disease, cardiac disease, and psychiatric disease; SCCs not associated with age, sex, marital status, living status, serum albumin, haemoglobin, dialysis adequacy (Kt/V), dialysis access, predialysis SBP, BMI, peripheral vasculopathy, diabetes, lung disease, or cancer

4Author & Year & 5Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
6Lopes et al., 2019, 7Brazil (109)	Controlled intervention study	HD: 50, 54.2 (12.4), 40.0%	KDQOL-CF	HD: M = 87.38	N/A	No change in SCCs from baseline to 12 weeks in HD patients (control group)	N/A
10Ma et al., 2021, China 11(110)	Observational cross- sectional study	HD: 190, 61.7 (13.4), 38.4%	KDQOL-CF	HD: M = 32.81	N/A	N/A	SCCs associated with lower scores in the average positive factors, somatisation, obsessive compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism domains of the SCL-90
16Macedo et al., 2021, 17Brazil (111)	Observational cross- sectional study	HD: 170, 70.6 (7.2), 34.7%	KDQOL-CF	HD: M = 79.66	N/A	N/A	SCCs not associated with sarcopenia (muscle mass and muscle strength) or malnutrition (Subjective Global Assessment)
20Madariaga et al., 212016, US (112)	Observational cross- sectional study	KTx: 21, 34.4 (8.9), 52.4%	KDQOL-CF	KTx: M = 80.32	No difference in SCCs between conventional KTx patients maintained on chronic immunosuppression and KTx patients who achieved long-term immunosuppression-free renal allograft survival after combined kidney and bone marrow transplantation	N/A	N/A
32Malekmakan et al., 332016, Iran (113)	Observational cross- sectional study	HD: 68, 54.9 (12.1), 57.4%; PD: 72, 52.4 (12.1), 50.0%	KDQOL-CF	HD: M = 51.31; PD: M = 53.56	No difference in SCCs between HD and PD patients	N/A	N/A
36Malindretos et al., 372010, Greece (114)	Observational cross- sectional study	HD: 200, 62.9 (14.7), 45.0%	KDQOL-CF	HD: M = 70.06	N/A	N/A	SCCs associated with number of comorbidities (Index of Coexistent Disease)

1
2
3

4Author & Year & 5Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
6Manavalan et al., 72017, India (115)	Observational cross- sectional study	Predialysis: 57, 51.1 (12.5), 33.3%; HD & PD: 27 (HD), 15 (PD), 42.0 (13.4), 35.7%	KDQOL-CF	Predialysis: M = 62.22; HD: M = 68.89; PD: M = 75.56	No difference in SCCs between predialysis, HD, and PD patients	N/A	N/A
10Manju et al., 2020, 11India (116)	Observational cross- sectional study	HD: 112, 60.6 (11.8), 33.9%	KDQOL-CF	HD: M = 68.86	N/A	N/A	N/A
13Manns et al., 2002, 14Canada (117)	Observational cross- sectional study	HD: 128, 61.8 (N/A), 43.7%	KDQOL-CF	HD: M = 78.70	N/A	N/A	SCCs not associated with dialysis adequacy (Kt/V)
15Mansouri et al., 2020, 16Iran (118)	Controlled intervention study	HD: 60, 49.7 (N/A), 11.67%	KDQOL-CF	HD: M = 45.79	N/A	N/A	N/A
18Mapes et al., 2003, 19US, France, Germany, 20Italy, Spain, UK, and 21Japan (119)	Observational cohort study	HD: 10030, 58.9 (14.9), 42.4%	KDQOL-CF	N/A	N/A	N/A	SCCs associated with mortality and hospitalisation
22Marinho et al., 2017, 23Brazil (120)	Observational cross- sectional study	HD: 105, N/A (N/A), 42.9%	KDQOL-CF	HD: M = 86.41	N/A	N/A	N/A
24Martin et al., 2000, 25UK (121)	Observational cross- sectional study	PD: 72, 51.4 (14.6), 36.1%	KDQOL-CF	PD: M = 78.60	N/A	N/A	SCCs associated with higher depressive and anxious symptoms (HADS) and external locus of control orientation
28Martin et al., 2001, 29UK (122)	Observational cross- sectional study	PD: 48, 54.0 (13.9), 33.3%	KDQOL-CF	PD: M = 80.22	N/A	N/A	SCCs not associated with dialysis adequacy (Kt/V)
31Martin-Alemañy et 32al., 2016, Mexico 33(123)	Controlled intervention study	HD: 36, 34.0 (N/A), 58.3%	KDQOL-CF	HD: M = 35.03	N/A	N/A	N/A
34Masina et al., 2016, 35Malawi (124)	Observational cross- sectional study	HD: 22, 44.8 (16.0), 40.9%	KDQOL-CF	HD: M = 83.00	N/A	N/A	N/A
36Maynard et al., 2019, 37Brazil (125)	Controlled intervention study	HD: 40, 46.5 (13.6), 45.0%	KDQOL-CF	HD: M = 82.65	N/A	No change in SCCs from baseline to 12 weeks in HD patients (control group)	N/A

38
39
40
41
42
43
44
45
46

4Author & Year & 5Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
6Mazairac et al., 2011, 7Netherlands, Norway, 8and Canada (126)	Observational cross- sectional study	HD: 589, 64.0 (14.0), 38.0%	KDQOL-CF	HD: M = 79.00	N/A	N/A	SCCs associated with lower albumin and higher creatinine; SCCs not associated with Subjective Global Assessment score, Normalized Protein Nitrogen Appearance, BMI, cholesterol, or Composite Score on Protein-Energy Nutritional Status
14Mazairac et al., 2012, 15Netherlands (127)	Observational cross- sectional study	HD: 570, 64.0 (14.0), 38.0%	KDQOL-CF	HD: M = 80.00	N/A	N/A	N/A
16Mazairac et al., 2013, 17Netherlands, Norway, 18and Canada (128)	Controlled intervention study	HD: 356, 64.0 (13.0), 35.0%; HDF: 358, 64.0 (14.0), 40.0%	KDQOL-CF	HD: M = 78.00; HDF: M = 80.00	No difference in SCCs between HD and HDF patients at either time point	No change in SCCs over 2 years in HD patients; SCCs increased over 2 years in HDF patients	N/A
21McAdams-DeMarco 22et al., 2018, US (129)	Observational cohort study	KTx: 443, 52.0 (14.1), 37.3%	KDQOL-CF	KTx: M = 86.70	N/A	SCCs reduced from pre- KTx (HD/PD/preemptive) to 3 months post-KTx	SCCs associated with frailty; SCCs not associated with donor type or kidney donor profile index
24Medeiros et al., 2017, 25Brazil (130)	Observational cross- sectional study	HD: 6, 47.2 (14.9), 66.7%	KDQOL-CF	HD: M = 86.66	N/A	N/A	N/A
27Mentari et al., 2005, 28US (131)	Observational cohort study	HD: 1600, N/A (N/A), 47.0%	KDQOL-CF	HD: M = 81.10	N/A	N/A	No impact of change in Medicare reimbursement on SCCs
30Michels et al., 2011, 31Netherlands (132)	Observational cohort study	APD: 64, 52.0 (17.8), 21.9% CAPD: 486, 53.6 (14.2), 35.2%	KDQOL-CF	N/A	No difference in SCCs between APD and CAPD at any time point	No change in SCCs from baseline to 6, 12, 18, 24, 30, and 36 months in PD patients	N/A
33Milan Manani et al., 342020, Italy (133)	Observational cross- sectional study	PD: 73, N/A (N/A), 26.1%	KDQOL-CF	PD: Median = 80.00 and 83.30 for patients with and without remote monitoring	N/A	N/A	No difference in SCCs between PD patients with and without remote monitoring

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Moist et al., 2008, US, France, Germany, Italy, Spain, UK, and Japan (134)	Observational cross-sectional study	HD: 20994, 60.7 (14.8), 42.0%	KDQOL-CF	N/A	N/A	N/A	SCCs associated with longer travel time to HD sessions
Molsted et al., 2007, Denmark (135)	Observational cross-sectional study	HD: 71, 59.0 (16.0), 24.0%; PD: 59, 59.0 (13.0), 44.0%	KDQOL-CF	HD: M = 84.40; PD: M = 82.90	No difference in SCCs between HD and PD patients	N/A	SCCs associated with lower blood haemoglobin, lower plasma albumin, longer dialysis vintage, and comorbidity; SCCs not associated with age, sex, or dialysis adequacy (Kt/V)
Montinaro et al., 2010, Italy (136)	Observational cross-sectional study	HD: 30, 57.8 (14.1), 33.0%	KDQOL-CF	N/A	N/A	N/A	SCCs associated with higher IL-6, TNF-alpha, and IL-10; SCCs associated with higher depressive and anxious symptoms (HADS)
Moura et al., 2014, Portugal (137)	Observational cross-sectional study	HDF: 322, 64.9 (14.3), 40.4%	KDQOL-CF	HDF: M = 77.70	N/A	N/A	CVC associated with more SCCs than AVF; SCCs not associated with diabetes or location of AVF (right forearm, left forearm, right upper arm, left upper arm)
Moura et al., 2015a, Portugal (138)	Observational cross-sectional study	HDF: 322, 64.9 (14.3), 40.4%	KDQOL-CF	HDF: M = 77.77	N/A	N/A	N/A
Moura et al., 2015b, Portugal (139)	Observational cross-sectional study	HDF: 305, 64.9 (14.3), 40.3%	KDQOL-CF	HDF: M = 78.26	N/A	N/A	SCCs not associated with age or sex
Naderifar et al., 2019, Iran (140)	Observational cross-sectional study	HD: 200, 48.4 (14.9), 50.0%	KDQOL-CF	HD: M = 48.36	N/A	N/A	N/A
Nagasawa et al., 2018a, Japan (141)	Observational cross-sectional study	HD: 51, 67.7 (12.1), 29.4%	KDQOL-CF	HD: M = 91.20	N/A	N/A	SCCs not associated with caregivers' quality of life (EQ-5D, SF-36)
Nagasawa et al., 2018b, Japan (142)	Observational cross-sectional study	HD: 92, 67.0 (11.6), 22.8%	KDQOL-CF	HD: M = 94.10	N/A	N/A	SCCs not associated with medication adherence
Nayana et al., 2017, India (143)	Observational cross-sectional study	HD: 50, 51.9 (14.7), 20.0%	KDQOL-CF	HD: M = 61.86	N/A	N/A	N/A
Neumann et al., 2018, Germany (144)	Observational cohort study	HD: 96, 51.9 (15.9), 25.0%; PD: 101, 55.7 (14.7), 35.6%	KDQOL-CF	HD: M = 87.20; PD: M = 86.60	No difference in SCCs between HD and PD patients	No change in SCCs from baseline to 12 months in HD/PD patients	SCCs not associated with age, comorbidity, psychotropic drug intake, education level, employment status, or dialysis vintage; SCCs associated with higher depressive symptoms

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Ohtake et al., 2014, Japan (145)	Controlled intervention study	HD: 68, 69.7 (10.8), 33.8%	KDQOL-CF	HD: M = 84.65	N/A	N/A	N/A
Okpechi et al., 2013, South Africa (146)	Observational cross-sectional study	HD: 56, 38.6 (1.4), 53.6%; PD: 26, 36.0 (2.2), 34.6%	KDQOL-CF	HD: M = 78.20; PD: M = 79.50	No difference in SCCs between HD and PD patients	N/A	N/A
Oliveira et al., 2016, Brazil (147)	Observational cross-sectional study	HD: 286, 54.7 (14.1), 39.9%	KDQOL-CF	HD: M = 80.97	N/A	N/A	SCCs associated with more missed HD sessions
Grocco-González et al., 2021, Mexico (148)	Observational cross-sectional study	PD: 151, 36.8 (16.2), 43.7%	KDQOL-CF	PD: Median = 87.00, 67.00, and 67.00 in patients with normal nutrition, mild to moderate protein-energy wasting, and severe protein-energy wasting	N/A	N/A	SCCs associated with worse nutrition (more severe protein-energy wasting)
Ortega et al., 2007, Spain (149)	Observational cohort study	KTx: 307, 51.6 (12.0), 40.8%	ESRD-SCL-Limited Cognitive Capacity	KTx: M = 14.3	N/A	SCCs reduced from pre-KTx to 3 months post-KTx; no change in SCCs from 3 to 6 and 12 months post-KTx	SCCs associated with lower education levels, longer duration on RRT, and nonactive working status; SCCs associated with poorer quality of life in the physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health domains of SF-36; SCCs associated with poorer quality of life assessed by EuroQol-5D
Osthus et al., 2012, Norway (150)	Observational cross-sectional study	HD & PD: 301, 59.8 (16.2), 33.9%	KDQOL-CF	N/A	N/A	N/A	No difference in SCCs between patients accepted for KTx waiting list, permanently rejected for KTx, and pending for KTx acceptance
Ottaviani et al., 2016, Brazil (151)	Observational cross-sectional study	HD: 100, 53.3 (14.7), 34.0%	KDQOL-CF	HD: M = 88.06	N/A	N/A	SCCs associated with higher depressive and anxious symptoms (HADS)

1
2
3

4Author & Year & 5Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
6Painter et al., 2012, 7US (152)	Observational cohort study	HD: 13, 45.5 (10.4), 15.4%; HD switching to DHD: 10, 42.6 (12.4), 10.0%; HD switching to KTx: 20, 43.5 (10.9), 15.0%	KDQOL-CF	HD: M = 89.70; DHD: 91.30; KTx: 88.30	No difference in SCCs between HD, DHD, and KTx patients	No change in SCCs from baseline to 6 months in HD patients; No change in SCCs switching from HD (baseline) to DHD or KTx (6 months)	N/A
11Pakpour et al., 2011, 12Iran (153)	Observational cross- sectional study	HD: 212, 57.5 (14.7), 43.8%	KDQOL-CF	HD: M = 55.70	N/A	N/A	SCCs not associated with overall health rating
13Palanova et al., 2019, 14Czech Republic (154)	Pre-post study with no control group	PD: 14, 61.9 (8.7), 57.1%	KDQOL-CF	PD: M = 91.90	N/A	N/A	N/A
15Paniagua et al., 2005, 16Mexico (155)	Controlled intervention study	PD: 923, 47.1 (13.9), 42.3%	KDQOL-CF	PD: M = 28.20	N/A	N/A	PD patients with enhanced creatinine clearance target reported more SCCs at 6 months than patients on standard PD; presence of diabetes associated with fewer SCCs; SCCs not associated with age, sex, serum albumin, GFR, dialysis vintage, hematocrit, or nPNA
22Park et al., 2007, 23Korea (156)	Observational cross- sectional study	HD & PD: 132 (HD), 32 (PD), 54.1 (13.0), 41.5%	KDQOL-CF	N/A	N/A	N/A	SCCs associated with lower overall health rating
25Park et al., 2012, 26Korea (157)	Observational cross- sectional study	PD: 105, 49.3 (13.6), 47.6%	KDQOL-CF	N/A	N/A	N/A	SCCs associated with higher depressive symptoms (BDI)
27Park et al., 2017, 28Korea (158)	Observational cohort study	HD (thrice-weekly): 207, 61.7 (13.4), 40.1%; HD (incremental): 105, 60.2 (13.3), 41.9%	KDQOL-CF	HD: M = 83.24	N/A	N/A	No difference in SCCs between thrice- weekly and incremental HD
31Parsons et al., 2006, 32Canada (159)	Pre-post study with no control group	HD: 13, 53.0 (18.0), 38.5%	KDQOL-CF	HD: M = 92.00	N/A	N/A	N/A
34Peipert et al., 2020, 35US (160)	Observational cohort study	KTx: 477, 49.0 (N/A), 40.0%	KDQOL-CF	KTx: M = 81.99	N/A	SCCs reduced from pre- KTx (HD/PD/preemptive) to 3 months post-KTx; No change in SCCs from 3 to 12 months post-KTx	Increase in SCCs from 3 to 12 months post-KTx associated with death-censored graft failure; Change in SCCs associated with age at KTx, and use of HD or PD prior to KTx; Change in SCCs not associated with sex, race, education level, or BMI

45
46

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Pereira et al., 2019, Brazil (161)	Observational cross-sectional study	HD: 258, 56.8 (14.5), 59.7%	KDQOL-CF	HD: M = 94.16	N/A	N/A	N/A
Portela et al., 2020, Brazil (162)	Observational cross-sectional study	HD: 103, 84.4 (3.9), 38.8%	KDQOL-CF	HD: M = 81.00	N/A	N/A	N/A
Posegger et al., 2020, Brazil (163)	Observational cross-sectional study	KTx waiting list: 57, 36.7 (6.1), 28.1%; KTx: 103, 40.0 (8.2), 48.5%	KDQOL-CF	KTx: M = 8.80	N/A	N/A	No difference in SCCs between patients who received KTx < 1 year, patients who received KTx between 1 and 3 years, and patients who received KTx > 3 years
Poulsen et al., 2017, Denmark (164)	Observational cohort study	HD: 82, 62.0 (15.0), 32.0%	KDQOL-CF	N/A	N/A	No change in SCCs from baseline to 6 and 12 months in HD patients	SCCs associated with lower age, increased hospitalisation, higher GFR, and higher albumin; SCCs not associated with sex, diabetes, number of comorbidities, or number of serious adverse events
Pucheu et al., 2004, France (165)	Observational cross-sectional study	PD: 47, 56.6 (17.4), 38.3%	KDQOL-CF	PD: M = 68.20	N/A	N/A	N/A
Rajkumar et al., 2019, Australia (166)	Observational cohort study	KTx: 75, 47.0 (13.0), 44.0%	KDQOL-CF	KTx: M = 81.00	N/A	SCCs reduced from pre-KTx (HD/PD/preemptive) to 12 months post-KTx	N/A
Ramatillah et al., 2017, Malaysia (167)	Observational cross-sectional study	HD: 78, N/A (N/A), 38.5%	KDQOL-CF	HD: M = 75.66	N/A	N/A	SCCs not associated with age, sex, or race
Rebollo Rubio et al., 2017, Spain (168)	Observational cross-sectional study	HD & PD: 120 (HD), 32 (PD), 62.5 (14.1), 28.3%	KDQOL-CF	HD: M = 30.08; PD: M = 31.46	No difference in SCCs between HD and PD patients	N/A	N/A
Romano-Zelekha et al., 2017, Israel (169)	Observational cross-sectional study	HD: 1102, 65.5 (14.2), 48.8%	KDQOL-CF	HD: M = 71.70	N/A	N/A	SCCs not associated with race
Ryu et al., 2021, Korea (170)	Observational cohort study	KTx: 842, 45.3 (11.7), 36.9%	KDQOL-CF	N/A	N/A	No change in SCCs from 2 to 4 and 6 years post-KTx	N/A

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Salamon et al., 2018, Australia (171)	Controlled intervention study	PD: 13, N/A (N/A), 54.0%	KDQOL-CF	PD: Median = 73.33	N/A	N/A	N/A
Sawada et al., 2021, Japan (172)	Observational cross-sectional study	KTx: 67, N/A (N/A), 40.3%	KDQOL-CF	N/A	N/A	N/A	SCCs associated with poorer quality of life (EQ-5D-5L)
Scott et al., 2009, US (173)	Controlled intervention study	HD: 88, 54.7 (14.7), 46.6%	KDQOL-CF	HD: M = 76.50	N/A	No change in SCCs from baseline to 3 months in HD patients (control group)	N/A
Seica et al., 2009, Romania (174)	Observational cross-sectional study	HD: 606, 51.7 (12.6), 45.3%	KDQOL-CF	HD: M = 78.80	N/A	N/A	N/A
Shahnavazi et al., 2016, Iran (175)	Observational cross-sectional study	HD: 98, N/A (N/A), 41.9%	KDQOL-CF	HD: M = 42.88	N/A	N/A	N/A
Shahnavazi et al., 2018, Iran (176)	Controlled intervention study	HD: 43, N/A (N/A), 41.9%	KDQOL-CF	HD: M = 40.76	N/A	No change in SCCs from baseline to 6 and 12 weeks in HD patients (control group)	N/A
Shimoyama et al., 2003, Japan (177)	Observational cross-sectional study	PD: 26, 49.8 (14.7), 34.0%	KDQOL-CF	PD: M = 82.90	N/A	N/A	SCCs associated with worse quality of life in the bodily pain, general health, vitality, and mental health domains of SF-36; SCCs not associated with the physical functioning, role physical, social functioning, or role emotional domains of SF-36
Shombing et al., 2017, Indonesia (178)	Observational cohort study	HD: 113, N/A (N/A), 46.9%	KDQOL-CF	HD: M = 84.13	N/A	N/A	N/A
Simic-Ogrizovic et al., 2009, Serbia (179)	Observational cohort study	HD: 102, 55.4 (13.8), 53.9%	KDQOL-CF	N/A	N/A	No change in SCCs from baseline to 3 and 6 years in HD patients	N/A

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Soares et al., 2017, Brazil (180)	Controlled intervention study	HD: 50, 51.4 (13.3), 0.0%	KDQOL-CF	HD: M = 87.39	N/A	No change in SCCs from baseline to 6 months in HD patients (control group)	N/A
Song et al., 2015, US (181)	Observational cross-sectional study	HD & PD: 125 (HD), 10 (PD), 58.4 (12.8), 46.7%	PAOFI	N/A	No difference in SCCs between HD and PD patients	N/A	SCCs associated with fewer years of education; SCCs not associated with age, history of stroke, comorbidity, dialysis vintage, or dialysis adequacy (Kt/V); SCCs associated with more severe pain and other symptoms (ESAS), worse physical functioning (ADL, IADL), and higher depressive (CES-D-SF) and anxious symptoms (STAI); SCCs associated with poorer performance in backward counting task in BTACT; SCCs not associated with performance in other tests in BTACT
Song et al., 2018, US (182)	Observational cohort study	HD & PD: 216 (HD), 11 (PD), 58.7 (12.6), 48.0%	PAOFI	N/A	N/A	SCCs reduced from baseline to 12 months in HD and PD patients	White patients reported more SCCs than nonwhite patients; SCCs not associated with age or comorbidity; SCCs associated with more severe overall symptoms (ESAS), worse physical functioning (ADL, IADL), worse emotional well-being (CESD-SF, SAI, PANAS-PA), and worse spiritual well-being (FACIT-Sp)
Lorenzen et al., 2007, Denmark (183)	Observational cross-sectional study	HD & PD: 66 (HD), 12 (PD), 62.5 (12.5), 25.6%	KDQOL-CF	N/A	N/A	N/A	SCCs not associated with diabetes

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Sorensen et al., 2012, US (184)	Observational cross-sectional study	HD: 168, 62.0 (17.0), 49.0%	KDQOL-CF	HD: M = 76.00	N/A	N/A	SCCs associated with lower SBP; SCCs not associated with age, sex, race, education level, HD vintage, cause of ESRD, smoking status, comorbidity, DBP, BMI, dialysis adequacy (Kt/V), albumin, or phosphorus; SCCs associated with higher depressive symptoms (CES-D); SCCs associated with immediate recall (from the Wechsler Memory Scale-III); SCCs not associated with MMSE score, verbal IQ, delayed recall, short delay, percent retention, recognition, block design, digit symbol, digit span, Trail Making Test A & B, COWAT, or mental alterations
Stavrianou et al., 2007, Greece (185)	Observational cross-sectional study	HD: 146, 57.0 (15.7), N/A	KDQOL-CF	HD: M = 84.00	N/A	N/A	N/A
Stumm et al., 2019, Brazil (186)	Pre-post study with no control group	HD: 63, 58.9 (13.1), 33.3%	KDQOL-CF	HD: M = 86.98	N/A	N/A	N/A
Turgill et al., 2020, US (187)	Observational cross-sectional study	HD & PD & HHD: 71 (HD), 14 (PD), 7 (HHD), 56.1 (14.8), 40.2%	PROMIS-Cognition	HD: M = 49.57	N/A	N/A	SCCs not associated with dialysis adequacy (Kt/V), albumin, or haemoglobin
Vamilselvan et al., 2021, India (188)	Controlled intervention study	HD: 37, 47.5 (11.6), 35.1%	KDQOL-CF	HD: M = 48.50	N/A	N/A	N/A
Tanaka et al., 2020, Japan (189)	Observational cross-sectional study	HD: 103, 62.7 (13.8), 20.4%; PD: 90, 65.5 (12.3), 31.1%; HD+PD: 36, 57.4 (9.1), 25.0%	KDQOL-CF	HD: M = 85.40; PD: M = 89.80; HD+PD: M = 91.70	HD patients reported more SCCs than PD and HD+PD patients; No difference in SCCs between PD and HD+PD patients	N/A	N/A

4Author & Year & 5Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
6Tannor et al., 2017, 7South Africa (190)	Observational cross- sectional study	HD: 58, 42.8 (9.8), 70.7%; PD: 48, 36.1 (10.7), 56.3%	KDQOL-CF	HD: M = 77.90; PD: M = 72.00	No difference in SCCs between HD and PD patients	N/A	N/A
9Ting et al., 2003, US 10(191)	Observational cohort study	HD switching to DHD: 42, 59.9 (16.7), 33.0%	KDQOL-CF	HD: M = 71.60; DHD: M = 85.10	Patients reported more SCCs on HD (baseline) than on DHD (3 and 12 months)	SCCs reduced after switching from HD (baseline) to DHD (3 months); No change in SCCs from 3 to 12 months post-initiation of DHD	N/A
16Tsarpali et al., 2021, 17Norway (192)	Observational cohort study	KTx: 136, 71.5 (4.1), 30.1%	KDQOL-CF	KTx: M = 92.10	N/A	SCCs reduced from pre- KTx (HD/PD/preemptive) to 1 year post-KTx; no change in SCCs from 1 to 3 years post-KTx	N/A
20Yürk et al., 2020, 21Turkey (193)	Observational cross- sectional study	HD: 60, 56.6 (14.1), 41.7%; PD: 45, 52.0 (13.2), 51.1%	KDQOL-CF	HD: M = 68.00; PD: M = 77.80	HD patients reported more SCCs than PD patients	N/A	SCCs associated with number of hospitalisation, duration of hospitalisation, and higher serum ferritin levels
24Uchiyama et al., 252019a, Japan (194)	Controlled intervention study	PD: 47, 64.1 (9.3), 25.5%	KDQOL-CF	PD: M = 91.33	N/A	No change in SCCs from baseline to 12 weeks in PD patients (control group)	N/A
28Uchiyama et al., 292019b, Japan (195)	Observational cross- sectional study	PD: 50, 63.8 (9.6), 26.0%	KDQOL-CF	PD: M = 90.40	N/A	N/A	SCCs associated with poorer exercise capacity (Incremental Shuttle Walking Test, handgrip strength, quadriceps strength)
32Unruh et al., 2004, US 33(196)	Controlled intervention study	HD: 1813, 57.6 (14.0), 56.3%	KDQOL-CF	HD: M = 75.40	N/A	No change in SCCs from baseline to 1, 2, and 3 years in HD patients	No effect of HD dose (Kt/V 1.05 vs. 1.45) or flux membranes (high vs. low) on SCCs
36Unruh et al., 2008, US 37(197)	Observational cohort study	HD: 1813, 57.6 (14.0), 56.3%	KDQOL-CF	N/A	N/A	N/A	SCCs not associated with age at baseline; Patients aged 70 and older reported larger increase in SCCs over 3 years than patients younger than 70 years old

1

2

3

4Author & Year & 5Location	6Study Design	7Sample Characteristics (Modality: N, Age M (SD), % Female)	8SCC Measure	9Frequency/Severity of SCCs	10Modality Difference	11Course of SCCs	12Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
13van Doorn et al., 142004, Belgium (198)	15Observational cross- sectional study	16HD: 70, 67.9 (N/A), N/A	17KDQOL-CF	18HD: M = 81.10	19N/A	20N/A	21SCCs not associated with age
22van Eps et al., 2010, 23Australia (199)	24Observational cohort study	25HD switching to NHD: 63, 52.0 (13.0), 21.0%	26KDQOL-CF	27HD: Median = 13.33; NHD: Median = 6.67	28No difference in SCCs between HD (baseline) and NHD (6-12 months)	29No change in SCCs switching from HD (baseline) to NHD (6-12 months)	30N/A
31Varela et al., 2011, 32Spain (200)	33Observational cross- sectional study	34PD: 53, 49.5 (17.0), 54.7%	35KDQOL-CF	36PD: M = 77.73	37N/A	38N/A	39SCCs associated with higher depressive and anxious symptoms (HADS)
40Vázquez et al., 2005, 41Spain (201)	42Observational cross- sectional study	43HD: 194, 48.6 (16.1), 56.7%	44KDQOL-CF	45HD: M = 78.82	46N/A	47N/A	48SCCs associated with unemployment; SCCs not associated age, sex, social class, comorbidity, albumin, or haemoglobin; SCCs associated with higher anxious symptoms (STAI-T); SCCs not associated with depressive symptoms (CDI)
49von der Lippe et al., 502014, Norway (202)	51Observational cross- sectional study	52HD & PD: 301, 59.8 (16.2), 33.9%	53KDQOL-CF	54N/A	55N/A	56N/A	57SCCs associated with lower age; SCCs associated with previous renal graft loss; SCCs not associated with comorbidity, BMI, dialysis vintage
58von der Lippe et al., 592016, Norway (203)	60Observational cohort study	61KTx: 142, 51.0 (15.5), 32.4%	62KDQOL-CF	63KTx: M = 88.00	64No change in SCCs from pre-KTx (HD/PD) to post-KTx	65N/A	66
67Walters et al., 2002, 68US (204)	69Observational cross- sectional study	70HD: 422, 59.0 (15.8), 46.4%	71KDQOL-CF	72HD: M = 75.16	73N/A	74N/A	75SCCs not associated with age or sex; SCCs associated with higher depressive symptoms
76Wang et al., 2008, 77Canada (205)	78Controlled intervention study	79HD: 18, 56.0 (N/A), 5.6%	80KDQOL-CF	81HD: M = 81.35	82N/A	83N/A	84No difference in SCCs between standard HD, HD with increased dialysate flow, HD with increased session time, and HD with 2 dialysers
85Warsame et al., 2018, 86US (206)	87Observational cross- sectional study	88HD: 431, 54.0 (13.0), 35.3%	89KDQOL-CF	90N/A	91N/A	92N/A	93SCCs not associated with intradialytic activity levels

39

40

41

42

43

44

45

46

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Watanabe et al., 2014, Japan (207)	Observational cross-sectional study	HD: 34, 57.1 (7.6), 23.6%; HHD: 46, 54.0 (8.3), 13.0%	KDQOL-CF	HD: M = 87.50; HHD: M = 90.10	No difference in SCCs between HD and HHD patients	N/A	N/A
Watanabe et al., 2018, Japan (208)	Observational cohort study	PD switching to HD+PD: 10, 53.3 (7.8), 50.0%	KDQOL-CF	PD: M = 83.30; HD+PD: M = 88.70	No difference in SCCs between PD (baseline) and HD+PD (12 months)	No change in SCCs switching from PD (baseline) to HD+PD (12 months)	N/A
Wong et al., 2010, Singapore (209)	Controlled intervention study	PD: 98, 62.4 (N/A), 46.9%	KDQOL-CF	PD: M = 76.60	N/A	No change in SCCs from baseline to 7 and 13 weeks in PD patients (control group)	N/A
Woźniak et al., 2018, Poland (210)	Observational cross-sectional study	KTx: 136, 50.4 (N/A), 45.6%	KDQOL-CF	KTx: M = 81.35	N/A	N/A	SCCs not associated with number of prescribed drugs
Wright et al., 2015, US (211)	Observational cross-sectional study	HD: 29, N/A (N/A), 44.8%; PD: 26, N/A (N/A), 61.5%; HHD: 22, N/A (N/A), 40.9%	KDQOL-CF	HD: M = 80.40; PD: M = 84.50; HHD: M = 81.20	No difference in SCCs between HD, PD, and HHD patients	N/A	N/A
Wu et al., 2014, Mainland China (212)	Controlled intervention study	HD: 65, 48.8 (13.9), 15.4%	KDQOL-CF	HD: M = 65.32	N/A	No change in SCCs from baseline to 12 weeks in HD patients (control group)	N/A
Yamana, 2009, Japan (213)	Observational cross-sectional study	HD: 44, 57.0 (13.8), 27.3%	KDQOL-CF	HD: Median = 93.30	N/A	N/A	SCCs associated with shorter HD vintage; SCCs not associated with age, sex, primary disease, complications, length of HD sessions, IDWG, cardiothoracic ratio, hematocrit, albumin, systolic blood pressure, potassium, phosphorus, or calcium
Yang et al., 2021, Mainland China (214)	Observational cohort study	HD: 273, 59.9 (14.4), 41.4%	KDQOL-CF	N/A	N/A	N/A	SCCs associated with higher posttraumatic stress symptoms
Yıldırım et al., 2007, Turkey (215)	Observational cross-sectional study	HD: 82, 51.0 (12.0), 65.0%	KDQOL-CF	HD: M = 83.21	N/A	N/A	N/A

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Author & Year & Location	Study Design	Sample Characteristics (Modality: N, Age M (SD), % Female)	SCC Measure	Frequency/Severity of SCCs	Modality Difference	Course of SCCs	Association with sociodemographic and clinical variables, patient-reported outcomes, and objective cognition
Yoon et al., 2016, Korea (216)	Observational cohort study	PD: 481, 51.3 (11.1), 46.8%	KDQOL-CF	PD: M = 83.50	N/A	N/A	SCCs associated with increased hydration status
Zabel et al., 2012, Australia (217)	Observational cross-sectional study	HD: 62, 63.0 (16.0), 60.0%	KDQOL-CF	HD: M = 80.00	N/A	N/A	SCCs associated with poorer self-reported appetite
Zheng et al., 2019, Mainland China (218)	Controlled intervention study	HD: 46, 78.0 (5.1), N/A	KDQOL-CF	HD: M = 68.87	N/A	No change in SCCs from baseline to 3 months in HD patients (control group)	N/A
Ziaja et al., 2009, Poland (219)	Observational cross-sectional study	KTx: 38, N/A (N/A), N/A	KDQOL-CF	KTx: Median = 80.00; KTx (simultaneous pancreas transplantation): Median = 93.33	KTx patients reported more SCCs than patients who received simultaneous pancreas and kidney transplantation	N/A	N/A
Gimmerman et al., 2003, Canada (220)	Observational cohort study	HD switching to HF: 7, 60.0 (N/A), 14.3%	KDQOL-CF	HD: M = 81.90; HF: M = 93.33	No difference in SCCs between HD (baseline) and HF (4 weeks)	No change in SCCs switching from HD (baseline) to HF (4 weeks)	N/A
Zubair et al., 2017, Pakistan (221)	Observational cross-sectional study	HD: 137, N/A (N/A), 27.7%	BC-CCI	HD: prevalence = 86.90%	N/A	N/A	SCCs associated with shorter HD vintage and poorer sleep quality (PSQI); SCCs not associated with age, sex, family income, marital status, HD frequency, smoking status, education level, BMI, occupation, or use of naswar

Notes. ESRD = End-Stage Renal Disease; HD = Haemodialysis; PD = Peritoneal Dialysis; KTx = Kidney Transplantation; NHD = Nocturnal Haemodialysis; HHD = Home Haemodialysis; DHD = Daily Haemodialysis; HDF = Hemodiafiltration; HF = Hemofiltration; HD+PD = Combined haemodialysis and peritoneal dialysis therapy; APD = Automated Peritoneal Dialysis; CAPD = Continuous Ambulatory Peritoneal Dialysis; RRT = Renal Replacement Therapy; SCC = Subjective Cognitive Complaint; PAOFI = Patient's Assessment of Own Functioning Inventory; BC-CCI = British Columbia Cognitive Complaints Inventory; CDS = Cognitive Difficulties Scale; PDQ = Perceived Deficits Questionnaire; KDQOL-CF = Kidney Disease Quality of Life Cognitive Function subscale; HUI = Health Utilities Index; WHODAS = World Health Organisation Disability Assessment Schedule; PROMIS = Patient-Reported Outcomes

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Measurement Information System; DSI = Dialysis Symptoms Index; ESRD-SCL = End-Stage Renal Disease Symptom Checklist; MMSE = Mini-Mental State Examination; 3MS = Modified Mini-Mental State test; WAIS-R = Wechsler Adult Intelligence Scale-Revised; BTACT = Brief Test of Adult Cognition by Telephone; COWAT = Controlled Oral Word Association Test; WHOQOL-BREF = Abbreviated World Health Organisation Quality of Life questionnaire; SF-36 = 36-item Short Form survey; BDI = Beck Depression Inventory; CES-D = Centre for Epidemiologic Studies Depression scale; HADS = Hospital Anxiety and Depression Scale; STAI = State-Trait Anxiety Inventory; ESAS = Edmonton Symptom Assessment System; ADL = Activities of Daily Living; IADL = Instrumental Activities of Daily Living; PSQI = Pittsburgh Sleep Quality Index; BMI = Body Mass Index; GFR = Glomerular Filtration Rate; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; AVF = Arteriovenous Fistula; AVG = Arteriovenous Graft; CVC = Central Venous Catheter; IDWG = Interdialytic Weight Gain; M = Mean; SD = Standard Deviation; N = Sample size.

References

1. Abbasi Abianeh N, Abdollah Zargar S, Amirkhani A, Adelipouramlash A. The effect of self-care education through teach back method on the quality of life in hemodialysis patients. *Nephrol Ther* [Internet]. 2020;16(4):197–200. Available from: <https://doi.org/10.1016/j.nephro.2020.01.002>
2. Ahmadzadeh S, Matlabi H, Allahverdipour H, Khodaei Ashan S. The effectiveness of self-management program on quality of life among haemodialysis patients. *Prog Palliat Care*. 2017;25(4):177–84.
3. AL-Jumaih A, Al-Onazi K, Binsalih S, Hejaili F, Al-Sayyari A. A study of quality of life and its determinants among hemodialysis patients using the KDQOL-SF instrument in one center in Saudi Arabia. *Arab J Nephrol Transplant*. 2011;4(3):125–30.
4. Alarcon JC, Bunch A, Ardila F, Zuñiga E, Vesga JJ, Rivera A, et al. Impact of Medium Cut-Off Dialyzers on Patient-Reported Outcomes: COREXH Registry. *Blood Purif*. 2021;50:110–8.
5. Amro A, Waldum B, Dammen T, Miaskowski C, Os I. Symptom clusters in patients on dialysis and their association with quality-of-life outcomes. *J Ren Care*. 2014;40(1):23–33.
6. Anees M, Ibrahim M, Imtiaz M, Batool S, Elahi I, Malik MR. Translation, validation and reliability of the kidney diseases quality of life-short form (KDQOL-SF form) tool in Urdu. *J Coll Physicians Surg Pakistan*. 2016;26(8):651–4.
7. Anees M, Batool S, Imtiaz M, Ibrahim M. Socio-economic factors affecting quality of life of hemodialysis patients and its effects on mortality. *Pakistan J Med Sci*. 2018;34(4):811–6.
8. Aoun M, Sleilaty G, Antoun L, Dib R, Chelala D. Duchenne smile is associated with quality of life and survival in hemodialysis patients. *Am J Health Behav*. 2020;44(3):313–25.
9. Aramwit P, Keongamaroon O, Siritientong T, Bang N, Supasyndh O. Sericin cream reduces pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled experimental study. *BMC Nephrol*. 2012;13:119.
10. Bacci MR, Adami F, Figueiredo FWS, Alves BCA, Da Veiga GL, Fonseca FLA. Quality of life on hemodialysis and inflammation: A descriptive analysis. *Brazilian J Med Biol Res*. 2018;51(6):e7355.
11. Bagasha P, Namukwaya E, Leng M, Kalyesubula R, Mutebi E, Naitala R, et al. Comparison of the health-related quality of life of end stage kidney disease patients on hemodialysis and non-hemodialysis management in Uganda. *BMC Palliat Care*. 2021;20:52.
12. Bakewell AB, Higgins RM, Edmunds ME. Does ethnicity influence perceived quality of life of patients on dialysis and following renal transplant? *Nephrol Dial Transplant*. 2001;16:1395–401.
13. Barbosa JBN, Moura ECSC de, Lira CLOB de, Marinho PÉ de M. Quality of life and duration of hemodialysis in patients with chronic kidney disease (CKD): a cross-sectional study. *Fisioter em Mov*. 2017;30(4):781–8.
14. Barotfi S, Molnar MZ, Almasi C, Kovacs AZ, Rempert A, Szeifert L, et al. Validation of the Kidney Disease Quality of Life-Short Form questionnaire in kidney transplant patients. *J Psychosom Res*. 2006;60:495–504.

15. Barzegar H, Jafari H, Charati JY, Esmaeili R. Relationship between duration of dialysis and quality of life in hemodialysis patients. *Iran J Psychiatry Behav Sci.* 2017;11(4):e6409.
16. Bataclan RP, Dial MAD. Cultural adaptation and validation of the Filipino version of Kidney Disease Quality of Life - Short Form (KDQOL-SF version 1.3). *Nephrology.* 2009;14:663–8.
17. Bawazier LA, Suhardjono S. Comparison of Quality of Life between Patients Undergoing Chronic Hemodialysis with Reusable Dialyzer and Single-Use Dialyzer: A Retrospective Cohort Study. *Acta Med Indones.* 2018;50(3):222–9.
18. Bele S, Bodhare TN, Mudgalkar N, Saraf A, Valsangkar S. Health-related quality of life and existential concerns among patients with end-stage renal disease. *Indian J Palliat Care.* 2012;18(2):103–8.
19. Bettoni LC, Ottaviani AC, Orlandi FS. Association between self-care and quality of life in chronic kidney disease patients. *Rev Eletrônica Enferm [Internet].* 2017;19:a14. Available from: <https://revistas.ufg.br/fen/article/view/27442>
20. Boudville N, Horner M, McEwan E, Lim WH, Mudge DW, Markus HE. Effect of FX dialysers on systemic inflammation and quality of life in chronic haemodialysis patients. *Blood Purif.* 2009;27:187–93.
21. Boudida B, Rhou H, Ezaitouni F, Ouzeddoun N, Bayahia R, Elhajji K, et al. Translation, cultural adaptation and validation of the kidney disease quality of life-short form 1.3 in an African country. *Transplant Proc [Internet].* 2014;46:1295–301. Available from: <http://dx.doi.org/10.1016/j.transproceed.2014.02.011>
22. Braga SFM, Peixoto SV, Gomes IC, de Assis Acúrcio F, Andrade EIG, Cherchiglia ML. Factors associated with health-related quality of life in elderly patients on hemodialysis. *Rev Saude Publica.* 2011;45(6):1127–36.
23. Brickman AL, Yount SE, Blaney NT, Rothberg S, De-Nour AK. Pathogenesis of cognitive complaints in patients on hemodialysis. *Gen Hosp Psychiatry.* 1996;18:36–43.
24. Carmichael P, Popoola J, John I, Stevens PE, Carmichael AR. Assessment of quality of life in a single centre dialysis population using the KDQOL-SF(Tm) questionnaire. *Qual Life Res.* 2000;9:195–205.
25. Castro SS, Leite CF, Baldin JE, Accioly MF. Validation of the Brazilian version of WHODAS 2.0 in patients on hemodialysis therapy. *Fisioter em Mov.* 2018;31:e003130.
26. Cavalcante MCV, Lamy ZC, Lamy Filho F, França AKT da C, dos Santos AM, Thomaz EBAF, et al. Factors associated with the quality of life of adults subjected to hemodialysis in a city in northeast Brazil. *Brazilian J Nephrol.* 2013;35(2):79–86.
27. Cepeda Marte JL, Javier A, Ruiz-Matuk C, Paulino-Ramirez R. Quality of Life and Nutritional Status in diabetic patients on hemodialysis. *Diabetes Metab Syndr Clin Res Rev [Internet].* 2019;13:576–80. Available from: <https://doi.org/10.1016/j.dsx.2018.11.020>
28. Chan MF, Wong FKY, Chow SKY. Investigating the health profile of patients with end-stage renal failure receiving peritoneal dialysis: a cluster analysis. *J Clin Nurs.* 2010;19:649–57.
29. Chen L, Chen G, Kong X. Serum level of high mobility group box protein-1 and prognosis of patients with end-

- stage renal disease on hemodialysis and peritoneal dialysis. *Medicine (Baltimore)*. 2021;100(5):e24275.
30. Cheung YB, Seow YY, Qu LM, Yee ACP. Measurement properties of the Chinese version of the Kidney Disease Quality of Life-short form (KDQOL-SF™) in end-stage renal disease patients with poor prognosis in Singapore. *J Pain Symptom Manage* [Internet]. 2012;44(6):923–32. Available from: <http://dx.doi.org/10.1016/j.jpainsymman.2011.12.282>
 31. Cho MK, Kim SY, Shim HY. Validity and Reliability of the Korean Version of the Dialysis Symptom Index for Hemodialysis Patients. *J Nurs Res*. 2018;26(6):399–410.
 32. Chow SKY, Wong FKY. Health-related quality of life in patients undergoing peritoneal dialysis: Effects of a nurse-led case management programme. *J Adv Nurs*. 2010;66(8):1780–92.
 33. Chrifi Alaoui A, Touti W, Al Borgi Y, Sqalli Houssaini T, El Rhazi K. Comparison of quality of life in end-stage renal disease patients undergoing hemodialysis and peritoneal dialysis in a Moroccan city. *Semin Dial*. 2022;
 34. Costa-Requena G, Cantarell MC, Moreso F, Parramon G, Seron D. Health related quality of life in renal transplantation: 2 years of longitudinal follow-up. *Med Clin (Barc)* [Internet]. 2017;149(3):114–8. Available from: <http://dx.doi.org/10.1016/j.medcle.2017.06.028>
 35. Czyżewski Ł, Sańko-Resmer J, Wyzgał J, Kurowski A. Assessment of health-related quality of life of patients after kidney transplantation in comparison with hemodialysis and peritoneal dialysis. *Ann Transplant*. 2014;19:576–85.
 36. Czyżewski Ł, Frelik P, Wyzgał J, Szarpak Ł. Evaluation of Quality of Life and Severity of Depression, Anxiety, and Stress in Patients After Kidney Transplantation. *Transplant Proc*. 2018;50:1733–7.
 37. D’Onofrio G, Simeoni M, Rizza P, Caroleo M, Capria M, Mazzitello G, et al. Quality of life, clinical outcome, personality and coping in chronic hemodialysis patients. *Ren Fail*. 2017;39(1):45–53.
 38. Dai L, Lu C, Liu J, Li S, Jin H, Chen F, et al. Impact of twice-or three-times-weekly maintenance hemodialysis on patient outcomes: A multicenter randomized trial. *Medicine (Baltimore)*. 2020;99(20):e20202.
 39. de Oliveira Cordeiro ED, da Costa TC, Teixeira MF, Toledo NDN, de Almeida GS. Quality of life of individuals receiving kidney transplantation in Amazonas state. *Rev Lat Am Enfermagem*. 2020;28:1–9.
 40. de Oliveira MP, Kusumota L, Marques S, Ribeiro R de CHM, Rodrigues RAP, Haas VJ. Work and Health-Related Quality of Life of patients on peritoneal dialysis. *ACTA Paul Enferm*. 2012;25(3):352–7.
 41. de Roij van Zuijdewijn CLM, Grooteman MPC, Bots ML, Blankestijn PJ, van den Dorpel MA, Nubé MJ, et al. Comparing Tests Assessing Protein-Energy Wasting: Relation With Quality of Life. *J Ren Nutr*. 2016;26(2):111–7.
 42. Debnath S, O’Connor J, Hura C, Kasinath B, Lorenzo C. Quality of Life and Depression Among Mexican Americans on Hemodialysis: A Preliminary Report. *Ther Apher Dial*. 2018;22(2):166–70.
 43. Dehesa-López E, Correa-Rotter R, Olvera-Castillo D, González-Parra C, Baizabal-Olarte R. Clinical, Dialytic, and Laboratory Factors Associated With Poor Health-Related Quality of Life in Mexican Patients on Hemodialysis. *Rev Investig Clínica*. 2016;68:192–200.
 44. Dehghan M, Namjoo Z, Bahrami A, Tajedini H, Shamsaddini-lori Z, Zarei A, et al. The use of complementary and

- alternative medicines, and quality of life in patients under hemodialysis: A survey in southeast Iran. *Complement Ther Med*. 2020;51:102431.
45. Diamant MJ, Young A, Gallo K, Xi W, Suri RS, Garg AX, et al. Hemodialysis in a satellite unit: Clinical performance target attainment and health-related quality of life. *Clin J Am Soc Nephrol*. 2011;6:1692–9.
46. Duarte PS, Ciconelli RM, Sesso R. Cultural adaptation and validation of the “Kidney Disease and Quality of Life - Short Form (KDQOL-SF™ 1.3)” in Brazil. *Brazilian J Med Biol Res*. 2005;38:261–70.
47. Duarte PS, Miyazaki MC, Blay SL, Sesso R. Cognitive-behavioral group therapy is an effective treatment for major depression in hemodialysis patients. *Kidney Int*. 2009;76:414–21.
48. Fan SS, Lin LF, Chen VCH, Hsieh CW, Hsiao HP, McIntyre RS, et al. Effects of Lower Past-Year Serum Sodium and Hyponatremia on Depression Symptoms and Cognitive Impairments in Patients With Hemodialysis. *Ther Apher Dial*. 2020;24(2):169–77.
49. Fiderkiewicz B, Rydzewska-Rosołowska A, Myśliwiec M, Birecka M, Kaczanowska B, Rydzewska G, et al. Factors associated with irritable bowel syndrome symptoms in hemodialysis patients. *World J Gastroenterol*. 2011;17(15):1976–81.
50. Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: A randomized trial. *Clin J Am Soc Nephrol*. 2009;4:726–33.
51. Fong E, Bargman JM, Chan CT. Cross-sectional comparison of quality of life and illness intrusiveness in patients who are treated with nocturnal home hemodialysis versus peritoneal dialysis. *Clin J Am Soc Nephrol*. 2007;2:1195–200.
52. Frimat L, Durand PY, Loos-Ayav C, Villar E, Panescu V, Briançon S, et al. Impact of first dialysis modality on outcome of patients contraindicated for kidney transplant. *Perit Dial Int*. 2006;26:231–9.
53. Fructuoso MR, Castro R, Oliveira I, Prata C, Morgado T. Quality of life in chronic kidney disease. *Nefrologia*. 2011;31(1):91–6.
54. Fukuhara S, Lopes AA, Bragg-Gresham JL, Kurokawa K, Mapes DL, Akizawa T, et al. Health-related quality of life among dialysis patients on three continents: The Dialysis Outcomes and Practice Patterns Study. *Kidney Int*. 2003;64:1903–10.
55. Lopes GB, Silva LF, Pinto GB, Catto LF, Martins MTS, Dutra MMD, et al. Patient’s response to a simple question on recovery after hemodialysis session strongly associated with scores of comprehensive tools for quality of life and depression symptoms. *Qual Life Res*. 2014;23(8):2247–56.
56. Garcia TW, Veiga JPR, Da Motta LDC, De Moura FJD, Casulari LA. Depressed mood and poor quality of life in male patients with chronic renal failure undergoing hemodialysis. *Rev Bras Psiquiatr*. 2010;32(4):369–74.
57. Giglio J, Kamimura MA, Lamarca F, Rodrigues J, Santin F, Avesani CM. Association of Sarcopenia With Nutritional Parameters, Quality of Life, Hospitalization, and Mortality Rates of Elderly Patients on Hemodialysis. *J Ren Nutr [Internet]*. 2018;28(3):197–207. Available from: <https://doi.org/10.1053/j.jrn.2017.12.003>

- 1
2
3 58. Goldfarb-Rumyantzev AS, Leypoldt JK, Nelson N, Kutner NG, Cheung AK. A crossover study of short daily
4 haemodialysis. *Nephrol Dial Transplant*. 2006;21:166–75.
5
6 59. Gonçalves FA, Dalosso IF, Borba JMC, Bucaneve J, Valerio NMP, Okamoto CT, et al. Quality of life in chronic
7 renal patients on hemodialysis or peritoneal dialysis: a comparative study in a referral service of Curitiba - PR. *J*
8 *Bras Nefrol*. 2015;37(4):467–74.
9
10 60. Gorodetskaya I, Zenios S, McCulloch CE, Bostrom A, Hsu CY, Bindman AB, et al. Health-related quality of life
11 and estimates of utility in chronic kidney disease. *Kidney Int*. 2005;68:2801–8.
12
13 61. Green J, Fukuhara S, Shinzato T, Miura Y, Wada S, Hays RD, et al. Translation, cultural adaptation, and initial
14 reliability and multitrait testing of the Kidney Disease Quality of Life Instrument for use in Japan. *Qual Life Res*.
15 2001;10:93–100.
16
17 62. Griva K, Davenport A, Harrison M, Newman SP. Non-adherence to Immunosuppressive Medications in Kidney
18 Transplantation: Intent Vs. Forgetfulness and Clinical Markers of Medication Intake. *Ann Behav Med*. 2012;44:85–
19 93.
20
21 63. Gumprecht J, Zelobowska K, Gosek K, Zywiec J, Adamski M, Grzeszczak W. Quality of life among diabetic and
22 non-diabetic patients on maintenance haemodialysis. *Exp Clin Endocrinol Diabetes*. 2010;118:205–8.
23
24 64. Hasan LM, Shaheen DAH, El Kannishy GAH, Sayed-Ahmed NAH, Abd El Wahab AM. Is health-related quality of
25 life associated with adequacy of hemodialysis in chronic kidney disease patients? *BMC Nephrol*. 2021;22:334.
26
27 65. Hayashi A, Yamaguchi S, Waki K, Fujiu K, Hanafusa N, Nishi T, et al. Testing the feasibility and usability of a
28 novel smartphone-based self-management support system for dialysis patients: A pilot study. *JMIR Res Protoc*.
29 2017;6(4):e63.
30
31 66. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the Kidney Disease Quality of Life
32 (KDQOL) Instrument. *Qual Life Res*. 1994;3:329–38.
33
34 67. Henry SL, Jamner LD, Choi SE, Pahl M V. The effect of the interdialytic interval on cognitive function in patients
35 on haemodialysis. *J Ren Care*. 2018;44(1):44–51.
36
37 68. Hernández Sánchez S, Carrero JJ, Morales JS, Ruiz JR. Effects of a resistance training program in kidney transplant
38 recipients: A randomized controlled trial. *Scand J Med Sci Sport*. 2021;31:473–9.
39
40 69. Ho SE, Ho CCK, Norshazwani N, Teoh KH, Ismail MS, Jaafar MZ, et al. Perception of quality of life amongst end
41 stage renal failure patients undergoing haemodialysis. *Clin Ter*. 2013;164(6):391–7.
42
43 70. Hornik B, Duława J. Frailty, quality of life, anxiety, and other factors affecting adherence to physical activity
44 recommendations by hemodialysis patients. *Int J Environ Res Public Health*. 2019;16:1827.
45
46 71. Hyodo T, Ishida H, Masui N, Taira T, Yamamoto S, Oka M, et al. Kidney disease quality of life of Japanese
47 dialysis patients who desire administration of sildenafil and the treatment of erectile dysfunction using sildenafil.
48 *Ther Apher Dial*. 2004;8(4):340–6.
49
50 72. Lopes JM, Fukushima RLM, Inouye K, Pavarini SCI, Orlandi FDS. Quality of life related to the health of chronic
51
52
53
54
55
56
57
58
59
60

- renal failure patients on dialysis. *ACTA Paul Enferm.* 2014;27(3):230–6.
73. Jansz TT, Bonenkamp AA, Boereboom FTJ, Van Reekum FE, Verhaar MC, Van Jaarsveld BC. Health-related quality of life compared between kidney transplantation and nocturnal hemodialysis. *PLoS One.* 2018;13(9):e0204405.
 74. Jassal S V., Devins GM, Chan CT, Bozanovic R, Rourke S. Improvements in cognition in patients converting from thrice weekly hemodialysis to nocturnal hemodialysis: A longitudinal pilot study. *Kidney Int [Internet].* 2006;70:956–62. Available from: <http://dx.doi.org/10.1038/sj.ki.5001691>
 75. Jayanti A, Foden P, Brenchley P, Wearden A, Mitra S. The Burden of Cognitive Impairment in Patients With End-Stage Renal Disease and Impact on Dialysis Modality Choice. *Kidney Int Reports [Internet].* 2016;1:240–9. Available from: <http://dx.doi.org/10.1016/j.ekir.2016.07.010>
 76. Jiao Y, Gao S, Wu L, Song A. Continuity of care for quality of life and clinical outcomes in patients with peritoneal dialysis. *Int J Clin Exp Med.* 2017;10(12):16586–94.
 77. Joshi VD, Mooppil N, Lim JFY. Validation of the kidney disease quality of life-short form: A cross-sectional study of a dialysis-targeted health measure in singapore. *BMC Nephrol.* 2010;11:36.
 78. Jung HY, Jang HM, Kim YW, Cho S, Kim HY, Kim SH, et al. Depressive symptoms, patient satisfaction, and quality of life over time in automated and continuous ambulatory peritoneal dialysis patients: a prospective multicenter propensity-matched study. *Medicine (Baltimore).* 2016;95(21):1–10.
 79. Kanamori H, Nagai K, Matsubara T, Mima A, Yanagita M, Iehara N, et al. Comparison of the psychosocial quality of life in hemodialysis patients between the elderly and non-elderly using a visual analogue scale: The importance of appetite and depressive mood. *Geriatr Gerontol Int.* 2012;12:65–71.
 80. Kang SH, Do JY, Lee SY, Kim JC. Effect of dialysis modality on frailty phenotype, disability, and health-related quality of life in maintenance dialysis patients. *PLoS One.* 2017;12(5):e0176814.
 81. Kim KH, Kim TH, Kang JW, Sul JU, Lee MS, Kim JI, et al. Acupuncture for symptom management in hemodialysis patients: A prospective, observational pilot study. *J Altern Complement Med.* 2011;17(8):741–8.
 82. Kim DH, Park JI, Lee JP, Kim YL, Kang SW, Yang CW, et al. The effects of vascular access types on the survival and quality of life and depression in the incident hemodialysis patients. *Ren Fail [Internet].* 2020;42(1):30–9. Available from: <https://doi.org/10.1080/0886022X.2019.1702558>
 83. Kim JC, Young Do J, Kang SH. Comparisons of physical activity and understanding of the importance of exercise according to dialysis modality in maintenance dialysis patients. *Sci Rep [Internet].* 2021;11:21487. Available from: <https://doi.org/10.1038/s41598-021-00924-0>
 84. Knudsen S de P, Eidemak I, Molsted S. Health related quality of life in 2002 and 2015 in patients undergoing hemodialysis: a single center study. *Ren Fail.* 2016;38(8):1234–9.
 85. Ko B, Khurana A, Spencer J, Scott B, Hahn M, Hammes M. Religious beliefs and quality of life in an American inner-city haemodialysis population. *Nephrol Dial Transplant.* 2007;22:2985–90.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
86. Kontodimopoulos N, Niakas D. Determining the basic psychometric properties of the Greek KDQOL-SF™. *Qual Life Res.* 2005;14:1967–75.
87. Korevaar JC, Merkus MP, Jansen MAM, Dekker FW, Boeschoten EW, Krediet RT. Validation of the KDQOL-SF™: A dialysis-targeted health measure. *Qual Life Res.* 2002;11:437–47.
88. Kostro JZ, Hellmann A, Kobiela J, Skóra I, Lichodziejewska-Niemierko M, Dębska-Slizień A, et al. Quality of life after kidney transplantation: A prospective study. *Transplant Proc.* 2016;48:50–4.
89. Krishnasamy R, Wilkinson CI, McClure CD, Wilson M, Bashford J, Clark CJ, et al. Contact precautions for colonisation with multidrug-resistant organisms and haemodialysis patient quality of life and mood: a pilot case-control study. *Ren Soc Australas J.* 2019;14(3):19–25.
90. Kurella M, Luan J, Yaffe K, Chertow GM. Validation of the Kidney Disease Quality of Life (KDQOL) Cognitive Function subscale. *Kidney Int.* 2004;66:2361–7.
91. Kusumoto L, Marques S, Haas VJ, Rodrigues RAP. Adults and elderly on hemodialysis evaluation of health related quality of life. *Acta Paul Enferm.* 2008;21:152–9.
92. Kutner NG, Zhang R, Barnhart H, Collins AJ. Health status and quality of life reported by incident patients after 1 year on haemodialysis or peritoneal dialysis. *Nephrol Dial Transplant.* 2005;20:2159–67.
93. Kutner NG, Zhang R, Brogan D. Race, gender, and incident dialysis patients' reported health status and quality of life. *J Am Soc Nephrol.* 2005;16:1440–8.
94. Kutner NG, Zhang R, Huang Y, Bliwise DL. Association of sleep difficulty with kidney disease quality of life cognitive function score reported by patients who recently started dialysis. *Clin J Am Soc Nephrol.* 2007;2:284–9.
95. Lai S, Amabile MI, Bargagli MB, Musto TG, Martinez A, Testorio M, et al. Peritoneal dialysis in older adults: Evaluation of clinical, nutritional, metabolic outcomes, and quality of life. *Medicine (Baltimore).* 2018;97(35):e11953.
96. Lazarus ER. Effectiveness of education and exercise on quality of life among patients undergoing hemodialysis. *Clin Epidemiol Glob Heal [Internet].* 2019;7:402–8. Available from: <https://doi.org/10.1016/j.cegh.2018.07.003>
97. Lee AJ, Morgan CL, Conway P, Currie CJ. Characterisation and comparison of health-related quality of life for patients with renal failure. *Curr Med Res Opin.* 2005;21(11):1777–83.
98. Lee J, Kim YC, Kwon S, Li L, Oh S, Kim DH, et al. Impact of health-related quality of life on survival after dialysis initiation: A prospective cohort study in Korea. *Kidney Res Clin Pract.* 2020;39(4):426–40.
99. Leone DRR, Pereira GA, de Paula Silva AC, de Aguiar AS. Level of activation and quality of life related to the health of people in hemodialysis. *Esc Anna Nery [Internet].* 2021;25(4):e20200486. Available from: <https://web-b-ebsscohost-com.ezp.twu.edu/ehost/detail/detail?vid=3&sid=4b5fb3ce-642f-4d00-be73-3fb620c49199%40pdv-sessionmgr01&bdata=JnNpdGU9ZWWhvc3QtbGl2ZQ%3D%3D#AN=149825317&db=ccm>
100. Li J, Wang H, Xie H, Mei G, Cai W, Ye J, et al. Effects of post-discharge nurse-led telephone supportive care for patients with chronic kidney disease undergoing peritoneal dialysis in China: A randomized controlled trial. *Perit*

- Dial Int. 2014;34:278–88.
101. Li Y-N, Shapiro B, Kim JC, Zhang M, Porszasz J, Bross R, et al. Association between quality of life and anxiety, depression, physical activity and physical performance in maintenance hemodialysis patients. *Chronic Dis Transl Med* [Internet]. 2016;2(2):110–9. Available from: <http://dx.doi.org/10.1016/j.cdtm.2016.09.004>
 102. Lim JH, Park Y, Yook JM, Choi SY, Jung HY, Choi JY, et al. Randomized controlled trial of medium cut-off versus high-flux dialyzers on quality of life outcomes in maintenance hemodialysis patients. *Sci Rep* [Internet]. 2020;10:7780. Available from: <http://dx.doi.org/10.1038/s41598-020-64622-z>
 103. Lo C, Li L, Lo W, Chan M, So E, Tang S, et al. Benefits of exercise training in patients on continuous ambulatory peritoneal dialysis. *Am J Kidney Dis*. 1998;32(6):1011–8.
 104. Lønning K, Heldal K, Bernklev T, Brunborg C, Andersen MH, Von Der Lippe N, et al. Improved health-related quality of life in older kidney recipients 1 year after transplantation. *Transplant Direct*. 2018;4(4):e351.
 105. Lønning K, Midtvedt K, Bernklev T, Brunborg C, Andersen MH, von der Lippe N, et al. Changes in health-related quality of life in older candidates waiting for kidney transplantation. *Nephrology*. 2018;23:948–56.
 106. Loos-Ayav C, Frimat L, Kessler M, Chanliau J, Durand PY, Briançon S. Changes in health-related quality of life in patients of self-care vs. in-center dialysis during the first year. *Qual Life Res*. 2008;17:1–9.
 107. Lopes AA, Bragg-Gresham JL, Satayathum S, McCullough K, Pifer T, Goodkin DA, et al. Health-related quality of life and associated outcomes among hemodialysis patients of different ethnicities in the United States: The dialysis outcomes and practice patterns study (DOPPS). *Am J Kidney Dis*. 2003;41(3):605–15.
 108. Lopes AA, Bragg-Gresham JL, Goodkin DA, Fukuhara S, Mapes DL, Young EW, et al. Factors associated with health-related quality of life among hemodialysis patients in the DOPPS. *Qual Life Res*. 2007;16:545–57.
 109. Lopes LCC, Mota JF, Prestes J, Schincaglia RM, Silva DM, Queiroz NP, et al. Intradialytic Resistance Training Improves Functional Capacity and Lean Mass Gain in Individuals on Hemodialysis: A Randomized Pilot Trial. *Arch Phys Med Rehabil*. 2019;100(11):2151–8.
 110. Ma S-J, Wang W-J, Tang M, Chen H, Ding F. Mental health status and quality of life in patients with end-stage renal disease undergoing maintenance hemodialysis. *Ann Palliat Med*. 2021;10(6):6112–21.
 111. Macedo C, Amaral TF, Rodrigues J, Santin F, Avesani CM. Malnutrition and Sarcopenia Combined Increases the Risk for Mortality in Older Adults on Hemodialysis. *Front Nutr*. 2021;8:721941.
 112. Madariaga MLL, Spencer PJ, Shanmugarajah K, Crisalli KA, Chang DC, Markmann JF, et al. Effect of tolerance versus chronic immunosuppression protocols on the quality of life of kidney transplant recipients. *JCI Insight*. 2016;1(8):e87019.
 113. Malekmakan L, Roozbeh J, Zonnoor SL, Azadian F, Sayadi M, Tadayoni A. The Comparison of Quality of Life among Peritoneal and Hemodialysis Patients. *Int J Med Res Heal Sci*. 2016;5(4):127–32.
 114. Malindretos P, Sarafidis P, Spaia S, Sioulis A, Zeggos N, Raptis V, et al. Adaptation and validation of the Kidney Disease Quality of Life-Short Form questionnaire in the Greek language. *Am J Nephrol*. 2010;31:9–14.

- 1
2
3 115. Manavalan M, Majumdar A, Harichandra Kumar KT, Priyamvada PS. Assessment of health-related quality of life
4 and its determinants in patients with chronic kidney disease. *Indian J Nephrol.* 2017;27:37–43.
- 5
6 116. Manju L, Joseph J, Beevi N. Validation of Kidney Disease Quality of Life Short Form 36 (KDQOL- SF™) in
7 Malayalam among Patients Undergoing Haemodialysis in South Kerala. *Indian J Nephrol.* 2020;30(5):316–20.
- 8
9 117. Manns BJ, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C. Dialysis adequacy and health related quality of
10 life in hemodialysis patients. *ASAIO J.* 2002;48(5):565–9.
- 11
12 118. Mansouri S, Jalali A, Rahmati M, Salari N. Educational supportive group therapy and the quality of life of
13 hemodialysis patients. *Biopsychosoc Med.* 2020;14:27.
- 14
15 119. Mapes DL, Lopes AA, Satayathum S, McCullough KP, Goodkin DA, Locatelli F, et al. Health-related quality of
16 life as a predictor of mortality and hospitalization: The dialysis outcomes and practice patterns study (DOPPS).
17 *Kidney Int.* 2003;64:339–49.
- 18
19 120. Marinho CLA, de Oliveira JF, Borges JE da S, Silva RS da, Fernandes FECV. Quality of life of chronic renal
20 patients undergoing hemodialysis. *Rev da Rede Enferm do Nord.* 2017;18(3):396.
- 21
22 121. Martin CR, Thompson DR. Prediction of quality of life in patients with end-stage renal disease. *Br J Health*
23 *Psychol.* 2000;5:41–55.
- 24
25 122. Martin CR, Thompson DR. Does dialysis adequacy impact on the quality of life of end-stage renal disease patients?
26 *Clin Eff Nurs.* 2001;5:57–65.
- 27
28 123. Martin-Alemañy G, Valdez-Ortiz R, Olvera-Soto G, Gomez-Guerrero I, Aguire-Esquivel G, Cantu-Quintanilla G,
29 et al. The effects of resistance exercise and oral nutritional supplementation during hemodialysis on indicators of
30 nutritional status and quality of life. *Nephrol Dial Transplant.* 2016;31:1712–20.
- 31
32 124. Masina T, Chimera B, Kamponda M, Dreyer G. Health related quality of life in patients with end stage kidney
33 disease treated with haemodialysis in Malawi: a cross sectional study. *BMC Nephrol* [Internet]. 2016;17:61.
34 Available from: <http://dx.doi.org/10.1186/s12882-016-0292-9>
- 35
36 125. Maynard LG, De Menezes DL, Lião NS, De Jesus EM, Andrade NLS, Santos JCD, et al. Effects of Exercise
37 Training Combined with Virtual Reality in Functionality and Health-Related Quality of Life of Patients on
38 Hemodialysis. *Games Health J.* 2019;8(5):339–48.
- 39
40 126. Mazairac AHA, de Wit GA, Penne EL, van der Weerd NC, Grooteman MPC, van den Dorpel MA, et al. Protein-
41 Energy Nutritional Status and Kidney Disease-specific Quality of Life in Hemodialysis Patients. *J Ren Nutr.*
42 2011;21(5):376–86.
- 43
44 127. Mazairac AHA, Grooteman MPC, Blankestijn PJ, Lars Penne E, Van Der Weerd NC, Den Hoedt CH, et al.
45 Differences in quality of life of hemodialysis patients between dialysis centers. *Qual Life Res.* 2012;21:299–307.
- 46
47 128. Mazairac AHA, de Wit GA, Grooteman MPC, Penne EL, van der Weerd NC, den Hoedt CH, et al. Effect of
48 hemodiafiltration on quality of life over time. *Clin J Am Soc Nephrol.* 2013;8:82–9.
- 49
50 129. McAdams-DeMarco MA, Olorundare IO, Ying H, Warsame F, Haugen CE, Hall R, et al. Frailty and Postkidney
51
52
53
54
55
56
57
58
59
60

- Transplant Health-Related Quality of Life. *Transplantation*. 2018;102(2):291–9.
130. Medeiros NCB de, dos Santos Silva J, Priscila Dantas de Oliveira N, Regina Silva Cavalcante A, Taveira Gonçalves C, Luciana Magnani K. Effects of non-invasive ventilatory support in tolerance to the effort of patients with hemodialysis. *Fisioter Mov* [Internet]. 2017;30(1):151–8. Available from: <http://dx.doi.org/10.1590/1980-5918.030.001.AO16>
131. Mentari EK, Deoreo PB, O'Connor AS, Love TE, Ricanati ES, Sehgal AR. Changes in medicare reimbursement and patient-nephrologist visits, quality of care, and health-related quality of life. *Am J Kidney Dis*. 2005;46(4):621–7.
132. Michels WM, van Dijk S, Verduijn M, le Cessie S, Boeschoten EW, Dekker FW, et al. Quality of life in automated and continuous ambulatory peritoneal dialysis. *Perit Dial Int*. 2011;31(2):138–47.
133. Milan Manani S, Baretta M, Giuliani A, Virzi GM, Martino F, Crepaldi C, et al. Remote monitoring in peritoneal dialysis: benefits on clinical outcomes and on quality of life. *J Nephrol* [Internet]. 2020;33(6):1301–8. Available from: <https://doi.org/10.1007/s40620-020-00812-2>
134. Moist LM, Bragg-Gresham JL, Pisoni RL, Saran R, Akiba T, Jacobson SH, et al. Travel Time to Dialysis as a Predictor of Health-Related Quality of Life, Adherence, and Mortality: The Dialysis Outcomes and Practice Patterns Study (DOPPS). *Am J Kidney Dis*. 2008;51(4):641–50.
135. Molsted S, Prescott L, Heaf J, Eidemak I. Assessment and clinical aspects of health-related quality of life in dialysis patients and patients with chronic kidney disease. *Nephron - Clin Pract*. 2007;106:c24–33.
136. Montinaro V, Iaffaldano GP, Granata S, Porcelli P, Todarello O, Schena FP, et al. Emotional symptoms, quality of life and cytokine profile in hemodialysis patients. *Clin Nephrol*. 2010;73(1):36–43.
137. Moura A, Madureira J, Alija P, Fernandes JC, Oliveira JG, Lopez M, et al. Type of vascular access and location in online hemodiafiltration and its association with patient's perception of health-related quality of life. *J Vasc Access*. 2014;15(3):175–82.
138. Moura A, Madureira J, Alija P, Fernandes JC, Oliveira JG, Lopez M, et al. Predictors of health-related quality of life perceived by end-stage renal disease patients under online hemodiafiltration. *Qual Life Res*. 2015;24:1327–35.
139. Moura A, Madureira J, Alija P, Fernandes JC, Oliveira JG, Lopez M, et al. Effect of aging in the perception of health-related quality of life in end-stage renal disease patients under online-hemodiafiltration. *Aging Dis*. 2015;6(1):17–26.
140. Naderifar M, Tafreshi MZ, Ilkhani M, Akbarizadeh MR, Ghaljaei F. Correlation between quality of life and adherence to treatment in hemodialysis patients. *J Ren Inj Prev*. 2019;8(1):22–7.
141. Nagasawa H, Sugita I, Tachi T, Esaki H, Yoshida A, Kanematsu Y, et al. The Relationship Between Dialysis Patients' Quality of Life and Caregivers' Quality of Life. *Front Pharmacol*. 2018;9:770.
142. Nagasawa H, Tachi T, Sugita I, Esaki H, Yoshida A, Kanematsu Y, et al. The effect of quality of life on medication compliance among dialysis patients. *Front Pharmacol*. 2018;9:488.

- 1
2
3 143. Nayana SA, Balasubramanian T, Nathaliya PM, Nimsha Hussain P, Mohammed Salim KT, Muhammed Lubab P. A
4 cross sectional study on assessment of health related quality of life among end stage renal disease patients
5 undergoing hemodialysis. *Clin Epidemiol Glob Heal* [Internet]. 2017;5(3):148–53. Available from:
6 <http://dx.doi.org/10.1016/j.cegh.2016.08.005>
7
8
9
10 144. Neumann D, Mau W, Wienke A, Girndt M. Peritoneal dialysis is associated with better cognitive function than
11 hemodialysis over a one-year course. *Kidney Int* [Internet]. 2018;93:430–8. Available from:
12 <https://doi.org/10.1016/j.kint.2017.07.022>
13
14
15 145. Ohtake T, Sato M, Nakazawa R, Kondoh M, Miyaji T, Moriya H, et al. Randomized pilot trial between
16 prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. *Ther Apher*
17 *Dial*. 2014;18(1):1–8.
18
19
20 146. Okpechi IG, Nthite T, Swanepoel CR. Health-related quality of life in patients on hemodialysis and peritoneal
21 dialysis. *Saudi J Kidney Dis Transplant*. 2013;24(3):519–26.
22
23
24 147. Oliveira APB, Schmidt DB, Amatneeks TM, Santos JC Dos, Cavallet LHR, Michel RB. Quality of life in
25 hemodialysis patients and the relationship with mortality, hospitalizations and poor treatment adherence. *J Bras*
26 *Nefrol*. 2016;38(4):411–20.
27
28
29 148. Orozco-González CN, Márquez-Herrera RM, Cortés-Sanabria L, Cueto-Manzano AM, Gutiérrez-Medina M,
30 Gómez-García EF, et al. Severity of protein-energy wasting and obesity are independently related with poor quality
31 of life in peritoneal dialysis patients. *Nefrología* [Internet]. 2021; Available from:
32 <https://doi.org/10.1016/j.nefro.2021.04.003>
33
34
35 149. Ortega T, Valdés C, Rebollo P, Ortega F. Evaluation of reliability and validity of Spanish version of the end-stage
36 renal disease symptom checklist-transplantation module. *Transplantation*. 2007;84(11):1428–35.
37
38
39 150. Østhus TBH, Preljevic V, Sandvik L, Dammen T, Os I. Renal transplant acceptance status, health-related quality of
40 life and depression in dialysis patients. *J Ren Care*. 2012;38(2):98–106.
41
42
43 151. Ottaviani AC, Betoni LC, Pavarini SCI, Gramani Say K, Zazzetta MS, Orlandi F de S. Association Between
44 Anxiety and Depression and Quality of Life of Chronic Renal Patients on Hemodialysis. *Texto Context - Enferm*.
45 2016;25(3):1–8.
46
47
48 152. Painter P, Krasnoff JB, Kuskowski M, Frassetto L, Johansen K. Effects of modality change on health-related quality
49 of life. *Hemodial Int*. 2012;16(3):377–86.
50
51
52 153. Pakpour AH, Yekaninejad M, Molsted S, Harrison AP, Hashemi F, Saffari M. Translation, cultural adaptation
53 assessment, and both validity and reliability testing of the Kidney Disease Quality of Life - Short Form version 1.3
54 for use with Iranian patients. *Nephrology*. 2011;16:106–12.
55
56
57 154. Palanova P, Mrkvicova V, Nedbalkova M, Sosikova M, Konecny P, Jarkovsky J, et al. Home-based training using
58 neuromuscular electrical stimulation in patients on continuous ambulatory peritoneal dialysis: A pilot study. *Artif*
59 *Organs*. 2019;43(8):796–805.
60

- 1
2
3 155. Paniagua R, Amato D, Vonesh E, Guo A, Mujais S. Health-related quality of life predicts outcomes but is not
4 affected by peritoneal clearance: The ADEMEX trial. *Kidney Int.* 2005;67:1093–104.
5
6 156. Park HJ, Kim S, Yong JS, Han SS, Yang DH, Meguro M, et al. Reliability and validity of the Korean version of
7 kidney disease quality of life instrument (KDQOL-SF™). *Tohoku J Exp Med.* 2007;211:321–9.
8
9 157. Park HC, Lee H, Lee JP, Kim DK, Oh KH, Joo KW, et al. Lower residual renal function is a risk factor for
10 depression and impaired health-related quality of life in korean peritoneal dialysis patients. *J Korean Med Sci.*
11 2012;27:64–71.
12
13 158. Park JI, Park JT, Kim YL, Kang SW, Yang CW, Kim NH, et al. Comparison of outcomes between the incremental
14 and thrice-weekly initiation of hemodialysis: A propensity-matched study of a prospective cohort in Korea. *Nephrol*
15 *Dial Transplant.* 2017;32(2):355–63.
16
17 159. Parsons TL, Toffelmire EB, King-VanVlack CE. Exercise Training During Hemodialysis Improves Dialysis
18 Efficacy and Physical Performance. *Arch Phys Med Rehabil.* 2006;87:680–7.
19
20 160. Peipert JD, Caicedo JC, Friedewald JJ, Abecassis MMI, Cella D, Ladner DP, et al. Trends and predictors of
21 multidimensional health-related quality of life after living donor kidney transplantation. *Qual Life Res [Internet].*
22 2020;29(9):2355–74. Available from: <https://doi.org/10.1007/s11136-020-02498-2>
23
24 161. Pereira CV, Leite ICG. Health-related quality of life of patients receiving hemodialysis therapy. *ACTA Paul*
25 *Enferm.* 2019;32(3):267–74.
26
27 162. Portela OT, Belasco AGS, Casarin BF, Lana LD, Nascimento IP, Barbosa DA, et al. Quality of life and cognitive
28 and functional performance of octogenarians and nonagenarians undergoing hemodialysis. *Int Urol Nephrol*
29 *[Internet].* 2020;52(1):179–85. Available from: <https://doi.org/10.1007/s11255-019-02323-x>
30
31 163. Posegger KR, Linhares MM, Mucci S, Romano TM, Gonzalez AM, Salzedas Netto AA, et al. The quality of life in
32 type I diabetic patients with end-stage kidney disease before and after simultaneous pancreas-kidney
33 transplantation: a single-center prospective study. *Transpl Int.* 2020;33:330–9.
34
35 164. Poulsen CG, Kjaergaard KD, Peters CD, Jespersen B, Jensen JD. Quality of life development during initial
36 hemodialysis therapy and association with loss of residual renal function. *Hemodial Int.* 2017;21:409–21.
37
38 165. Pucheu S, Consoli SM, D'Auzac C, Français P, Issad B. Do health causal attributions and coping strategies act as
39 moderators of quality of life in peritoneal dialysis patients? *J Psychosom Res.* 2004;56:317–22.
40
41 166. Rajkumar T, Mazid S, Vucak-Dzumhur M, Sykes TM, Elder GJ. Health-related quality of life following kidney and
42 simultaneous pancreas kidney transplantation. *Nephrology.* 2019;24:975–82.
43
44 167. Ramatillah DL, Sulaiman SAS, Khan AH, Meng OL. Quality of Life among Patients Undergoing Hemodialysis in
45 Penang, Malaysia. *J Pharm Bioallied Sci.* 2017;9(4):229–38.
46
47 168. Rebollo Rubio A, Morales Asencio JM, Eugenia Pons Raventos M. Depression, anxiety and health-related quality
48 of life amongst patients who are starting dialysis treatment. *J Ren Care.* 2017;43(2):73–82.
49
50 169. Romano-Zelekha O, Golan E, Ifrah A, Weinstein T, Shohat T. Differences in quality of life between Jewish and
51
52
53
54
55
56
57
58
59
60

- Arab patients on hemodialysis. *Qual Life Res.* 2017;26(12):3343–52.
170. Ryu JH, Koo TY, Ro H, Cho JH, Kim MG, Huh KH, et al. Better health-related quality of life in kidney transplant patients compared to chronic kidney disease patients with similar renal function. *PLoS One* [Internet]. 2021;16(10):e0257981. Available from: <http://dx.doi.org/10.1371/journal.pone.0257981>
 171. Salamon KM, Lambert K. Oral nutritional supplementation in patients undergoing peritoneal dialysis: a randomised, crossover pilot study. *J Ren Care.* 2018;44(2):73–81.
 172. Sawada A, Hiragi S, Tamura H, Goto R, Matsuyama Y, Sakai K, et al. Evaluation of the Quality of Life and Health-Related Quality of Life of Patients With End-Stage Kidney Disease Resulting From Kidney Transplantation Using the Kidney Disease Quality of Life-Short Form and EuroQOL-5 Dimension-5 Level Questionnaires. *Transplant Proc* [Internet]. 2021;53(3):881–4. Available from: <https://doi.org/10.1016/j.transproceed.2020.09.018>
 173. Scott MK, Shah NA, Vilay AM, Thomas J, Kraus MA, Mueller BA. Effects of Peridialytic Oral Supplements on Nutritional Status and Quality of Life in Chronic Hemodialysis Patients. *J Ren Nutr* [Internet]. 2009;19(2):145–52. Available from: <http://dx.doi.org/10.1053/j.jrn.2008.08.004>
 174. Seica A, Segall L, Verzan C, Văduva N, Madincea M, Rusoiu S, et al. Factors affecting the quality of life of haemodialysis patients from Romania: A multicentric study. *Nephrol Dial Transplant.* 2009;24:626–9.
 175. Shahnnavazi M, Parsa-Yekta Z, Rigi F, Yekaninejad MS. The relationship between emotional intelligence and quality of life hemodialysis patients. *Int J Med Res Heal Sci.* 2016;5(7S):564–70.
 176. Shahnnavazi M, Parsa-Yekta Z, Yekaninejad MS, Amaniyan S, Griffiths P, Vaismoradi M. The effect of the emotional intelligence education programme on quality of life in haemodialysis patients. *Appl Nurs Res.* 2018;39:18–25.
 177. Shimoyama S, Hirakawa O, Yahiro K, Mizumachi T, Schreiner A, Kakuma T. Health-related quality of life and caregiver burden among peritoneal dialysis patients and their family caregivers in Japan. *Perit Dial Int.* 2003;23(SUPPL. 2):200–5.
 178. Sihombing J, Hakim L, Andayani TM, Irijanto F. Quality of Life of Chronic Kidney Disease Patients With Routine Hemodialysis in General Hospitals in Sleman Yogyakarta. *Int J Pharm Pharm Sci.* 2017;9(2):213–6.
 179. Simic-Ogrizovic S, Jemcov T, Pejanovic S, Stosovic M, Radovic M, Djukanovic L. Health-related quality of life, treatment efficacy, and hemodialysis patient outcome. *Ren Fail.* 2009;31:201–6.
 180. Soares V, Oliveira-Silva I, Silva MS, Venâncio PEM, Oliveira LVF, Lima WA, et al. Inspiratory muscle training improves strength and health-related quality of life in hemodialysis patients. *Man Ther Posturology Rehabil J.* 2017;15:506.
 181. Song M-K, Ward SE, Bair E, Weiner LJ, Bridgman JC, Hladik GA, et al. Patient-reported cognitive functioning and daily functioning in chronic dialysis patients. *Hemodial Int.* 2015;19:90–9.
 182. Song M-K, Paul S, Ward SE, Gilet CA, Hladik GA. One-Year Linear Trajectories of Symptoms, Physical Functioning, Cognitive Functioning, Emotional Well-being, and Spiritual Well-being Among Patients Receiving

- Dialysis. *Am J Kidney Dis* [Internet]. 2018;72(2):198–204. Available from: <https://doi.org/10.1053/j.ajkd.2017.11.016>
183. Sørensen VR, Mathiesen ER, Watt T, Bjorner JB, Andersen MVN, Feldt-Rasmussen B. Diabetic patients treated with dialysis: complications and quality of life. *Diabetologia*. 2007;50:2254–62.
 184. Sorensen EP, Sarnak MJ, Tighiouart H, Scott T, Giang LM, Kirkpatrick B, et al. The Kidney Disease Quality of Life Cognitive Function subscale and cognitive performance in maintenance hemodialysis patients. *Am J Kidney Dis* [Internet]. 2012;60(3):417–26. Available from: <http://dx.doi.org/10.1053/j.ajkd.2011.12.029>
 185. Stavrianou K, Pallikarakis N. Quality of life of end-stage renal disease patients and study on the implementation of nocturnal home hemodialysis in Greece. *Hemodial Int*. 2007;11:204–9.
 186. Stumm EMF, Benetti ERR, Pretto CR, Barbosa DA. Effect of educational intervention on the quality of life of hyperphosphatemic chronic renal patients on hemodialysis. *Texto e Context Enferm*. 2019;28:9888.
 187. Sturgill DA, Bal N, Nagavally S, Wolfgram DF. The Relationship between Dialysis Metrics and Patient-Reported Cognition, Fatigue, and Physical Function. *Kidney Dis*. 2020;6:364–70.
 188. Tamilselvan S, William DB, Jagadeesan S, Suresh A. Impact of Pharmacist-Given Patient-Counseling on Health-Related Quality of Life (HRQOL) of Haemodialysis Patients. *J Evol Med Dent Sci*. 2021;10(12):856–60.
 189. Tanaka M, Ishibashi Y, Hamasaki Y, Kamijo Y, Idei M, Kawahara T, et al. Health-related quality of life on combination therapy with peritoneal dialysis and hemodialysis in comparison with hemodialysis and peritoneal dialysis: A cross-sectional study. *Perit Dial Int*. 2020;40(5):462–9.
 190. Tannor EK, Archer E, Kapembwa K, Van Schalkwyk SC, Davids MR. Quality of life in patients on chronic dialysis in South Africa: A comparative mixed methods study. *BMC Nephrol* [Internet]. 2017;18:4. Available from: <http://dx.doi.org/10.1186/s12882-016-0425-1>
 191. Ting GO, Kjellstrand C, Freitas T, Carrie BJ, Zarghamee S. Long-Term Study of High-Comorbidity ESRD Patients Converted From Conventional to Short Daily Hemodialysis. *Am J Kidney Dis*. 2003;42(5):1020–35.
 192. Tsarpali V, Midtvedt K, Lønning K, Bernklev T, Lippe N von der, Reisæter AV, et al. Health-Related Quality of Life in Older Kidney Transplant Recipients: A National Cohort Study of Short- and Longer-Term Outcomes. *Kidney Med* [Internet]. 2021;3(6):974–83. Available from: <https://doi.org/10.1016/j.xkme.2021.05.007>
 193. Türk İ, Ateş K, Bıyıklı Z. Quality of life and associated factors in hemodialysis and peritoneal dialysis patients. *Cukurova Med J*. 2020;45(1):79–88.
 194. Uchiyama K, Washida N, Morimoto K, Muraoka K, Kasai T, Yamaki K, et al. Home-based Aerobic Exercise and Resistance Training in Peritoneal Dialysis Patients: A Randomized Controlled Trial. *Sci Rep*. 2019;9:2632.
 195. Uchiyama K, Washida N, Muraoka K, Morimoto K, Kasai T, Yamaki K, et al. Exercise capacity and association with quality of life in peritoneal dialysis patients. *Perit Dial Int*. 2019;39(1):66–73.
 196. Unruh ML, Benz R, Greene T, Yan G, Beddhu S, DeVita M, et al. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. *Kidney Int*. 2004;66:355–66.

197. Unruh ML, Newman AB, Larive B, Dew MA, Miskulin DC, Greene T, et al. The influence of age on changes in health-related quality of life over three years in a cohort undergoing hemodialysis. *J Am Geriatr Soc*. 2008;56:1608–17.
198. van Doorn KJ, Heylen M, Mets T, Verbeelen D. Evaluation of functional and mental state and Quality of Life in chronic haemodialysis patients. *Int Urol Nephrol*. 2004;36:263–7.
199. van Eps CL, Jeffries JK, Johnson DW, Campbell SB, Isbel NM, Mudge DW, et al. Quality of life and alternate nightly nocturnal home hemodialysis. *Hemodial Int*. 2010;14:29–38.
200. Varela L, Vázquez MI, Bolaños L, Alonso R. Psychological predictors for health-related quality of life in patients on peritoneal dialysis. *Nefrologia*. 2011;31(1):97–106.
201. Vázquez I, Valderrábano F, Fort J, Jofré R, López-Gómez JM, Moreno F, et al. Psychosocial factors and health-related quality of life in hemodialysis patients. *Qual Life Res*. 2005;14:179–90.
202. Von der Lippe N, Waldum B, Østhus TBH, Reisæter A V., Os I. Health related quality of life in patients in dialysis after renal graft loss and effect of gender. *BMC Womens Health*. 2014;14:34.
203. Von der Lippe N, Waldum-Grevbo B, Varberg Reisæter A, Os I. Is HRQOL in dialysis associated with patient survival or graft function after kidney transplantation? *BMC Nephrol* [Internet]. 2016;17:94. Available from: <http://dx.doi.org/10.1186/s12882-016-0316-5>
204. Walters BAJ, Hays RD, Spritzer KL, Fridman M, Carter WB. Health-related quality of life, depressive symptoms, anemia, and malnutrition at hemodialysis initiation. *Am J Kidney Dis*. 2002;40(6):1185–94.
205. Wang W, Tonelli M, Hemmelgarn B, Gao S, Johnson JA, Taub K, et al. The Effect of Increasing Dialysis Dose in Overweight Hemodialysis Patients on Quality of Life: A 6-Week Randomized Crossover Trial. *Am J Kidney Dis*. 2008;51(5):796–803.
206. Warsame F, Ying H, Haugen CE, Thomas AG, Crews DC, Shafi T, et al. Intradialytic activities and health-related quality of life among hemodialysis patients. *Am J Nephrol*. 2018;48:181–9.
207. Watanabe Y, Ohno Y, Inoue T, Takane H, Okada H, Suzuki H. Home hemodialysis and conventional in-center hemodialysis in Japan: A comparison of health-related quality of life. *Hemodial Int*. 2014;18:S32–8.
208. Watanabe Y, Okada H. Effect of Combined Peritoneal Dialysis and Hemodialysis on Health-Related Quality of Life. *Contrib Nephrol*. 2018;196:135–40.
209. Wong FKY, Chow SKY, Chan TMF. Evaluation of a nurse-led disease management programme for chronic kidney disease: A randomized controlled trial. *Int J Nurs Stud* [Internet]. 2010;47:268–78. Available from: <http://dx.doi.org/10.1016/j.ijnurstu.2009.07.001>
210. Woźniak I, Kolonko A, Chudek J, Nowak, Farnik M, Więcek A. Influence of Polypharmacy on the Quality of Life in Stable Kidney Transplant Recipients. *Transplant Proc*. 2018;50:1896–9.
211. Wright LS, Wilson L. Quality of Life and Self-Efficacy in Three Dialysis Modalities: Incenter Hemodialysis, Home Hemodialysis, and Home Peritoneal Dialysis. *Nephrol Nurs J*. 2015;42(5):463–77.

212. Wu Y, He Q, Yin X, He Q, Cao S, Ying G. Effect of individualized exercise during maintenance haemodialysis on exercise capacity and health-related quality of life in patients with uraemia. *J Int Med Res.* 2014;42(3):718–27.

213. Yamana E. The relationship of clinical laboratory parameters and patient attributes to the quality of life of patients on hemodialysis. *Japan J Nurs Sci.* 2009;6:9–20.

214. Yang ZH, Pan XT, Chen Y, Wang L, Chen QX, Zhu Y, et al. Psychological Profiles of Chinese Patients With Hemodialysis During the Panic of Coronavirus Disease 2019. *Front Psychiatry.* 2021;12:616016.

215. Yıldırım A, Ogutmen B, Bektas G, Isci E, Mete M, Tolgay HI. Translation, Cultural Adaptation, Initial Reliability, and Validation of the Kidney Disease and Quality of Life-Short Form (KDQOL-SF 1.3) in Turkey. *Transplant Proc.* 2007;39:51–4.

216. Yoon HE, Kwon YJ, Song HC, Kim JK, Song YR, Shin SJ, et al. Overhydration negatively affects quality of life in peritoneal dialysis patients: Evidence from a prospective observational study. *Int J Med Sci.* 2016;13(9):683–95.

217. Zabel R, Ash S, King N, Juffs P, Bauer J. Relationships between appetite and quality of life in hemodialysis patients. *Appetite* [Internet]. 2012;59:194–9. Available from: <http://dx.doi.org/10.1016/j.appet.2012.02.016>

218. Zheng Z, Chen J, He D, Xu Y, Chen L, Zhang T. The effects of megestrol acetate on nutrition, inflammation and quality of life in elderly haemodialysis patients. *Int Urol Nephrol* [Internet]. 2019;51(9):1631–8. Available from: <https://doi.org/10.1007/s11255-019-02245-8>

219. Ziaja J, Bozek-Pajak D, Kowalik A, Król R, Cierpka L. Impact of Pancreas Transplantation on the Quality of Life of Diabetic Renal Transplant Recipients. *Transplant Proc.* 2009;41:3156–8.

220. Zimmerman DL, Swedko PJ, Posen GA, Burns KD. Daily hemofiltration with a simplified method of delivery. *ASAIO J.* 2003;49:426–9.

221. Zubair U Bin, Butt B. Association Of Quality Of Sleep With Cognitive Decline Among The Patients Of Chronic Kidney Disease Undergoing Haemodialysis. *J Ayub Med Coll Abbottabad.* 2017;29(4):619–22.

Table S3. *Quality assessment of observational cross-sectional studies.*

Author & Year	1. Was the research question or objective in this paper clearly stated?	2. Was the study population clearly specified and defined?	3. Was the participation rate of eligible persons at least 50%?	4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	5. Was a sample size justification, power description, or variance and effect estimates provided?	6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	10. Was the exposure(s) assessed more than once over time?	11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	12. Were the outcome assessors blinded to the exposure status of participants?	13. Was loss to follow-up after baseline 20% or less?	14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?
AL-Jumaih et al., 2011	Y	Y	NR	N	N	NA	NA	N	N	NA	Y	NA	NA	N
Amro et al., 2014	Y	Y	Y	N	N	NA	NA	Y	Y	N	Y	N	NA	Y
Anees et al., 2016	Y	Y	NR	Y	N	NA	NA	N	N	NA	Y	NA	NA	N
Bacci et al., 2018	Y	N	Y	Y	N	NA	NA	Y	Y	N	Y	Y	NA	N
Bagasha et al., 2021	Y	N	Y	N	Y	NA	NA	N	N	NA	Y	NR	NA	N
Bakewell et al., 2001	Y	N	CD	CD	N	NA	NA	Y	N	NA	Y	NA	NA	N
Barbosa et al., 2017	Y	Y	Y	Y	N	NA	NA	Y	Y	NA	Y	NR	NA	N
Barotfi et al., 2006	Y	N	Y	N	N	NA	NA	Y	Y	N	Y	NR	NA	Y
Barzegar et al., 2017	Y	Y	NR	Y	N	NA	NA	Y	Y	NA	Y	N	NA	N
Bataclan et al., 2009	Y	N	NR	CD	Y	NA	NA	Y	Y	N	Y	N	NA	N
Bele et al., 2012	Y	Y	Y	Y	N	NA	NA	Y	N	N	Y	NR	NA	N
Bettoni et al., 2017	Y	Y	Y	Y	N	NA	NA	Y	Y	N	Y	N	NA	N
Boudida et al., 2014	Y	N	NR	NR	N	NA	NA	Y	Y	N	Y	NR	NA	N
Braga et al., 2011	Y	Y	Y	Y	N	NA	NA	N	Y	NA	Y	NA	NA	N
Brickman et al., 1996	Y	N	NR	NR	N	NA	NA	Y	Y	N	Y	N	NA	Y
Carmichael et al., 2000	Y	N	Y	NR	N	NA	NA	Y	Y	N	Y	NR	NA	Y
Castro et al., 2018	Y	Y	NR	Y	N	NA	NA	Y	Y	N	Y	N	NA	N
Cavalcante et al., 2013	Y	N	Y	NR	N	NA	NA	N	Y	NA	Y	NA	NA	N
Cepeda Marte et al., 2019	Y	Y	NR	Y	N	NA	NA	N	Y	NA	Y	NA	NA	N
Chan et al., 2010	Y	Y	NR	Y	Y	NA	NA	Y	Y	N	Y	N	NA	Y
Cho et al., 2018	Y	Y	Y	Y	Y	NA	NA	N	Y	NA	Y	NA	NA	N
Chrifi Alaoui et al., 2022	Y	Y	Y	Y	N	NA	NA	Y	Y	NA	Y	NR	NA	Y
Czyzewski et al., 2018	Y	Y	NR	N	N	NA	NA	Y	Y	NA	Y	NR	NA	N
D'Onofrio et al., 2017	Y	Y	Y	Y	N	NA	NA	N	Y	NA	Y	NA	NA	N
de Oliveira Cordeiro et al., 2020	Y	Y	Y	N	N	NA	NA	NA	Y	NA	Y	NA	NA	N

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

de Oliveira et al., 2012	Y	Y	Y	Y	N	NA	NA	Y	Y	NA	Y	NR	NA	N
de Roij van Zuijdewijn et al., 2016	Y	Y	NR	N	N	NA	NA	Y	Y	Y	Y	NR	NA	Y
Debnath et al., 2018	Y	N	Y	N	N	NA	NA	Y	Y	N	Y	N	NA	Y
Dehesa-Lopez et al., 2016	Y	N	NR	CD	N	NA	NA	Y	N	NR	Y	NR	NA	N
Dehghan et al., 2020	Y	N	Y	N	Y	NA	NA	Y	Y	N	Y	N	NA	N
Diamant et al., 2011	Y	Y	Y	N	N	NA	NA	Y	Y	NA	Y	NR	NA	Y
Duarte et al., 2005	Y	N	NR	N	N	NA	NA	Y	Y	N	Y	N	NA	N
Fan et al., 2020	Y	Y	NR	Y	N	NA	NA	Y	Y	Y	Y	NR	NA	Y
Fiderkiewicz et al., 2011	Y	N	Y	CD	N	NA	NA	Y	Y	N	Y	N	NA	Y
Fong et al., 2007	Y	Y	Y	Y	N	NA	NA	Y	Y	NA	Y	NR	NA	Y
Fructuoso et al., 2011	Y	N	Y	NR	N	NA	NA	Y	Y	NA	Y	NR	NA	N
Fukuhara et al., 2003	Y	N	Y	N	N	NA	NA	Y	Y	NA	Y	NA	NA	Y
G. B. Lopes et al., 2014	Y	Y	NR	N	N	NA	NA	Y	N	N	Y	N	NA	Y
Garcia et al., 2010	Y	N	NR	N	N	NA	NA	Y	Y	N	Y	N	NA	N
Giglio et al., 2018	Y	Y	NR	Y	N	NA	NA	Y	Y	N	Y	Y	NA	N
Gonçalves et al., 2015	Y	N	NR	N	Y	NA	NA	Y	Y	NA	Y	NR	NA	CD
Green et al., 2001	Y	N	NR	N	N	NA	NA	Y	Y	NA	Y	NA	NA	N
Griva et al., 2012	Y	Y	Y	Y	N	NA	NA	Y	Y	N	Y	N	NA	N
Gumprecht et al., 2010	Y	Y	Y	N	N	NA	NA	NA	Y	NR	Y	NR	NA	N
Hays et al., 1994	N	Y	Y	CD	N	NA	NA	Y	Y	N	Y	N	NA	N
Henry et al., 2017	Y	N	NR	N	N	NA	NA	Y	Y	N	N	Y	NA	N
Ho et al., 2013	Y	Y	Y	Y	Y	NA	NA	Y	Y	NA	Y	NA	NA	N
Hornik et al., 2019	Y	N	NR	NR	N	NA	NA	N	Y	N	Y	N	NA	N
Hyodo et al., 2004	N	Y	NR	Y	N	NA	NA	N	Y	N	Y	N	NA	N
J. M. Lopes et al., 2014	Y	N	NR	N	N	NA	NA	N	Y	NA	Y	NA	NA	N
Jansz et al., 2018	Y	Y	Y	N	N	NA	NA	Y	Y	NA	Y	NR	NA	Y
Jayanti et al., 2016	Y	N	Y	N	N	NA	NA	Y	Y	N	Y	NR	NA	Y
Joshi et al., 2010	Y	Y	Y	Y	N	NA	NA	Y	Y	N	Y	N	NA	N
Kim et al., 2021	Y	Y	NR	N	N	NA	NA	N	Y	N	Y	N	NA	Y
Knudsen et al., 2016	Y	Y	Y	N	N	NA	NA	N	N	NA	Y	NA	NA	N
Ko et al., 2007	Y	Y	Y	N	N	NA	NA	N	N	NA	Y	NA	NA	N
Kontodimopoulos et al., 2005	Y	N	Y	N	N	NA	NA	Y	Y	N	Y	N	NA	Y
Krishnasamy et al., 2019	Y	N	NR	N	N	NA	NA	N	Y	NA	Y	NR	NA	N
Kurella et al., 2004	Y	N	NR	N	N	NA	NA	Y	Y	N	Y	N	NA	Y
Kusumoto et al., 2008	Y	Y	Y	Y	N	NA	NA	Y	Y	NA	Y	N	NA	N
Kutner et al., 2005b	Y	Y	Y	Y	N	NA	NA	Y	Y	NA	Y	NA	NA	Y
Kutner et al., 2007	N	Y	NR	Y	N	NA	NA	Y	N	N	Y	N	NA	Y
Lee et al., 2005	Y	Y	N	NR	N	NA	NA	Y	Y	NA	Y	N	NA	N
Leone et al., 2021	Y	Y	Y	Y	N	NA	NA	Y	Y	N	Y	N	NA	Y
Li et al., 2016	Y	N	NR	NR	N	NA	NA	Y	Y	N	Y	N	NA	Y
Lopes et al., 2007	Y	Y	NR	N	Y	NA	NA	Y	Y	N	Y	NR	NA	Y
Ma et al., 2021	Y	Y	Y	Y	N	NA	NA	Y	Y	N	Y	N	NA	N
Macedo et al., 2021	Y	Y	Y	Y	N	NA	NA	Y	Y	N	Y	NR	NA	N
Madariaga et al., 2016	Y	Y	NR	CD	N	NA	NA	Y	Y	NA	Y	Y	NA	N
Malekmakan et al., 2016	Y	N	NR	CD	Y	NA	NA	Y	Y	NA	Y	NR	NA	N
Malindretos et al., 2010	Y	N	Y	CD	Y	NA	NA	Y	Y	N	Y	NR	NA	N
Manavalan et al., 2017	Y	Y	NR	Y	N	NA	NA	Y	Y	NA	Y	N	NA	N

Manju et al., 2020	Y	Y	Y	Y	Y	NA	NA	N	Y	NA	Y	NA	NA	N
Manns et al., 2002	Y	Y	Y	CD	N	NA	NA	Y	Y	Y	Y	Y	NA	N
Marinho et al., 2017	Y	Y	Y	Y	Y	NA	NA	N	Y	NA	Y	NA	NA	N
Martin et al., 2000	Y	N	Y	N	N	NA	NA	Y	Y	N	Y	N	NA	Y
Martin et al., 2001	Y	N	NR	CD	Y	NA	NA	Y	Y	N	Y	NR	NA	N
Masina et al., 2016	Y	Y	Y	N	N	NA	NA	N	Y	NA	Y	NA	NA	N
Mazairac et al., 2011	Y	Y	NR	N	N	NA	NA	Y	Y	N	Y	NR	NA	Y
Mazairac et al., 2012	Y	N	NR	Y	N	NA	NA	N	Y	NA	Y	NA	NA	N
Medeiros et al., 2017	Y	Y	N	Y	N	NA	NA	N	Y	NA	Y	NA	NA	N
Milan Manani et al., 2020	Y	Y	Y	Y	N	NA	NA	Y	Y	NA	Y	NR	NA	N
Moist et al., 2008	Y	Y	Y	N	N	NA	NA	Y	Y	NA	Y	N	NA	Y
Molsted et al., 2007	Y	Y	Y	N	N	NA	NA	Y	Y	N	Y	NR	NA	Y
Montinaro et al., 2010	Y	N	NR	N	N	NA	NA	Y	Y	N	N	N	NA	N
Moura et al., 2014	Y	N	NR	N	N	NA	NA	Y	Y	NA	Y	NR	NA	Y
Moura et al., 2015a	Y	N	NR	N	N	NA	NA	N	Y	NA	Y	NA	NA	N
Moura et al., 2015b	Y	N	NR	N	N	NA	NA	Y	Y	NA	Y	NR	NA	N
Naderifar et al., 2019	Y	Y	NR	Y	Y	NA	NA	N	Y	NA	Y	NA	NA	N
Nagasawa et al., 2018a	Y	Y	Y	Y	N	NA	NA	Y	Y	N	Y	NR	NA	Y
Nagasawa et al., 2018b	Y	Y	Y	N	N	NA	NA	Y	Y	N	Y	NR	NA	Y
Nayana et al., 2016	Y	Y	Y	Y	Y	NA	NA	N	Y	NA	Y	NA	NA	N
Okpechi et al., 2013	Y	N	NR	N	N	NA	NA	Y	Y	N	Y	NR	NA	N
Oliveira et al., 2016	Y	Y	NR	Y	Y	NA	NA	Y	Y	N	Y	Y	NA	N
Orozco-González et al., 2021	Y	Y	NR	Y	N	NA	NA	Y	Y	N	Y	NR	NA	N
Østhus et al., 2012	Y	Y	Y	Y	N	NA	NA	Y	Y	N	Y	NR	NA	N
Ottaviani et al., 2016	Y	Y	Y	Y	N	NA	NA	Y	Y	N	Y	N	NA	N
Pakpour et al., 2011	Y	N	NR	N	N	NA	NA	Y	Y	N	Y	N	NA	N
Park et al., 2007	Y	N	NR	N	N	NA	NA	Y	Y	N	Y	N	NA	N
Park et al., 2012	Y	Y	Y	CD	N	NA	NA	Y	Y	N	Y	N	NA	N
Pereira et al., 2019	Y	Y	Y	N	N	NA	NA	Y	Y	N	Y	NR	NA	CD
Portela et al., 2020	Y	Y	NR	Y	N	NA	NA	Y	Y	NA	Y	NR	NA	N
Posegger et al., 2019	Y	N	Y	N	N	NA	NA	Y	Y	NA	Y	CD	NA	N
Pucheu et al., 2004	Y	Y	NR	Y	N	NA	NA	N	Y	NA	Y	NA	NA	N
Ramatillah et al., 2017	Y	N	NR	N	N	NA	NA	Y	Y	NA	Y	N	NA	N
Rebollo Rubio et al., 2017	Y	Y	Y	Y	N	NA	NA	Y	Y	NA	Y	NR	NA	N
Romano-Zelekha et al., 2017	Y	Y	Y	Y	Y	NA	NA	Y	Y	NA	Y	NA	NA	Y
Sawada et al., 2020	Y	N	NR	N	N	NA	NA	Y	Y	N	Y	N	NA	N
Seica et al., 2009	Y	N	Y	N	N	NA	NA	N	N	NA	Y	NA	NA	N
Shahnavazi et al., 2016	Y	Y	NR	Y	N	NA	NA	N	Y	NA	Y	NA	NA	N
Shimoyama et al., 2003	Y	Y	Y	CD	N	NA	NA	Y	Y	N	Y	N	NA	N
Song et al., 2015	Y	Y	Y	Y	N	NA	NA	Y	Y	N	Y	N	NA	Y
Sørensen et al., 2007	Y	Y	Y	N	N	NA	NA	N	Y	N	Y	NR	NA	N
Sorensen et al., 2012	Y	N	Y	N	N	NA	NA	Y	Y	N	Y	N	NA	Y
Stavrianou et al., 2007	Y	Y	Y	CD	N	NA	NA	N	N	NA	Y	NA	NA	N
Sturgill et al., 2020	Y	N	NR	N	N	NA	NA	Y	Y	N	Y	Y	NA	Y
Tanaka et al., 2020	Y	Y	Y	Y	N	NA	NA	Y	Y	NA	Y	NR	NA	Y
Tannor et al., 2017	Y	Y	Y	Y	N	NA	NA	Y	Y	NA	Y	NR	NA	N
Türk et al., 2020	Y	Y	Y	Y	N	NA	NA	Y	Y	N	Y	NR	NA	Y

Uchiyama et al., 2019b	Y	Y	Y	Y	N	NA	NA	Y	Y	N	Y	NR	NA	Y
van Doorn et al., 2004	Y	Y	Y	N	N	NA	NA	Y	Y	NA	Y	NR	NA	N
Varela et al., 2011	Y	N	Y	N	N	NA	NA	Y	Y	N	Y	N	NA	Y
Vázquez et al., 2005	Y	N	NR	N	N	NA	NA	Y	Y	N	Y	NR	NA	Y
von der Lippe et al., 2014	Y	Y	Y	Y	N	NA	NA	Y	Y	N	Y	NR	NA	Y
Walters et al., 2002	Y	Y	Y	Y	N	NA	NA	Y	Y	N	Y	NR	NA	N
Warsame et al., 2018	Y	Y	NR	CD	N	NA	NA	Y	Y	N	Y	N	NA	Y
Watanabe et al., 2014	Y	Y	NR	Y	N	NA	NA	Y	Y	NA	Y	NR	NA	N
Wozniak et al., 2018	Y	N	NR	N	N	NA	NA	Y	Y	N	Y	NR	NA	Y
Wright et al., 2015	Y	N	Y	N	Y	NA	NA	Y	Y	NA	Y	N	NA	N
Yamana, 2009	Y	Y	NR	Y	N	NA	NA	Y	Y	N	Y	NR	NA	N
Yıldırım et al., 2007	Y	N	NR	N	N	NA	NA	N	N	NA	Y	NA	NA	N
Zabel et al., 2012	Y	Y	N	Y	N	NA	NA	Y	Y	N	Y	N	NA	N
Ziaja et al., 2009	Y	N	Y	N	N	NA	NA	Y	Y	NA	Y	Y	NA	N
Zubair et al., 2017	Y	Y	Y	Y	N	NA	NA	Y	Y	N	Y	N	NA	Y

Notes. Quality assessment was performed using the quality assessment tool for observational cohort and cross-sectional studies developed by the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH); Y = Yes; N = No; NR = Not reported; CD = Cannot determine; NA = Not applicable.

Table S4. *Quality assessment of observational cohort studies.*

Author & Year	1. Was the research question or objective in this paper clearly stated?	2. Was the study population clearly specified and defined?	3. Was the participation rate of eligible persons at least 50%?	4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?	5. Was a sample size justification, power description, or variance and effect estimates provided?	6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?	7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?	8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?	9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	10. Was the exposure(s) assessed more than once over time?	11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?	12. Were the outcome assessors blinded to the exposure status of participants?	13. Was loss to follow-up after baseline 20% or less?	14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?
Alarcon et al., 2021	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	N	N	N
Anees et al., 2018	Y	N	NR	Y	N	Y	Y	Y	Y	N	Y	Y	NR	N
Aoun et al., 2020	Y	Y	NR	Y	N	Y	Y	Y	Y	N	Y	Y	NR	Y
Bawazier et al., 2018	N	Y	NR	Y	Y	Y	CD	Y	Y	Y	N	N	NR	Y
Chen et al., 2021	Y	Y	Y	Y	N	NR	CD	Y	Y	CD	Y	NR	NR	N
Cheung et al., 2012	Y	Y	NR	Y	Y	N	N	Y	Y	Y	Y	N	Y	N
Costa-Requena et al., 2017	Y	Y	Y	Y	N	Y	Y	N	Y	Y	Y	NA	N	N
Czyżewski et al., 2014	Y	Y	NR	N	N	Y	Y	Y	Y	Y	Y	NR	NR	N
Frimat et al., 2006	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	NR	N	Y
Gorodetskaya et al., 2005	Y	Y	NR	N	N	Y	Y	Y	N	Y	Y	NR	Y	Y
Hasan et al., 2021	Y	Y	Y	Y	N	Y	N	Y	Y	Y	Y	NR	Y	N
Jassal et al., 2006	Y	Y	NR	Y	N	Y	Y	Y	Y	Y	Y	N	Y	N
Jung et al., 2016	Y	Y	NR	Y	N	Y	Y	Y	Y	Y	Y	NR	N	Y
Kanamori et al., 2012	Y	N	Y	N	N	Y	Y	Y	Y	N	Y	NA	NA	Y
Kang et al., 2017	Y	Y	Y	N	N	Y	Y	Y	Y	N	Y	NR	NA	Y
Kim et al., 2020	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	NR	N	Y
Korevaar et al., 2002	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	N	N	Y
Kostro et al., 2016	Y	N	NR	N	N	Y	Y	Y	Y	Y	Y	NR	NR	N
Kutner et al., 2005a	Y	Y	NR	Y	N	Y	Y	Y	Y	Y	Y	NR	Y	Y
Lai et al., 2018	Y	Y	NR	Y	N	Y	Y	N	Y	NA	Y	NR	NR	N
Lee et al., 2020	Y	Y	NR	Y	N	Y	Y	Y	Y	N	Y	NA	NA	Y
Lønning et al., 2018a	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	NR	Y	Y
Lønning et al., 2018b	Y	Y	Y	Y	N	Y	Y	N	Y	Y	Y	NR	N	N
Loos-Ayav et al., 2008	Y	Y	NR	N	N	Y	Y	NA	Y	Y	Y	N	N	Y
Lopes et al., 2003	Y	Y	NR	N	N	Y	CD	Y	Y	N	Y	NA	NA	Y

Mapes et al., 2003	Y	Y	Y	N	N	Y	Y	Y	Y	N	Y	NA	NA	Y
McAdams-DeMarco et al., 2018	Y	Y	NR	N	N	Y	N	Y	Y	N	Y	NR	NR	Y
Mentari et al., 2005	Y	Y	NR	N	N	Y	CD	NA	Y	NA	Y	N	NR	N
Michels et al., 2011	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	Y	NR	N	Y
Neumann et al., 2018	Y	Y	Y	N	N	Y	Y	Y	Y	Y	Y	NR	N	Y
Ortega et al., 2007	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	N	Y	N
Painter et al., 2012	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	Y	Y	N	CD
Park et al., 2017	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	Y	N	Y
Peipert et al., 2020	Y	Y	N	Y	N	Y	Y	Y	Y	Y	Y	Y	Y	Y
Poulsen et al., 2017	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	Y	N	Y
Rajkumar et al., 2019	Y	Y	NR	Y	N	Y	Y	N	Y	Y	Y	NA	N	N
Ryu et al., 2021	Y	Y	NR	CD	N	Y	Y	N	Y	Y	Y	NR	Y	N
Sihombing et al., 2017	Y	Y	NR	Y	N	Y	CD	N	Y	Y	Y	NR	NR	N
Simic-Ogrizovic et al., 2009	Y	Y	Y	Y	N	Y	Y	N	Y	Y	Y	NA	N	N
Song et al., 2018	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	N	Y	Y
Ting et al., 2003	Y	Y	NR	Y	N	Y	Y	Y	Y	Y	Y	NR	N	N
Tsarpali et al., 2021	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	NR	N	Y
Unruh et al., 2008	Y	Y	Y	N	N	Y	Y	Y	Y	NA	Y	NA	N	Y
van Eps et al., 2010	Y	Y	NR	Y	N	Y	Y	Y	Y	Y	Y	Y	N	N
von der Lippe et al., 2016	Y	Y	NR	N	N	Y	Y	N	Y	Y	Y	NR	N	N
Watanabe et al., 2018	Y	N	NR	N	N	Y	Y	Y	N	Y	Y	NR	NR	N
Yang et al., 2021	Y	Y	NR	N	N	N	CD	Y	Y	CD	Y	CD	Y	N
Yoon et al., 2016	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	NR	Y	Y
Zimmerman et al., 2003	Y	N	NR	N	N	Y	N	Y	Y	Y	Y	NR	Y	N

Notes. Quality assessment was performed using the quality assessment tool for observational cohort and cross-sectional studies developed by the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH); Y = Yes; N = No; NR = Not reported; CD = Cannot determine; NA = Not applicable.

Table S5. *Quality assessment of controlled intervention studies.*

Author & Year	1. Was the study described as randomized, a randomized trial, a randomized clinical trial, or an RCT?	2. Was the method of randomization adequate (i.e., use of randomly generated assignment)?	3. Was the treatment allocation concealed (so that assignments could not be predicted)?	4. Were study participants and providers blinded to treatment group assignment?	5. Were the people assessing the outcomes blinded to the participants' group assignments?	6. Were the groups similar at baseline on important characteristics that could affect outcomes (e.g., demographics, risk factors, co-morbid conditions)?	7. Was the overall drop-out rate from the study at endpoint 20% or lower of the number allocated to treatment?	8. Was the differential drop-out rate (between treatment groups) at endpoint 15 percentage points or lower?	9. Was there high adherence to the intervention protocols for each treatment group?	10. Were other interventions avoided or similar in the groups (e.g., similar background treatments)?	11. Were outcomes assessed using valid and reliable measures, implemented consistently across all study participants?	12. Did the authors report that the sample size was sufficiently large to be able to detect a difference in the main outcome between groups with at least 80% power?	13. Were outcomes reported or subgroups analyzed prespecified (i.e., identified before analyses were conducted)?	14. Were all randomized participants analyzed in the group to which they were originally assigned, i.e., did they use an intention-to-treat analysis?
Boudville et al., 2009	Y	Y	Y	N	N	NR	Y	NR	NR	NR	Y	N	Y	CD
Chow et al., 2010	Y	Y	NR	NR	NR	Y	Y	Y	Y	Y	Y	Y	Y	N
Dai et al., 2020	Y	Y	Y	N	N	Y	Y	Y	Y	Y	Y	Y	Y	Y
Duarte et al., 2009	Y	N	Y	Y	Y	N	Y	Y	Y	NR	Y	N	Y	CD
Foley et al., 2009	Y	CD	Y	Y	Y	Y	N	NR	Y	Y	Y	Y	Y	Y
Hayashi et al., 2017	N	N	N	NR	NR	N	N	Y	Y	NR	Y	N	Y	N
Hernández Sánchez et al., 2021	Y	Y	Y	NR	NR	Y	Y	Y	Y	NR	Y	N	Y	Y
Jiao et al., 2017	N	Y	Y	N	N	Y	Y	Y	NR	NR	Y	N	Y	N
Lazarus, 2019	Y	N	Y	Y	Y	Y	Y	Y	NR	NR	Y	Y	Y	Y
Li et al., 2014	Y	Y	Y	Y	Y	Y	Y	Y	NR	Y	Y	Y	Y	N
Lim et al., 2020	Y	Y	N	N	N	Y	Y	Y	Y	Y	Y	Y	Y	N
Lo et al., 1998	N	N	N	N	N	Y	Y	N	NR	Y	Y	N	CD	N
Lopes et al., 2019	Y	N	NR	N	Y	Y	N	Y	Y	Y	Y	N	Y	N
Mansouri et al., 2020	N	N	Y	N	NR	Y	Y	Y	Y	Y	Y	Y	Y	N
Martin-Alemañy et al., 2016	Y	Y	NR	N	NR	Y	Y	Y	Y	NR	Y	N	Y	N
Maynard et al., 2019	Y	Y	Y	N	NR	Y	Y	Y	Y	Y	Y	Y	Y	N
Mazairac et al., 2013	Y	N	N	N	N	Y	N	Y	N	Y	Y	N	CD	Y
Ohtake et al., 2014	Y	N	NR	NR	NR	Y	Y	Y	Y	Y	Y	N	Y	N
Paniagua et al., 2005	Y	NR	NR	NR	NR	Y	N	Y	NR	NR	Y	N	Y	Y
Salamon et al., 2017	Y	Y	Y	NR	NR	Y	N	Y	NR	NR	Y	N	Y	N
Scott et al., 2009	N	N	N	N	NR	Y	Y	Y	Y	NR	Y	Y	Y	N
Shahnavazi et al., 2018	Y	Y	NR	NR	NR	Y	Y	Y	Y	Y	Y	N	Y	N
Soares et al., 2017	Y	CD	Y	NR	NR	CD	N	N	NR	NR	Y	N	Y	N
Tamilselvan et al., 2021	N	Y	NR	NR	NR	CD	Y	NR	NR	NR	Y	Y	Y	N
Uchiyama et al., 2019a	Y	N	NR	N	N	Y	Y	Y	N	NR	Y	Y	Y	Y
Unruh et al., 2004	Y	CD	NR	NR	Y	Y	N	NR	NR	NR	Y	N	Y	N

Wang et al., 2008	Y	CD	Y	Y	Y	NR	N	NR	Y	NR	Y	N	Y	Y
Wong et al., 2010	Y	CD	NR	NR	Y	Y	Y	Y	Y	NR	Y	Y	Y	N
Wu et al., 2014	N	Y	NR	NR	NR	Y	Y	Y	NR	NR	Y	N	Y	N
Zheng et al., 2019	Y	Y	NR	NR	NR	Y	Y	Y	Y	Y	Y	N	Y	N

Notes. Quality assessment was performed using the quality assessment tool for controlled intervention studies developed by the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH); Y = Yes; N = No; NR = Not reported; CD = Cannot determine; NA = Not applicable.

Table S5. *Quality assessment of before-after (pre-post) studies with no control group.*

Author & Year	1. Was the study question or objective clearly stated?	2. Were eligibility/selection criteria for the study population prespecified and clearly described?	3. Were the participants in the study representative of those who would be eligible for the test/service/intervention in the general or clinical population of interest?	4. Were all eligible participants that met the prespecified entry criteria enrolled?	5. Was the sample size sufficiently large to provide confidence in the findings?	6. Was the test/service/intervention clearly described and delivered consistently across the study population?	7. Were the outcome measures prespecified, clearly defined, valid, reliable, and assessed consistently across all study participants?	8. Were the people assessing the outcomes blinded to the participants' exposures/interventions?	9. Was the loss to follow-up after baseline 20% or less? Were those lost to follow-up accounted for in the analysis?	10. Did the statistical methods examine changes in outcome measures from before to after the intervention? Were statistical tests done that provided p values for the pre-to-post changes?	11. Were outcome measures of interest taken multiple times before the intervention and multiple times after the intervention (i.e., did they use an interrupted time-series design)?	12. If the intervention was conducted at a group level (e.g., a whole hospital, a community, etc.) did the statistical analysis take into account the use of individual-level data to determine effects at the group level?
Abbasi Abianeh et al., 2020	Y	Y	Y	NR	CD	Y	Y	NR	NR	Y	N	NA
Ahmadzadeh et al., 2017	Y	Y	Y	NR	CD	Y	Y	NR	N	Y	N	NA
Aramwit et al., 2012	Y	Y	Y	NR	CD	Y	Y	Y	N	N	N	NA
Goldfarb-Rumyantzev et al., 2006	N	Y	Y	N	CD	Y	Y	NR	Y	Y	Y	NA
Kim et al., 2011	Y	Y	Y	Y	CD	Y	Y	Y	Y	Y	Y	NA
Palanova et al., 2019	N	Y	Y	N	CD	Y	Y	NR	N	Y	N	NA
Parsons et al., 2006	Y	Y	Y	NR	N	Y	Y	NR	N	N	Y	NA
Stumm et al., 2019	Y	Y	Y	Y	CD	Y	Y	N	Y	Y	N	NA

Notes. Quality assessment was performed using the quality assessment tool for before-after (pre-post) studies with no control group developed by the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH); Y = Yes; N = No; NR = Not reported; CD = Cannot determine; NA = Not applicable.




Figure S1. Forest plot showing the results of 11 studies reporting correlation coefficients between subjective cognitive complaints and depressive symptoms. r = Correlation coefficient; CI = Confidence interval. The pooled correlation coefficient was 0.46 (95% confidence interval 0.39 to 0.53; 95% prediction interval 0.27 to 0.62), suggesting that subjective cognitive complaints were associated with higher depressive symptoms. There was evidence of heterogeneity across studies (Q = 20.29, df = 10, p = .027; I² = 49.8%). Egger's test did not detect funnel plot asymmetry (z = 0.26, p = .796).




Figure S2. Forest plot showing the results of six studies reporting correlation coefficients between subjective cognitive complaints and anxious symptoms. r = Correlation coefficient; CI = Confidence interval. The pooled correlation coefficient was 0.40 (95% confidence interval 0.33 to 0.47; 95% prediction interval 0.30 to 0.50), suggesting that subjective cognitive complaints were associated with higher anxious symptoms. There was no evidence of heterogeneity across studies ($Q = 5.73, df = 5, p = .333; I^2 = 17.0\%$). Egger's test did not detect funnel plot asymmetry ($z = 1.25, p = .212$).




Figure S3. Forest plot showing the results of six studies reporting correlation coefficients between subjective cognitive complaints and overall health ratings. r = Correlation coefficient; CI = Confidence interval. The pooled correlation coefficient was 0.22 (95% confidence interval 0.12 to 0.32; 95% prediction interval 0.01 to 0.42), suggesting that subjective cognitive complaints were associated with worse overall health ratings. There was evidence of heterogeneity across studies ($Q = 16.19, df = 5, p = .006; I^2 = 62.1\%$). Egger's test detected funnel plot asymmetry ($z = -3.67, p < .001$).




Figure S4. Forest plot showing the results of five studies reporting correlation coefficients between subjective cognitive complaints and general health perception. r = Correlation coefficient; CI = Confidence interval. The pooled correlation coefficient was 0.35 (95% confidence interval 0.20 to 0.48; 95% prediction interval 0.04 to 0.60), suggesting that subjective cognitive complaints were associated with worse perceived general health. There was evidence of heterogeneity across studies ($Q = 15.74, df = 4, p = .003; I^2 = 75.2\%$). Egger's test did not detect funnel plot asymmetry ($z = -0.14, p = .888$).




Figure S5. Forest plot showing the results of six studies reporting correlation coefficients between subjective cognitive complaints and bodily pain. r = Correlation coefficient; CI = Confidence interval. The pooled correlation coefficient was 0.35 (95% confidence interval 0.23 to 0.46; 95% prediction interval 0.09 to 0.57), suggesting that subjective cognitive complaints were associated with higher level of bodily pain. There was evidence of heterogeneity across studies ($Q = 15.31, df = 5, p = .009; I^2 = 66.9\%$). Egger's test did not detect funnel plot asymmetry ($z = -0.44, p = .663$).




Figure S6. Forest plot showing the results of six studies reporting correlation coefficients between subjective cognitive complaints and fatigue symptoms. r = Correlation coefficient; CI = Confidence interval. The pooled correlation coefficient was 0.49 (95% confidence interval 0.45 to 0.54; 95% prediction interval 0.45 to 0.54), suggesting that subjective cognitive complaints were associated with higher fatigue symptoms. There was no evidence of heterogeneity across studies ($Q = 1.11, df = 5, p = .953; I^2 = 0.0\%$). Egger's test did not detect funnel plot asymmetry ($z = -0.87, p = .383$).




Figure S7. Forest plot showing the results of six studies reporting correlation coefficients between subjective cognitive complaints and self-reported physical functioning. $r =$ Correlation coefficient; CI = Confidence interval. The pooled correlation coefficient was 0.33 (95% confidence interval 0.27 to 0.39; 95% prediction interval 0.25 to 0.41), suggesting that subjective cognitive complaints were associated with worse physical functioning. There was no evidence of heterogeneity across studies ($Q = 3.56, df = 5, p = .614; I^2 = 9.6\%$). Egger's test did not detect funnel plot asymmetry ($z = -0.55, p = .581$).




Figure S8. Forest plot showing the results of six studies reporting correlation coefficients between subjective cognitive complaints and social functioning. r = Correlation coefficient; CI = Confidence interval. The pooled correlation coefficient was 0.36 (95% confidence interval 0.18 to 0.51; 95% prediction interval -0.08 to 0.68), suggesting that subjective cognitive complaints were associated with worse social functioning. There was evidence of heterogeneity across studies ($Q = 37.37, df = 5, p < .001; I^2 = 85.4\%$). Egger's test did not detect funnel plot asymmetry ($z = -1.04, p = .297$).




Figure S9. Forest plot showing the results of five studies reporting correlation coefficients between subjective cognitive complaints and role limitation due to physical health. r = Correlation coefficient; CI = Confidence interval. The pooled correlation coefficient was 0.31 (95% confidence interval 0.25 to 0.37; 95% prediction interval 0.25 to 0.37), suggesting that subjective cognitive complaints were associated with role limitation due to physical health. There was no evidence of heterogeneity across studies (Q = 2.90, df = 4, p = .575; I² = 0.0%). Egger's test did not detect funnel plot asymmetry (z = -1.58, p = .114).




Figure S10. Forest plot showing the results of five studies reporting correlation coefficients between subjective cognitive complaints and role limitation due to emotional problems. r = Correlation coefficient; CI = Confidence interval. The pooled correlation coefficient was 0.43 (95% confidence interval 0.37 to 0.48; 95% prediction interval 0.37 to 0.48), suggesting that subjective cognitive complaints were associated with role limitation due to emotional problems. There was no evidence of heterogeneity across studies ($Q = 3.45, df = 4, p = .486; I^2 = 0.0\%$). Egger's test did not detect funnel plot asymmetry ($z = -1.57, p = .117$).